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Abstract 
 
There is a clear clinical need for small diameter blood vessel grafts. Previous studies have 
shown that decellularised porcine arteries have potential for future development and clinical 
translation. However, in order to overcome the problems of thrombogenesis and encourage 
endothelialisation in small diameter applications, it will be necessary to devise innovative 
approaches. In this study it was hypothesised that a bioactive peptide could be self-assembled 
within the decellularised tissue to overcome the problems of thrombogenesis and to aid and 
enhance re-endothelialisation. A method for self-assembling the tape forming peptide, P11-4 
within decellularised tissues was developed. The study then went on to explore the P11 series 
of peptides as materials for tissue engineering by examining biocompatibility and 
haemocompatibility and demonstrated the use of self-assembled peptide coatings to prevent 
thrombus formation and enhance re-endothelialisation. The self-assembly of peptide P11-4 
within decellularised porcine internal carotid artery was assessed using a range of microscopic 
and spectroscopic techniques. Fluorescent microscopy was used to show the penetration of 
the peptide throughout the decellularised conduit. Self-assembly of the peptide was assessed 
by FTIR spectroscopy. Using CLSM and MPLSM it was shown that the peptide self-assembled 
around the extracellular matrix of the acellular tissue. Fluorescent microscopy was used in 
conjunction with a specially designed flow cell to show that the peptide coating remained in 
the decellularised vessel for over 14 days under model flow conditions. The biocompatibility 
and haemocompatibility of a library of 43 peptides was assessed to identify ideal candidate 
peptides for use and to develop design characteristics for the application of self-assembling 
peptides in biomedical settings. Testing was carried out using cytotoxicity testing, the Chandler 
loop thrombosis model, a haemolysis assay and a complement inhibition assay. The results 
showed that large poly-cationic peptides were non-bio or haemo compatible, large neutral 
peptides enhanced thrombosis formation and that poly-anionic peptides with hydrophobic 
cores inhibited the complement system. Peptide coatings of P11-4, P11-8 and P11-12 were 
shown to decrease, and in the case of P11-12 prevent, thrombus formation; showing potential 
for application in small diameter acellular blood vessels. Peptide P11-4, functionalised with 
cyclic RGD, was shown to enhance the attachment and retention of ovine endothelial cells on 
the decellularised vessel, demonstrating the potential of functionalised peptide to enhance re-
endothelialisation.  In conclusion, this study has demonstrated the potential of self assembling 
peptide technology for improving the function of acellular porcine arteries in vitro.     
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1 Introduction 
 
1.1 Clinical need  
 
Cardiovascular disease (CVD) is the main cause of mortality in the UK with almost 200,000 
deaths a year attributed to CVD (Capewell et al., 2008). Over 100,000 people a year in the UK 
are diagnosed with peripheral artery disease (PAD), a major indicator of widespread 
atherosclerosis (Belch et al., 2007). Around 40 % of people who are diagnosed with PAD are 
symptomatic and require some form of intervention ranging from lifestyle changes to surgical 
bypass dependent upon the severity of the disease (Belch et al., 2007). Medication and 
vascular stenting are widely used to control and treat vascular disease; however, in some cases 
there is no other option than to perform a vascular bypass graft. In the UK over 29,000 
coronary artery bypass grafts (CABG) are performed each year (Allender et al., 2008). Medical 
intervention techniques have had reasonable success with large diameter (>6 mm) grafts 
maintaining high long term patency rates. However, small diameter (<6 mm) grafts often fail 
due to thrombosis and occlusion. There is currently a high demand for small diameter grafts 
which have high patency rates and remain fully functional. 
 
1.2 Blood vessels 
1.2.1 Structure  
 
Arteries and veins with a diameter less than 6 mm are taken to be small blood vessels (Zhang 
et al., 2007). Capillaries whilst small in scale have significantly different structures and 
functions and are not the target of surgical interventions. The basic structure of an artery and 
vein is similar (Figure 1.1) with the only differences being related to the elastin content, vessel 
size and thickness with veins also having valves to prevent the back flow of blood.  Arteries 
handle higher pressures than veins and so have thicker layers of muscle; in a similar manner, 
the level of elastin in an artery is higher than that found in a vein and reduces the further away 
from the heart the artery gets as the vessel is required to handle less pressure. The structure 
of a large blood vessel is the same as the structure of a smaller blood vessel: as the vessel size 
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decreases, so does the thickness of the layers that make up the blood vessel (Mulvany and 
Aalkjaer, 1990). The vessel is composed of three layers, the tunica interna (intima), the tunica 
media (media) and the tunica externa (adventitia) (Zhang et al., 2007). The intima is the inner 
most layer of the vessel and is constructed of a longitudinal monolayer of vascular endothelial 
cells that are in contact with the blood flow. The endothelial cells are attached to a 
subendothelial layer that is comprised of connective tissue that is interlaced with an internal 
elastic lamina (Bou-Gharios et al., 2004, Zhang et al., 2007). The elastic lamina is a membrane 
comprised of elastic fibres that anastomose with each other forming a netlike structure that is 
found in-between each of the layers (Bou-Gharios et al., 2004, Venkatraman et al., 2008). The 
media is the middle layer of a blood vessel; it is comprised of circumferentially arranged layers 
of vascular smooth muscle cells (Bou-Gharios et al., 2004, Zhang et al., 2007). The number of 
smooth muscle cell layers changes with the size of the vessel and the location in the body 
(Mulvany and Aalkjaer, 1990). The smooth muscle cells are surrounded by extracellular matrix 
(ECM), made up of collagen, elastin and fibrillin, that is rich in proteoglycans and orientated in 
the same direction as the cells (Bou-Gharios et al., 2004). The adventitia is comprised of 
connective tissue, collagen and elastin, separated from the media by an external elastic lamina 
and primarily contains adventitial fibroblasts (Bou-Gharios et al., 2004, Zhang et al., 2007). 
Nerves are believed to play a major role in vascular function, however, nerves are sparse in 
blood vessels and are limited to the adventitia and do not penetrate into the other layers 
(Mulvany and Aalkjaer, 1990).  
 
 
Figure 1.1; Schematic of blood vessel structure 
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1.2.2 Extracellular matrix  
 
The structure and composition of the ECM is specific to each tissue and location (Nisbet et al., 
2009). The ECM of a blood vessel is made of a range of fibrous proteins (collagen and elastin 
being the most abundant), linker proteins (fibrillin, fibronectin, laminin, etc) and space filling 
glycosaminoglycans important to normal vessel function. These molecules are ordered into a 
3-dimentional network via self-assembly and cell directed assembly/remodelling (Chen and 
Hunt, 2007). The ECM also acts as a reservoir for soluble macromolecules (growth factors, 
cytokines etc) and acts to control the diffusion of soluble factors (Chen and Hunt, 2007). The 
different constituents of the ECM of blood vessels have different turnover rates; overall, the 
blood vessel ECM has a slow turnover time (Stock et al., 2001, Bou-Gharios et al., 2004). The 
different layers of a blood vessel have different ECM compositions.  
Of the many different types of collagen known to exist in blood vessels, collagen types I and III 
are the major fibrillar collagens in the vessel representing 60 % and 30 % of the collagen, 
respectively (Jacob et al., 2001). The remaining collagens found in blood vessels are fibrillar 
collagen type V, fibril-associated collagens with interrupted triple helices (FACIT) type XII and 
type XIV, micro-fibrillar collagen type VI, basement-membrane collagen type IV and collagen 
type VIII (Jacob et al., 2001).  
Elastin is the major component that imparts elasticity to tissues. Elastin forms part of an elastic 
fibre and requires the presence of other extracellular proteins to assemble outside the cell 
(Wagenseil and Mecham, 2009). Most of the elastin in a blood vessel is found in the medial 
layer and is arranged in lamellae with collagen fibres and layers of proteoglycan rich ECM with 
smooth muscle cells in between; the elastic lamellae are connected in 3-dimensions with thin 
elastic fibres which also connect the lamellae with the smooth muscle cells (Wagenseil and 
Mecham, 2009).  
There is a distinct difference between elastin and elastic fibres: elastin is an amorphous gel like 
material, whereas elastic fibres are complex structures made of elastin and microfibrils (Rock 
et al., 2004, Kozel et al., 2005, Wagenseil and Mecham, 2009). Microfibrils are made of fibrillin 
molecules and are needed for the formation of elastic fibres; microfibrils are present in the 
body without elastin but rarely is elastin found without microfibrils (Rock et al., 2004, Kozel et 
al., 2005, Wagenseil and Mecham, 2009). The mammalian elastin gene encodes a protein 
called tropoelastin which is around 60 -70 kDa; tropoelastin has an arrangement of 
hydrophobic sequences alternating with lysine-containing cross-linking motifs (Rock et al., 
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2004, Kozel et al., 2005, Wagenseil and Mecham, 2009). In the ECM >80 % of the lysine 
residues in tropoelastin are modified to from covalent cross-links (Rock et al., 2004, Kozel et 
al., 2005, Wagenseil and Mecham, 2009). It is the cross-linked form of tropoelastin that gives 
the functional form of the protein. The large number of elastin cross-links is responsible for the 
recoil properties that contribute to the mechanical properties of a blood vessel; the cross-
linking is also responsible for the insolubility and longevity of the protein, where <1 % of total 
body elastin is turned over in one year (Wagenseil and Mecham, 2009). 
It is believed that tropoelastin released from cells is cross-linked by lysyl oxidase to make 
elastin; elastin is then “chaperoned” to microfibillar scaffolds where the elastin and 
microfibrils assemble into elastic fibres (Figure 1.2)(Rock et al., 2004, Kozel et al., 2005, 
Wagenseil and Mecham, 2009). Other ECM proteins fibronectin, vitronectin, laminin, 
entactin/nidogen, tenascin and thrombospondin play essential roles in the structure and 
function of the ECM, comprising a multi-domain structure that could enable the interaction of 
cells and other ECM components (Jacob et al., 2001).  
 
 
Figure 1.2; Schematic of classical model of elastogenesis, A. Tropoelastin released from cells and 
cross-linked into elastin. B. Elastin molecules “chaperoned” to microfibrils assembly. C. Elastin and 
microfibrils assemble to form elastic fibres. Taken from (Moore and Thibeault, 2012). 
 
There are numerous proteoglycans contained in the vascular wall: large aggregating 
proteoglycans such as aggrecan and versican, small non-aggregating proteoglycans including 
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biglycan, decorin and fibromodulin and cell associated proteoglycans such as syndecan (Jacob 
et al., 2001). Aggrecan and versican belong to a family of hyaluronan-binding proteoglycans 
that play important roles in ECM structure, biomechanical properties and also influence 
cellular behaviour (Wight, 2002). Versican expression is upregulated in vascular smooth muscle 
cells by mitogens, such as platelet-derived growth factors which contribute to the expansion of 
pericellular ECM needed for smooth muscle cell migration and proliferation (Wight, 2002).  
It has been reported that biglycan, secreted from endothelial and smooth muscle cells, binds 
to collagen and is actively involved in the control of collagen deposition. Mutations in biglycan 
gene expression have been observed to result in abnormal collagen fibrils in tendons; the 
effect upon the vasculature is unknown. However, high levels of biglycan have been observed 
in diseased arteries (Shimizu-Hirota et al., 2004). Biglycan has been reported to increase the 
migration and proliferation of vascular smooth muscle cells and the overexpression of biglycan 
in transgenic mice has shown resultant thickening of the medial layer (Shimizu-Hirota et al., 
2004). Normal arterial media and intima are rich in biglycan but have little to no decorin which 
is found in the adventitia (Riessen et al., 1994). High levels of biglycan and decorin have been 
observed in atherosclerotic plaque linked to collagen types I and III. Nonetheless, no biglycan 
or decorin have been observed linked to collagen type IV, indicating that these proteoglycans 
are not part of the basement membrane (Riessen et al., 1994).  
Fibromodulin regulates collagen fibril formation binding to a different site on collagen than 
decorin (Hocking et al., 1998). Fibromodulin and decorin interact with collagen to inhibit 
fibrillogenesis and control fibre diameter resulting in thinner fibre diameters (Hocking et al., 
1998). Syndecans are heparin sulphate proteoglycans that can interact with a wide range of 
growth factors, cytokines, chemokines, and ECM molecules involved in cell growth and 
attachment (Alexopoulou et al., 2007). Results from experimental models show that syndecans 
are involved in endothelial cell growth and migration (Alexopoulou et al., 2007). 
 
1.2.3 Cells  
 
The vascular ECM is synthesised by three cell types: intimal endothelial cells, medial smooth 
muscle cells and adventitial fibroblasts (Jacob et al., 2001). Smooth muscle and endothelial 
cells show a range of functionality and diverse phenotypes. The cells may exhibit different 
6 
 
characteristics, such as different morphologies, behaviour, biochemical or physiological 
properties and different development pathways (Bou-Gharios et al., 2004).  
The endothelial cells of small arteries form a continuous cover and are reported to project 
through fenestrations in the elastic lamina and make contact with the smooth muscle cells in 
the media layer, allowing for endothelial control of vascular contraction (Mulvany and 
Aalkjaer, 1990). In the intima, the endothelial cells produce and attach to a basal lamina that is 
supported on the internal elastic lamina (Wagenseil and Mecham, 2009). Vascular endothelial 
cells produce elastin and so are believed to contribute to the formation and maintenance of 
the internal elastic lamina (Wagenseil and Mecham, 2009). Whilst endothelial cells maintain 
some fundamental features regardless of their origin, site-specific differences can be seen 
between endothelial cells from different locations (Murphy et al., 1998). As well as the 
different makeup of the ECM affecting the cells, endothelial cells residing in different 
mechanical environments have been demonstrated to have different characteristics (Topper 
and Gimbrone Jr, 1999, Nerem, 2000, Chiu et al., 2009, O'Keeffe et al., 2009). The differences 
between endothelial cells relates not only to their metabolic activity but also to their response 
to inflammation and tissue damage (Murphy et al., 1998). As such, it is believed that 
endothelial cell dysfunction is one of the key initiators in CVD.   
Around 70 % of the volume of the tunica media comprises mainly smooth muscle cells (SMC) 
(Mulvany and Aalkjaer, 1990). The number of smooth muscle cell layers in the tunica media 
decreases with decreasing vessel size (Mulvany and Aalkjaer, 1990). The smooth muscle cells in 
the tunica media are arranged circumferentially with a slight pitch angle (< 2°) and are 
connected by membranous contacts (Mulvany and Aalkjaer, 1990). It has been reported that 
the embryonic origins of vascular SMCs arise from different distinct sources dependent upon 
the vessel location and even from different sources in the same vessel (Wagenseil and 
Mecham, 2009). Coronary SMCs display a highly differentiated phenotype. However, SMCs 
from other vascular beds, aorta and Iliac arteries, show greater phenotypic heterogeneity 
(Patel et al., 2000). Vascular smooth muscle cells can become activated by several mechanical, 
haemo-dynamic or infectious factors that lead to a change in the cellular composition of the 
vessel, which in turn is associated with several CVDs (Patel et al., 2000).  
The cells found in the adventitia are mainly fibroblasts, mast cells and macrophages with a 
small number of Schwann cells that are associated with nerve axons (Mulvany and Aalkjaer, 
1990). Fibroblasts are the predominant long-lived stromal cell type, the main feature of which 
is ECM production. Fibroblasts are a heterogeneous cell population and can vary widely in 
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smooth muscle -actin content, morphology, and organisation of structures involved in 
adhesion, in vitro (Sartore et al., 2001). Adventitial fibroblasts in models of vessel injury have 
been observed to be converted into smooth muscle-like cells (Sartore et al., 2001). Activation 
of fibroblasts induces contraction that correlates to smooth muscle -actin content and the 
development of a micro-filamentous cytoplasmic system, fibronexus junctions and other 
smooth muscle cell properties leading to the formation of hybrid cells called myofibroblasts 
(Sartore et al., 2001). The tunica adventitia has a high collagen content produced by a 
heterogeneous population of adventitial myofibroblasts (Wagenseil and Mecham, 2009). 
Adventitial fibroblasts can migrate and overgrow medial SMCs to become myofibroblasts that 
display -SM actin expression (Patel et al., 2000). Stimulation of coronary adventitial 
fibroblasts resulted in changes typically attributed to “synthetic” SMCs (Patel et al., 2000).  
The cells of a blood vessel play a major role in vascular repair with several mechanisms for this 
proposed. One idea, based on observations of cultured vascular SMCs losing their contractile 
features and becoming “synthetic” cells, assumes the cells involved in vascular repair are SMCs 
and that all medial SMCs modulate their phenotype in response to stimulation (Patel et al., 
2000). The second concept suggests an heterogeneity of medial SMCs with only a fraction of 
the cells being able to rapidly respond to stimulation (Patel et al., 2000). The third concept is 
that vascular repair is due to non-muscle cells, adventitial fibroblasts, that proliferate and 
migrate from the adventitia into the medial and intimal layers (Patel et al., 2000). Whilst there 
is much debate as to which concept is correct, they are not mutually exclusive. Regional 
differences have been observed in arterial repair suggesting that different vessels may repair 
in different ways dependent upon the function of the different vascular phenotypes (Patel et 
al., 2000). Medial smooth muscle cells and adventitial fibroblasts have a high capacity to 
synthesise new ECM and protease inhibitors, although new ECM from repair is never as 
organised as the ECM synthesised during development (Jacob et al., 2001).  
 
1.2.4 Mechanical properties 
 
The ability of the vasculature to respond to the flow of blood has been well documented. 
There is conclusive evidence that biomechanical forces have a direct effect on endothelial 
structure and function (Resnick et al., 2003). Arteries have many different mechanical 
properties, all of which contribute to the normal health of the vessel. The main mechanical 
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force placed on the vasculature is stress. Stresses on a vessel wall include shear stresses from 
the flow of blood across the vessel, longitudinal stresses from surrounding tissue and 
circumferential stresses from the blood pressure (Wagenseil and Mecham, 2009). Mechanical 
stimuli can be “sensed” and recognised by a number of different “sensors”. Integrins can be 
used to transduce mechanical stimuli into biochemical signals. Cell-cell-junction molecules that 
undergo changes in response to mechanical stimuli can change cell interactions. Adherence 
junctions in endothelial cells can interact with the cytoskeleton and transfer information 
intracellularly. Membrane structures such as flow activated ion channels, flow activated 
receptors, caveolae (cholesterol rich areas of the membrane with high numbers of signalling 
molecules) and machanotransducing G proteins can also function as mechano-sensors (Resnick 
et al., 2003, Chatzizisis et al., 2007).  
In healthy individuals a shear stress in the range of 0.5 – 4 Pa is normally experienced by the 
endothelial cells as a result of blood flow (Resnick et al., 2003, Qiao et al., 2006). Changes in 
the artery structure can create regions of re-circulated flow where the shear stress can vary 
greatly. This can lead to vascular remodelling and even disease states such as atherosclerosis 
(Resnick et al., 2003). Atherosclerosis may be linked with shear stress as atherosclerosis is 
most likely in areas of the vasculature like branch points, the outer wall of bifurcations and the 
inner wall of curvatures, where disturbed blood flow occurs (Chatzizisis et al., 2007). It has 
been reported that endothelial cells require shear stress to adopt the correct characteristics 
for formation of healthy endothelium and that loss of this shear stress could result in 
endothelial dysfunction and so trigger atherosclerosis (Resnick et al., 2003, Chatzizisis et al., 
2007).  
Circumferential stress is important to an artery’s ability to handle the changes in blood 
pressure as blood moves through the vasculature in a pulsatile fashion. The circumferential 
stress in a vessel wall is dependent upon the force being applied by the blood, and the 
thickness, composition and uniformity of the vessel wall. In disease states, such as 
atherosclerosis and aneurysm, the uniformity of the vessel wall is severely compromised and 
can lead to changes in the circumferential stresses within the vessel wall (Cheng et al., 1993, 
Lee et al., 1996). It is believed that one of the factors that can contribute to rupture of 
atherosclerotic lesions is the build-up of circumferential stress. However, rupture does not 
always happen at the site of highest stress suggesting that other factors are involved as well 
(Cheng et al., 1993, Lee et al., 1996).  
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Vascular distensibility is the resistance presented by a vessel to stretching and swelling. 
Arterial distensibility is complex. The internal mammary artery has been shown to have a 
distensibility of between 56 and 47 Pa at pressures between 50 and 150 mmHg (Chamiot-Clerc 
et al., 1998). When the vessel is relaxed, the distensibility is dependent upon the amount, 
arrangement and characteristics of the connective tissue. When under pressure the 
distensibility is dependent upon the amount and type of connective tissue, the fraction volume 
and activity level of smooth muscle cells all of which is influenced by the intravascular pressure 
(Mulvany and Aalkjaer, 1990).  
The widest reported measure of blood vessels’ mechanical properties is the burst pressure. 
The saphenous vein has a burst pressure of 1599 ± 877 mmHg (n=7) and the internal 
mammary artery has a burst pressure of 3196 ± 1264 mmHg (n=16), both commonly used in 
coronary artery bypass surgery, where the coronary artery has a burst pressure > 2300 mmHg 
(Lamm et al., 2001, Conklin et al., 2002, Konig et al., 2009). Most blood vessels will normally 
only handle arterial pressures in the range of hundreds of mmHg and so blood vessels can 
withstand much higher pressures than experienced giving a degree of safety. This means that 
the vessels are unlikely to burst or plastically deform under normal in vivo conditions (Nerem, 
2000).  
Arterial compliance is the change in blood volume due to a given blood pressure and is an 
index of the elasticity of arteries. Internal mammary artery and common femoral artery have 
been shown to have a compliance of 5.4% to 9.8% dilation at pressures between 50 and 2000 
mmHg (Chamiot-Clerc et al., 1998, Wilshaw et al., 2011) Endothelial dysfunction can cause a 
reduction in compliance as can hypertension and aging; some diseases such as diabetes can 
cause a reduction in compliance as can smoking cigarettes (Cohn, 2001). A reduction in arterial 
compliance can cause or exacerbate hypertension, can aggravate atherosclerosis and is a risk 
factor and indicator of CVD (Cohn, 2001). It has been shown that arteries respond to changes 
in blood flow by remodelling the diameter of the vessel to keep the wall shear stress the same. 
Where compliance is mismatched in bypass grafts, the flow rate of blood is changed and 
intimal growth can be stimulated to increase the wall shear stress; this can ultimately lead to 
the narrowing and occlusion of the vessel, resulting in failure of the graft (Stewart and Lyman, 
1992). Compliance mismatch can also cause the degradation of the graft and result in 
aneurysm formation. The biomechanical properties of an artery are important stimuli for the 
growth, development, remodelling and maintenance of arteries and are required for normal 
vessel function. 
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The mechanical properties of the coronary artery have been shown to change dependent upon 
age and sex. Below the age of 50 it has been shown that the coronary artery dilates about 10% 
when subjected to physiological pressure (60 – 140 mmHg) over the age of 50 there is a 
decrease in compliance (Ozolanta et al., 1998). The elastic modulus of the arterial walls slowly 
increases with age going from around 1 MPa to around 4 MPa, this increase in elastic modulus 
is higher after the age of 50 and is higher in men than in women (Ozolanta et al., 1998).  
The mechanical properties of bypass grafts are important to the success of the graft. If the 
bypass graft is not able to match the mechanical properties of the natural vessel this can lead 
to intimal hyperplasia, aneurysm formation, cellular dysfunction, thrombus formation and 
graft failure. This can be seen in the failure of early attempts to use synthetic grafts which did 
not possess the correct mechanical properties. Much of the focus on the design of grafts is on 
matching the mechanical properties. 
 
1.3 Arterial disease 
 
Cardiovascular disease is the biggest killer in the developed world and has many different 
forms. Most forms of vascular disease have been linked to or commonly occur as a result of 
atherosclerosis. Atherosclerosis is the formation of a lesion in the vessel wall. Initially, 
atherosclerosis was considered to mainly be caused by the accumulation of lipids within the 
arterial wall as high levels of cholesterol, in particular low-density lipoprotein (LDL) cholesterol, 
is the primary associated risk factor (Stary et al., 1994, Epstein and Ross, 1999). A second 
theory linked atherosclerosis to damage: it is believed that atherosclerosis is the result of the 
vessel’s response to injury, in particular the response to damage or dysfunction of the 
endothelium (Stary et al., 1994, Epstein and Ross, 1999, Libby et al., 2002). There is much 
debate over the causes of atherosclerosis, however, advances in the understanding of cellular 
and molecular mechanisms has lead to a wider adoption of the “response to injury” 
hypothesis.  
Atherosclerosis is a series of highly specific cellular and molecular responses and reactions that 
can be best described as an inflammatory disease. Most of the data available on 
atherosclerosis is related to the coronary arteries and aorta as this is the area in which major 
life threatening conditions occur (Stary et al., 1994). The different stages of the disease can be 
considered as three distinct lesions that represent a stage in the chronic inflammation of the 
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arterial wall (Epstein and Ross, 1999, Libby et al., 2002). There are many possible causes of 
atherosclerosis: elevated LDL cholesterol, free radical damage (mainly caused by cigarette 
smoking), hypertension, diabetes, infectious microorganisms (herpes viruses, Chlamydia 
pneumonia etc), genetic mutations, and combinations of these and other factors (Epstein and 
Ross, 1999). The damage or dysfunction of the endothelium results in a change in the 
homeostatic properties of the vessel, allowing the increased adhesion of leukocytes to the 
vessel wall and causing increased endothelial permeability (Epstein and Ross, 1999, Libby et 
al., 2002). Endothelial dysfunction also results in a change from the endothelium having 
anticoagulant properties to pro-coagulant properties. The attachment of these cells and 
various factors forms the initial lesion most often observed in children or in areas of the 
vasculature not prone to lesion formation. The lesion initially consists of lipid-laden monocytes 
and macrophages along with T lymphocytes; as the lesion becomes more distinctly defined it 
becomes known as a fatty-streak (Figure 1.3) (Stary et al., 1994, Epstein and Ross, 1999). 
If the initial response is not effectively neutralised, the secretion of growth factors, cytokines 
and other inflammatory products from the monocytes, lymphocytes and macrophages can 
cause the migration and proliferation of SMCs (Epstein and Ross, 1999). The inflammatory 
response causes medial SMCs to express enzymes that degrade the collagen and elastic fibres 
of the ECM and permits the penetration of SMCs through the elastic lamina and into the lesion 
(Libby et al., 2002). The SMCs become intermixed with the area of inflammation to form an 
intermediate lesion (Epstein and Ross, 1999).  There are areas of the vasculature, the coronary 
arteries for example, where lesion progression is more likely (Stary et al., 1994).  
As the SMCs proliferate, the lesion thickens and the artery wall compensates by 
dilating/remodelling (Epstein and Ross, 1999). Expansion and continued inflammation results 
in the recruitment of higher numbers of macrophages and lymphocytes which migrate from 
the blood and multiply within the lesion. These cells release more enzymes, cytokines, 
chemokines and growth factors which cause further damage. This reaction forms a cycle of 
mononuclear cell recruitment followed by SMC migration and proliferation that leads to the 
formation of more fibrous tissue causing the expansion of the lesion into an advanced 
complicated lesion (Figure 1.3) (Epstein and Ross, 1999). The progress of a fatty-streak lesion 
into an intermediate and advanced lesion involves the formation of a fibrous cap that walls off 
the lesion from the lumen and contains a reservoir of leukocytes, lipids, debris and can contain 
necrotic tissue(Epstein and Ross, 1999). The lesion eventually grows too large and begins to 
alter and obstruct blood flow as the artery cannot compensate.  
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The distinctions that separate the individual lesion types are based on constant morphological 
characteristics that represent a temporary or permanent stabilisation. As the lesions can 
stabilise at each step, the progression from fatty-streak to intermediate lesion to advanced 
lesion may require an additional stimulus (Stary et al., 1994). Some lesions are stable and have 
a uniform dense fibrous cap, while others are unstable and pose a major health risk. 
Rupture of the fibrous cap often results from enzymatic action that can be stimulated in many 
different ways. The most implicated cause is an immune response where activated T cells are 
known to stimulate macrophages in the lesion to produce metalloproteinases (Epstein and 
Ross, 1999, Libby et al., 2002). The action of the T lymphocytes on the macrophages causes the 
heightened expression of pro-coagulant tissue factor (Libby et al., 2002). Rupture of the 
fibrous cap can lead to haemorrhage from the vasa vasorum, from the lumen of the artery and 
the release of tissue factor resulting in thrombus formation and occlusion (Figure 1.3). Rupture 
of the lesion is responsible for the most acute complications of arthrosclerosis with as much as 
50 % of acute coronary syndromes and myocardial infarctions being caused by plaque rupture 
and resultant thrombosis (Epstein and Ross, 1999, Libby et al., 2002). 
 
 
Figure 1.3; Schematic of endothelial dysfunction, fatty-streak lesion, advanced lesion and lesion 
rupture in atherosclerosis adapted from (Epstein and Ross, 1999) 
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Aneurysms are a major concern in CVD. Aneurysms can be fatal themselves if they rupture, but 
they can also be sites for the formation of thrombus that lead to strokes. An aneurysm is a 
localised swelling or bulging of the blood vessel wall. The most common site for aneurysms to 
form is in the aorta, but they are widely seen at the base of the brain and can be found in any 
vasculature (Virmani et al., 1986). 
Aneurysm is the result of an injury overcoming the capacity of smooth muscle cells or 
adventitial fibroblasts to synthesise new ECM and repair the damage to the vessel (Jacob et al., 
2001). The balance between proteases and their inhibitors is temporally destroyed by the 
expression of matrix metalloproteinase genes and the secretion of enzymes from 
inflammatory cells (Jacob et al., 2001). 
Aneurysms of the artery are characterised by abnormal, localised or diffuse dilation of the 
arterial wall and can be caused by a range of conditions including but not limited to: 
atherosclerosis, that narrows and hardens the arteries weakening the walls; hypertension, that 
expands the vessel wall beyond its elastic limit; injury, that thins and weakens the arterial wall; 
congenital anomalies, where weaknesses are created or exist in the vessel wall as a symptom 
of a disease or disorder; or by ageing, where the vessel is weakened over time. 
Aneurysms can be congenital or acquired; the majority of adults with aneurysm suffer from 
the acquired condition (Virmani et al., 1986). Acquired aneurysms in children are most 
commonly due to Kawasaki’s disease, a disease that affects the lymph nodes. In adults, arterial 
aneurysms are commonly found alongside atherosclerosis suggesting that there could be a link 
between atherosclerosis and arterial aneurysm (Virmani et al., 1986). The cause of arterial 
dilation and aneurysms is widely debated with suggestions that it is directly caused by 
atherosclerosis. Others propose that weaknesses in the vessel wall could be present from 
childhood and that factors such as hypertension and atherosclerosis may only play a role in the 
rupture of an aneurysm (Virmani et al., 1986, Kamitani et al., 2000). 
There are many disease states that are involved in aneurysms. What is not clear is the actual 
role these different diseases have in aneurysm formation and rupture. This is further 
complicated by the observable differences dependent upon the location of the aneurysm in 
the vasculature. Arterial aneurysm is a progressive degenerative disease that, if left 
uncorrected, can result in rupture and in many cases death. 
It is likely that increased production of matrix degrading enzymes such as matrix 
metalloproteinases plays a key role in the pathogenesis of arterial aneurysm (Raffetto and 
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Khalil, 2008). The expression of matrix metalloproteinases in patients with aortic aneurysms 
has been observed to be significantly increased and transgenic animals with deficiencies in 
matrix metalloproteinases have been shown to be protected from experimentally induced 
aneurysm (Raffetto and Khalil, 2008).  
The most common matrix metalloproteinase, MMP-9, has been shown to be the most 
abundantly expressed enzyme in aneurysms and is mainly produced by aneurysm-infiltrating 
macrophages (Raffetto and Khalil, 2008). Matrix metalloproteinases have been observed to 
prevent the contraction of SMCs; SMC contraction has been shown to contribute to the 
structural integrity of the arterial wall. Matrix metalloproteinase have also been shown to 
induce inhibition of SMC contraction and may therefore contribute to further weakening of the 
arterial wall (Raffetto and Khalil, 2008).  
There are a range of treatment methods dependent upon the location of an aneurysm. Aortic 
or peripheral aneurysms tend to be treated by replacement with bypass grafts. Intracranial 
aneurysms are treated with surgical clips or endovascular coiling. Endovascular coiling involves 
placing a platinum coil in the aneurysm via a catheter, resulting in clot formation which, if 
successful, eliminates the aneurysm.  
 
1.4 Approaches to developing small diameter blood vessel 
replacements  
1.4.1 Autografts 
 
An autograft is the transplantation of a tissue from one area of a patient’s body to another. In 
the case of vascular surgery, an artery or vein is removed from a site of easy access and used 
for the purposes of a bypass or to repair damage, as in the case of an aneurysm. An autograft 
is a surgeon’s preferred option and is the gold standard to which all other vessel replacements 
are compared (Reix et al., 2000, Arima et al., 2005, Leask et al., 2005, Wang et al., 2007c). The 
choice of vessel for autograft is dependent upon the intended use. The standard vessel used 
for the repair of a popliteal artery aneurysm is the saphenous vein (Reix et al., 2000). In the 
case of a coronary artery bypass, the graft of choice is the left internal thoracic artery, also 
known as the internal mammary artery (Figure 1.4) (Arima et al., 2005, Baguneid et al., 2006).  
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Figure 1.4; Schematic of bypass graft 
 
Bypass grafts are placed at as shallow an angle as is possible when being implanted as to 
reduce the disturbance to the flow of blood which has been linked to the development of 
several CVDs. It is possible to use the saphenous vein for coronary bypass surgery but the use 
of arteries is favoured where possible. Comparison studies have shown that saphenous vein is 
more prone to intimal thickening and atherosclerosis than arterial grafts, such as the internal 
mammary artery; arterial grafts also have a higher rate of long-term patency (Uydes-Dogan et 
al., 1996, Taki et al., 1997). Current saphenous vein autografts suffer from a 30 % to 50 % 
occlusion rate after ten years, whilst arterial grafts have a failure rate of around 5 % in the 
same period (Uydes-Dogan et al., 1996, Taki et al., 1997, Wang et al., 2007c). The use of 
saphenous vein is more complex and prone to failure as the tributaries to the vein have to be 
tied off and the valves removed (Arima et al., 2005, Leask et al., 2005). Arteries have also been 
shown to respond to vasodilators, an important medication post-operatively to treat graft 
spasm that has been related to an increased risk of morbidity and mortality (Uydes-Dogan et 
al., 1996). 
Autografts are known to fail due to surgical difficulties. They are often subject to intimal 
thickening at the anastamosis due to graft-wall shear stress and surgical trauma at the points 
of suture (Leask et al., 2005). Autologous vessel transplant still remains the gold standard in 
vascular surgery; the main problem with autografts is the limited availability of viable grafts as 
a third of patients are not suitable for autografts due to pre-existing vascular disease or prior 
graft harvest (Wang et al., 2007c, Cittadella et al., 2013).  
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1.4.2  Allografts 
 
An allograft is the transplantation of a tissue from a genetically non-identical member of the 
same species.  Allografts are more often thought of in terms of whole organ transplantation. 
The lack of available autografts means that alternative graft material must be considered for 
vascular replacement. Allograft transplantation is the next logical step as it provides an 
endothelium lined human biological conduit with the correct bio-mechanical properties 
(Carpenter and Tomaszewski, 1998, Fahner et al., 2006). 
Fresh vascular allografts are, however, subject to frequent and early failure (Callow, 1996, 
Bilfinger et al., 1997, Carpenter and Tomaszewski, 1998, Lamm et al., 2001, Fahner et al., 
2006). Fresh allografts have been shown to be unusable as they suffer from rapid rejection and 
failure due to immune rejection (Callow, 1996). One of the main limitations to the use of 
allografts is tissue sourcing, unlike an autograft that can be collected just before implantation, 
an allograft has to be collected, transported and possibly stored for long periods of time. Using 
a range of techniques allografts have been preserved and many have been reported to 
demonstrate superior performance compared to fresh allografts, but in many cases still suffer 
from early rejection and failure (Callow, 1996).  
Several techniques have been investigated for the storage of allografts, the favoured method 
being cryopreservation. Cryopreservation unlike cold storage and freezing is intended to 
maintain cell viability and offer long term storage (Callow, 1996, Fahner et al., 2006). Clinical 
trials using cryo preserved vascular allografts have highlighted several problems. A number of 
studies have demonstrated that immune-rejection has a major role in graft failure. Allografts 
have been demonstrated to produce a strong cell-mediated immune response; endothelial 
cells being the locus of strong antigenicity (Carpenter and Tomaszewski, 1998). The failure of 
allografts has been related to the inability of the endothelium to modulate the adherence of 
leucocytes (Bilfinger et al., 1997).  
Even with a great deal of care, the best preservation techniques will not maintain normal cell 
function (Callow, 1996). Where the endothelium is lost, there is an increased infiltration of T-
cells and intimal thickening related to the loss of endothelial cell regulation of smooth muscle 
cells (Carpenter and Tomaszewski, 1998, Zhou et al., 2009b). It has been suggested that 
cryopreservation may even accelerate graft occlusion due to non immunogenic mechanisms 
involved in fibrosis and the loss of contractile function (Miller et al., 1993). Poor patency rates 
and other associated complications have rendered cryopreserved saphenous vein, human 
17 
 
umbilical artery and other arterial allografts unacceptable for routine use (Baguneid et al., 
2006). In whole organ transplantation, great effort is taken to match the histocompatibility 
antigens of the donor and recipient to reduce the risk of transplant rejection. This has been 
applied in vascular grafts and has been shown to improve the patency rates of the allografts; 
this is not practicable due to demand and sourcing restraints (Carpenter and Tomaszewski, 
1998, Fahner et al., 2006). 
Immunosuppressive drugs have been explored in an attempt to prevent graft rejection. 
Immunosuppression and antibody cross-matching have been shown to lower the failure rates 
of allografts but the grafts still suffer from accelerated degradation and failure (Miller et al., 
1993, Randon et al., 2010). The problem with these approaches is that immunosuppression 
does not always eliminate rejection and the economic and health costs of long term 
immunosuppression make it unjustifiable for use with vascular allografts (Callow, 1996, Fahner 
et al., 2006).  
Initial attempts to overcome the problems of allografts used fixation to maintain ECM integrity 
and mask immunogenic antigens. This proved to be a problem as it was reported that fixation 
caused a loss of mechanical properties, in particular compliance, which resulted in aneurismal 
degradation of the scaffolds (Courtman et al., 2001, Conklin et al., 2002, Schaner et al., 2004). 
The main issue with fixation is that masking of the antigens does not completely remove the 
immune response. The antigens are still present, but just inaccessible until the vessel is 
naturally degraded overtime: this can possibly lead to a long-term inflammatory response 
(Courtman et al., 2001, Conklin et al., 2002, Schaner et al., 2004).  
 
1.4.3  Xenografts  
 
A xenograft is the transplant of tissue from one species to another. The ability to use animal 
tissue would remove the complications of graft sourcing. The use of animal tissues would 
however raise concerns, mainly rejection and interspecies disease transmission (Schaner et al., 
2004). Hyperacute rejection of a xenograft is an inevitable consequence of the transplant of 
tissue between phylogenetically distinct species (Platt et al., 1991). This means that any animal 
tissue that has foreign antigens will elicit an immune response and suffer rapid rejection. In 
theory, the immune response can be overcome by decellularising the scaffold to remove all 
the cells and so remove the antigens that cause the immune response. Decellularised 
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xenografts have shown potential in animal models as blood vessel replacements as they have 
been shown to retain the mechanical properties of the vessel once decellularised and are 
easier to source than auto/allografts (Martin et al., 2005, Roy et al., 2005, Williams et al., 
2009). Xenografts which have not been successfully decellularised would however still run the 
risk of immune rejection and carry the risk of interspecies disease transmission, such as 
porcine endogenous retroviruses (PERVs) and BSE; this concern may limit or prohibit xenograft 
use (Prabha and Verghese, 2008). 
 
1.4.4 Synthetic biomaterials 
 
The need for vascular grafts has created an interest in the use of synthetic polymers for tissue 
engineering such grafts. There are two main potential uses of polymers in vascular bypass 
grafts. The initial, and most widely reported, use of polymers is as vascular prosthesis devices. 
In a synthetic polymer vascular prosthesis, a biostable polymer is used to create a conduit that 
can be used to restore normal blood flow. The prosthesis does not interact with the body and 
does not allow for the restoration of normal vascular function or eventual integration with the 
body. The second use of synthetic biomaterials is in the creation of tissue engineering scaffolds 
that use bio-resorbable polymers that will eventually be replaced by natural ECM and have the 
potential to eventually restore normal vascular function. 
 
1.4.4.1 Prostheses  
 
The use of synthetic polymer vascular prostheses in the replacement of large blood vessels (>6 
mm) has been a success with polyethylene terephthalate (Dacron) and expanded polytera-
fluroethylene (ePTFE) grafts having a high level of patency after ten years (Hoerstrup et al., 
2001, Conklin et al., 2002, Bujan et al., 2004, Wang et al., 2007c). Dacron and ePTFE are bio-
stable polymers that are used to create grafts that have a long lifetime in the body. When 
Dacron and ePTFE are, however, used for small calibre grafts, they occlude due to platelet 
activation and thrombosis (Hoerstrup et al., 2001, Conklin et al., 2002, Bujan et al., 2004, Wang 
et al., 2007c, Desai et al., 2011). A wide range of patency rates have been reported for small 
diameter (<6 mm) Dacron and ePTFE prostheses dependent upon the location the graft was 
inserted and the use of anti-clotting agents; on average patency rates tend to be below 50 % 
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after five years (Wang et al., 2007c). Dacron fails due to intimal thickening and thrombosis at 
the point of attachment causing graft occlusion and failure (Conklin et al., 2002, Venkatraman 
et al., 2008). ePTFE does not interact well with blood, this has been shown to contribute to the 
formation of thrombosis and intimal thickening at the point of attachment (Xue and Greisler, 
2003).  
One of the major problems with synthetic grafts is endothelialisation; most reported results 
show ePTFE and Dacron grafts fail to develop a full endothelial layer, other reported results 
show the seeding of cells and the coating of scaffolds with materials such as fibrin allow for the 
development of an endothelium (Zilla et al., 1993, Bujan et al., 2004, Meinhart et al., 2005, 
Tatterton et al., 2012). The combination of synthetic and natural materials is addressed later in 
Section 1.4.4.3. Another major problem with biostable grafts is infection. Prosthetic grafts 
have been reported to have increased rates of infection compared to autografts that can lead 
to life threatening situations and can be difficult to treat (Cittadella et al., 2013). Stable 
synthetic grafts are also a problem in paediatrics as the vessel needs to be able to grow with 
the patient; this means that children given biostable grafts often need replacement surgery as 
they grow (Cittadella et al., 2013). 
There are a range of other bio-stable polymers that have a history of use in the body, such as 
polyurethane. Polyurethane has been tested as a vascular graft material as it can be made to 
match the compliance of a blood vessel, whereas Dacron and ePTFE grafts cannot (Xue and 
Greisler, 2003, Wang et al., 2007c, Venkatraman et al., 2008). Initial results showed that 
polyurethanes elongated and degraded over time. Initial attempts at vascular replacements 
with polyurethane lead to high rates of aneurysm and thrombosis compared to ePTFE and 
Dacron grafts (Desai et al., 2011). This lead to the development of polycarbonate, polyester 
and silicone based polyurethanes.  
It has been reported that polycarbonate based polyurethanes have better mechanical 
properties and are more resistant to hydrolytic and oxidative damage (Xue and Greisler, 2003, 
Venkatraman et al., 2008). Polyester based urethanes have been demonstrated to have good 
mechanical properties and blood compatibility (Soldani et al., 2010). Most polyurethanes, 
however, suffer from platelet adhesion leading to graft failure and this lead to the 
development of silicone based polyurethanes that are reported to have anti-adhesive 
properties (Taite et al., 2008, Soldani et al., 2010). These different based polyurethanes have 
also been mixed together to combine their different properties. It has been demonstrated that 
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bio-stable polymers tend to elicit a foreign body response by the recipient immune system and 
are known to cause mild inflammation (Figure 1.5) (Venkatraman et al., 2008).  
 
 
Figure 1.5; Schematic of foreign body response 
 
1.4.4.2 Regenerative 
 
An alternative to a bio-stable polymer is a biodegradable polymer which is broken down by 
enzymatic and hydrolytic action in the body. As biodegradable polymers are degraded by the 
body and removed, the source of any long-term foreign body response is eliminated. 
Biodegradation also allows for the formation of a fully functioning natural ECM which is 
preferential to a non-responsive polymer.  
For a polymer to be used as a tissue engineering scaffold the degradation products produced 
cannot cause a toxic or inflammatory response (Freed et al., 1994). A range of biodegradable 
polymers have been used in the lab and in animal models as vascular grafts; the most common 
biodegradable polymers are polyglycolic acid (PGA), polylactic acid (PLA) and poly(lactic-co-
glycolic) acid (PLGA) copolymers. PLA and PGA are broken down into lactic acid and glutamic 
acid which can then be metabolised by the body, other polymers tested include degradable 
polyurethanes, polycaprolactone and polydiols (Freed et al., 1994, Gunatillake and Adhikari, 
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2003, Yang et al., 2005, Martina and Hutmacher, 2007, Guelcher, 2008, Pankajakshan et al., 
2008, Pektok et al., 2008). There is concern over the breakdown of biodegradable polymers 
causing an increase in acidity and the lower pH causing a toxic effect. This lower pH also runs 
the risk that the degradation rate of the polymers could be increased by autocatalysis (Taylor 
et al., 1994, Hoerstrup et al., 2001, Hemmrich et al., 2008, Lee et al., 2009).  
The biodegradation characteristics of a polymer are affected by the glass transition 
temperature (Tg); as the Tg decreases, the degradation rate increases. The problem with 
changing the Tg to improve degradation is that the mechanical properties of a material are 
heavily influenced by Tg (Wu et al., 2006, Watanabe et al., 2009). Tailoring a polymer for 
mechanical and degradation properties is therefore complex and often involves compromising 
one of the resultant material’s properties.  
This is further complicated by the loss of mechanical properties as the polymer degrades (Xue 
and Greisler, 2003, Venkatraman et al., 2008). PGA, PLA, PLGA and polyurethanes have been 
shown to degrade too quickly under physiological conditions: this would lead to aneurismal 
dilation making them unusable without further modification (Pektok et al., 2008).  
Polycaprolactone has the required degradation and mechanical properties but suffers from 
chondrioid metaplasia, calcification, following on from a foreign body immune response 
(Pankajakshan et al., 2008, Pektok et al., 2008).  
There are a range of other polymers which are being explored such as poly (diol citrates) which 
are biphasic polymers which form tubular scaffolds. Their mechanical properties and 
compliance closely match that of a natural blood vessel: they are biodegradable and allow for 
cell attachment (Yang et al., 2005). Anti-thrombogenic materials that biodegrade have also 
been explored for engineering of vascular grafts; polyurethane based nano-composite 
polyhedral-oligomeric-silesquioxane-poly(carbonate-urea) urethane (POSS-PCU) is a leading 
example which has been shown to be biocompatible and have the correct biomechanical 
properties needed for a blood vessel graft having been used in lower limb vascular bypass 
grafts (de Mel et al., 2009, Ahmed et al., 2011, Cittadella et al., 2013). Attempts have been 
made to overcome the limitations of polymers by the addition of growth factors, adhesion 
ligands and anti-thrombogenic factors (Hoerstrup et al., 2001, Xue and Greisler, 2003, Bujan et 
al., 2004, Wang et al., 2007c, Venkatraman et al., 2008).  
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1.4.4.3 Composite materials 
 
There is a large amount of research in the literature in which Dacron has been coated with 
various combinations of collagen, heparin, fibrin, gelatine, and various growth factors and 
attachment ligands. There have been some positive experimental results in animals where a 
fully formed endothelium has been created, resulting in an increase in the patency rate of the 
grafts (Zilla et al., 1993, Meinhart et al., 2005). Some experimental results showed an increase 
in the patency of a graft; however, the graft still failed to form an endothelial layer and 
occluded (Venkatraman et al., 2008). There are cases in which hybrid composite materials 
have been made with other polymers to improve biocompatibility and to incorporate anti-
adhesive properties to improve patency as opposed to the development of an endothelium 
(He et al., 2005, Pankajakshan et al., 2008, Taite et al., 2008). 
 
1.4.5 Natural biomaterials  
 
Natural biomaterials can be used to create scaffolds for the tissue engineering of vascular 
grafts. Natural biomaterials have several advantages over synthetically derived biomaterials: 
they are more responsive to the surrounding environment, allow for easy integration and 
repair upon implantation, should exhibit little to no foreign body immune reaction and should 
allow for cellular remodelling of the graft (L'heureux et al., 1998, Boland et al., 2004). Natural 
biomaterials can contain ligands that can be bound by cell adhesion molecules  for the purpose 
of cellular adhesion and that can act as templates for cell growth, proliferation, migration and 
function (Schmidt and Baier, 2000).  
There are a wide range of natural biomaterials that could be used with the most obvious 
choices being those materials that comprise the ECM of a natural blood vessel. Collagen and 
elastin are the main constituents of the vascular ECM. Collagen provides strength against the 
rupture of the blood vessel and elastin provides the elastic recoil properties that resist 
elongation and deformation (Figure 1.6) (Buttafoco et al., 2006).  
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Figure 1.6; Schematic of the structure of collagen and elastin 
 
Fibrin is another obvious choice for use in scaffold creation as it can be derived from a 
patient’s own blood (Jockenhoevel et al., 2001).  On their own, natural biomaterials have a 
limited potential as they lack mechanical strength. This can be overcome by using 
combinations of natural materials to create composites that more closely resemble the ECM 
(L'heureux et al., 1998, Buttafoco et al., 2006). Unmodified natural materials are subject to 
rapid chemical and enzymatic degradation and so require the material to be modified prior to 
use (Schmidt and Baier, 2000). 
Cross-linking the naturally derived biomaterials increases the resistance to enzymatic and 
chemical degradation. There are several ways in which the natural materials can be cross-
linked. Glutaraldehyde has been used extensively for the cross-linking of materials but has 
several limitations: it can compromise the mechanical properties, it is cytotoxic and the 
treated material is prone to calcification (Schmidt and Baier, 2000, Buttafoco et al., 2006). 
Polyepoxy compounds (Denacol) can be used for cross-linking and are less cytotoxic than 
glutaraldehyde and have a reduced rate of calcification. A preferred method is cross-linking 
using dye mediated photooxidation. Photooxidation uses a dye photosensitiser, added to the 
biomaterial, which oxidises amino acids such as tryptophan, histidine, tyrosine, and 
methionine when exposed to visible light. The dye biomaterial mixture is exposed to the 
correct wavelength of light to trigger cross-linking; the level of cross-linking in the biomaterial 
is a result of the exposure time. Photooxidation has no toxic effects, is not known to calcify and 
has a limited detrimental effect on the properties of natural materials and biomechanical 
integrity of the vessel (Schmidt and Baier, 2000). 
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There are various methods by which natural scaffolds can be prepared. Foams, hydrogels and 
fibrous scaffolds can be created by a range of techniques. Freeze drying, gas expansion, 
knitting, weaving, and cross-linking can all be used to create scaffolds with different properties 
and structures. One area of current interest is electrospinning (Figure 1.7). Electrospinning of 
natural biomaterials creates a non-woven mesh that has fibre dimensions that closely 
resemble the natural structure of the ECM. It is possible to electrospin multiple materials at 
the same time and create a composite material. The non-woven mesh can then be modified 
and cross linked to improve mechanical properties and cellular interactions (Buttafoco et al., 
2006).  
 
 
Figure 1.7; Schematic of electrospinning. Reproduced from (Badami et al., 2006). 
 
Random topography is known to enhance cellular attachment, but this is not necessarily an 
advantage in scaffold design (Badami et al., 2006). Cells that attach to orientated scaffold are 
influenced by the underlying structure. The organisation, migration, proliferation and activity 
of cells has been shown to be changed by the orientation of the scaffold (Vitte et al., 2004, 
Murugan and Ramakrishna, 2007). The natural extracellular matrix in blood vessels is 
orientated in different directions in the different layers and so this is of importance for normal 
vessel and cellular function (Boland et al., 2004). 
Blood clot and thrombus formation are still a major problem with natural materials as platelets 
are activated by interaction with a number of these bio-molecules in normal wound healing. As 
such, a confluent layer of endothelial cells or anti-clotting agents are needed to prevent blood 
clot formation (Boland et al., 2004). Nonetheless, natural materials have an advantage with 
regard to cellular interactions: fibronectin, vitronectin and laminin mediate contact between 
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endothelial cells and collagen. The use of these and other of bio-molecules has been shown to  
aid in the formation of a confluent endothelium (Dixit et al., 2001). Another method is to seed 
cells on to the scaffold. Cell seeding of natural scaffolds has been shown to enhance long-term 
function, prevent thrombus formation and allow the graft to develop into a responsive living 
tissue (Schmidt and Baier, 2000). 
One concern in the use of natural biomaterials is tissue shrinkage. As the cells interact and 
remodel the biomaterial, it has been shown to contracted and shrink. In vivo, this should be 
less of a problem but for in vitro, production and development may prove to be a major 
concern (Jockenhoevel et al., 2001). Other concerns about the use of biomaterials and cells 
include: intimal thickening, due to a lack of regulation of smooth muscle cell proliferation; cell 
sourcing; the sourcing of the natural biomaterial and the time taken to grow sufficient 
numbers of cells and seed the scaffolds. Many of the biomaterials used in laboratories are 
derived from animals and could carry disease or elicit an immune response. Some natural 
biomaterials such as fibrin can easily be isolated from a patient, while the collection of 
collagen and other materials is more complex (L'heureux et al., 1998, Boland et al., 2004, 
Hasegawa et al., 2007). 
Natural biomaterials can be useful as scaffolds, but a large focus has been placed on their use 
with synthetic scaffolds to improve cellular interactions and increase cell migration and 
proliferation (Dixit et al., 2001, Hasegawa et al., 2007). Fibrin is an example of a natural 
biomaterial that has been added to synthetic polymer scaffolds to create composites, in which 
the fibrin has been used to promote cell migration and proliferation (Hasegawa et al., 2007, 
Tschoeke et al., 2009). This method can be used to overcome the problems with mechanical 
properties but does not address the problems of sourcing and thrombogenesis. 
 
1.4.6 Cell derived replacements 
 
Instead of using a scaffold to tissue engineer a small diameter blood vessel, it has been shown 
that an alternative is to tissue engineer a scaffold directly from cells. A construct composed of 
cells surrounded by secreted ECM has the advantage of being highly responsive, of being able 
to self-repair, remodel and react according to environmental stimuli (L'heureux et al., 1998). 
Tissue engineered blood vessels using cells have been produced by forming cell sheets or by 
the template layering of cells. In cell sheet tissue engineering, cells are grown in conditions 
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that promote the production of ECM, for example, in ascorbic acid to promote collagen 
synthesis. The cells are cultured until they have formed a sheet of cells bound in ECM proteins. 
The cell sheets are then rolled on to porous tubes and cultured to allow for fusion into 
cohesive tissues (Figure 1.8). Many different cells types, different sources of cells, different 
growth techniques and handling methods have been explored in order to develop cell-based 
replacements; most follow the similar method of growing and rolling cell sheets to form tubes. 
 
 
Figure 1.8; Schematic of cell sheet formation of replacement blood vessel 
 
To create an anti-thrombogenic surface, endothelial cells have been seeded on the inner layer 
of the cell sheets to create the lumen (L'heureux et al., 1998, Isenberg et al., 2006, L'Heureux 
et al., 2007). Konig et al. and L’Heureux et al. used fibroblasts to create cell sheets (L'heureux 
et al., 1998, L'Heureux et al., 2007, Konig et al., 2009) Isenberg et al. used both smooth muscle 
and fibroblast cells to create different cell sheets (Isenberg et al., 2006).  L’Heureux et al. 
demonstrated how multilayered vessels could be created by rolling multiple cell sheets 
together (L'heureux et al., 1998, L'Heureux et al., 2007). This construct was shown to have 
burst pressure properties similar to natural arteries. The construct was, however, not ideal as 
the layers were composed of fibroblasts which are typically not found in the medial layer. 
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Konig et al. created an internal membrane free of viable cells by drying out the internal 
fibroblast cell sheet. A new layer of fibroblast cells was then rolled over the initial construct to 
create the adventitia and endothelial cells were seeded onto the construct to create a 
confluent endothelium (Konig et al., 2009). At the time of implantation, it was shown that 
these tissue engineered vessels had burst pressures similar to native arteries. Furthermore, the 
compliance of the vessels was significantly lower at the time of implantation, but after six 
months the vessel had achieved a compliance match (Konig et al., 2009). 
Isenberg et al. reported the creation of a cell sheet of smooth muscle cells to mimic the media 
layer and a sheet of fibroblasts to create the adventitia. The two layers were allowed to fuse 
and endothelial cells seeded to the inside of the vessel to create the lumen (Isenberg et al., 
2006). The vessel produced by Isenberg et al. was shown to be anti-thrombogenic and had a 
similar burst pressure to native arteries. Gauvin et al. showed that the mechanical properties 
of these cell sheets can be further improved by co-culturing the two cell sheets together into 
one larger sheet which was then rolled up leading to a denser ECM (Gauvin et al., 2010). 
A compliance mismatch between the tissue engineered blood vessels and native artery has 
been reported for several of the cell-based sheet approaches.  In tissue engineered vessels this 
is a major problem as compliance mismatch has been attributed to the development of intimal 
hyperplasia (Isenberg et al., 2006, L'Heureux et al., 2007). The major limitation of cell sheet 
tissue engineering of blood vessels is the quality of the ECM produced. The ECM in the cell 
sheets lacks the correct fibre alignment that gives native blood vessels some of their 
biomechanical properties; the ECM produced by the cell sheets is also composed of different 
amounts of ECM proteins compared to natural tissue, often having lower levels of elastin. This 
difference is important and is likely the cause of the compliance mismatch (L'heureux et al., 
1998, Isenberg et al., 2006, Konig et al., 2009, L'Heureux et al., 2007). The differing levels of 
different ECM components highlights the importance of the source of cells: the same cell type 
from different locations may produce different quantities and types of ECM (Gauvin et al., 
2010). 
Recent studies have focused on cell and tissue culture using biomechanical stimulation. Using 
bioreactors, Hoerstrup et al demonstrated the acceleration of tissue formation using a 
pulsatile flow system similar to the native tissue’s biomechanical environment (Hoerstrup et 
al., 2000, Barron et al., 2003). This produced a tissue that when analysed showed histological 
features closer to the native tissue than when compared to tissue without mechanical 
stimulation (Hoerstrup et al., 2000, Hoerstrup et al., 2001, Barron et al., 2003).  
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It has been reported that dynamic mechanical conditioning of tissue cultures leads to an 
improvement in the mechanical properties and histological organisation of tissues (Seliktar et 
al., 2000, Sodian et al., 2002, Barron et al., 2003). Dynamic mechanical stimulation may 
overcome some of the problems associated with cell-based techniques and may even speed up 
tissue growth. However, the need to create an enclosed bioreactor capable of the correct 
mechanical stimulation vastly increases the risk of infection and the sensitivity of the culture 
environment. 
The templating methods involve the ordered layering of cells to create small diameter tubes. 
This method often uses spheroids of cells to layer and create the tissue engineered vessels 
(Figure 1.9) (Norotte et al., 2009, Mironov et al., 2009). The advantage of using a template to 
order the cells is that a vessel of varying shape and size can be constructed with in-built 
branching. The disadvantage is that it is hard to maintain sterility in the templating process 
(Norotte et al., 2009, Mironov et al., 2009).  
 
 
Figure 1.9; Schematic of cell printing 
 
An alternative approach to the creation of arterial bypass grafts is to use the body’s natural 
actions to create an autologous vessel. A foreign material implanted into the body will produce 
a host response that will result in the formation of a cellular capsule that surrounds the 
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material (Campbell et al., 1999, L'Heureux et al., 2007). It has been shown that by implanting a 
silastic tube into the peritoneal cavity of rats that a layer of myofibroblasts, a collagen matrix 
and a mesothelium monolayer will be formed on the outside of the tube after two weeks 
(Campbell et al., 1999). It was shown that the tube could be removed and the resultant layer 
of cells inverted to create an anti-thrombogenic mesothelium. In rats, this approach produced 
a replacement vessel that remained patent for four months (Campbell et al., 1999). The graft 
grown in the body potentially overcomes the need to isolate and expand the cells from 
biopsies. However, the graft is composed of myofibroblasts and mesothelial cells, not smooth 
muscle and endothelial cells. The resultant  vessel also lacks the structure and biomechanical 
properties found in the native blood vessel (Campbell et al., 1999).  
There are two main problems with the use of cell-based tissue engineered constructs. Cell 
sourcing is a major problem as the availability of autologous vascular cells is limited due to 
poor vessel quality in patients needing vascular grafts. The isolation and purification of 
vascular cells is limited by technical ability and the isolated cells have a poor proliferative 
capacity and have been shown to change phenotype when cultured in vitro (Krenning et al., 
2008). The isolation of autologous cells also requires that a blood vessel or skin biopsy be 
taken and this introduces a new site of trauma (Krenning et al., 2008). 
The sourcing of cells from bone marrow and the extraction of progenitor cells from the blood 
is a possible solution to this problem, but this is still in the early stages of investigation 
(Krenning et al., 2008). The main problem with the in vitro use of cells is the time taken to 
culture and grow the cells needed for any application. The growth of cell sheets takes time as 
does the development of spheroids. This may be acceptable when time is not an issue but in 
the case of trauma and emergency situations, where time is a factor, the isolation and growth 
of cells is not viable (L'heureux et al., 1998, Krenning et al., 2008, Isenberg et al., 2006, 
L'Heureux et al., 2007, Norotte et al., 2009, Konig et al., 2009). 
 
1.4.7  Decellularised scaffolds  
 
The immunological problems associated with the use of allograft and xenograft tissues and the 
structural limitations of the biomaterial scaffolds have lead to the development of 
decellularised scaffolds. The idea is that by removing the cells from natural tissue the 
immunogenic molecules will be removed whilst maintaining the structure of the natural ECM 
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(Wang et al., 2007c). Since a decellularised vessel will have the same structure as the natural 
vessel, it should have similar mechanical properties and be resistant to rupture. The ideal 
vessel for decellularisation and for use in arterial bypass is an artery as its mechanical 
properties and compliance will most closely match that of the natural vessel (Conklin et al., 
2002, Schaner et al., 2004). 
Decellularised tissues may also serve as structural supports, providing attachment sites for 
recellularisation and a reservoir for growth factors and other bio-molecules. It is possible to 
decellularise a tissue in many ways: chemical, mechanical and enzymatic techniques can be 
used to remove the cells, most commonly by cell lysis (Figure 1.10) (Schmidt and Baier, 2000). 
The cellular debris then needs to be removed from the scaffold as cellular components and 
lipids are known to cause calcification and an inflammatory response (Schmidt and Baier, 
2000). Washing procedures are used to remove the cellular debris left following cell lysis; 
protease inhibitors may be used during washing to prevent degradation of the extracellular 
matrix and DNase and RNase enzymes are used to remove residual encoding DNA and RNA 
(Figure 1.10) (Meyer et al., 2006, Wilshaw et al., 2008a).  
 
 
Figure 1.10; Schematic of decellularisation process 
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Platelet activation, thrombus formation and intimal hyperplasia are problems that have been 
observed with the use of decellularised scaffolds in animal models (Patel et al., 2007, Wang et 
al., 2007b, Cai et al., 2009, Zhou et al., 2009b). The lack of an endothelium activates platelets, a 
natural response to damage to the blood vessel and exposure of the underlying ECM; this 
causes blood clotting and thrombus formation (Rendu and Brohard-Bohn, 2001, Conklin et al., 
2002, Wang et al., 2007b, Zhou et al., 2009b, Zhou et al., 2011). 
The lack of endothelial cells and the release of inflammatory products may result in the 
uncontrolled proliferation of SMCs resulting in intimal hyperplasia (Cai et al., 2009). It has been 
shown that cells are slow to re-cellularise acellular scaffolds in vivo, mainly migrating through 
the scaffold at its cut edge (Simionescu et al., 2006). It has been reported that the arterial 
geometry and structure change due to the removal of the cells causing a release in the pre-
stresses present in the normal tissue. This has been shown to be reversed under pressure 
when the voids left by the removed cells are filled with fluid (Roy et al., 2005).  
It has been shown that there is no significant difference between the burst pressure, stress 
modulus and compliance of decellularised vessels compared to natural vessels (Schaner et al., 
2004, Martin et al., 2005, Roy et al., 2005, Wilshaw et al., 2008a, Gui et al., 2009). It has, 
however, been reported that there may be an increase in the stiffness of the vessels following 
decellularisation (Roy et al., 2005, Williams et al., 2009). This is likely due to small changes in 
the ECM geometry and structure as a result of the removal of the cells. An increase in fibre 
mobility and a loss of collagen crimping has been associated with an increase in vessel stiffness 
(Williams et al., 2009).  
The burst pressure of common femoral arteries decellularised using the same method 
described in Section 2.2.3 has been shown to have no significant difference compared to the 
native human arteries with burst pressures of 3214 mmHg and 2562 mmHg respectively 
(Wilshaw et al., 2011). Using the same method it was also found that following tensile testing 
there was no significant difference in the transition stress and strain, ultimate tensile strength 
and failure strain in either circumferential or axial direction between decellularised and native 
arteries (Wilshaw et al., 2011). The same study also showed there was no significant difference 
in the compliance of the decellularised and native arteries with dilation of 9.8% and 7.9% 
respectively at 200 mmHg (Wilshaw et al., 2011). Others have shown that decellularisation of 
other tissues such as pericardium resulted in no ultrastructure damage and that there was no 
significant effect on fracture tension and percentage strain at fracture compared to fresh 
tissue (Wilson et al., 1995). It is believed that the early mechanical failures of decellularise 
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tissue was due to damage to the ECM and the use of cross-linking agents. It has been 
demonstrated that cross-linking tissue with glutaraldehyde or other cross linking agents failed 
to preserve tissue mechanics (Wilson et al., 1995). 
There has also been reported a loss of some ECM components due to the different 
decellularisation methods used (Heine et al., 2011). At the same time, different techniques 
have been shown not to affect the majority of natural proteoglycans and growth factors 
present in the scaffold (Courtman et al., 1994, Badylak, 2004).  
The source of natural tissue for the creation of a decellularised scaffold is of importance. 
Arteries and veins can be obtained from allogeneic or xenogeneic donors. It has been reported 
that  allografts elicit little to no immune response once decellularised, as the immune response 
is instigated by antigens on the cell surfaces (Allaire et al., 1997, Courtman et al., 2001). The 
response observed once decellularised allografts have been implanted in animals has been 
reported to be similar to the inflammatory response observed for autografts and to be 
significantly less than for fresh allografts (Martin et al., 2005, Ketchedjian et al., 2005).  
Acellular xenografts have demonstrated a range of different results. Some investigations into 
the use of xenografts have reported that xenografts elicit an immune response once 
decellularised due to interspecies differences in the primary structure of the extracellular 
matrix components (Allaire et al., 1997, Courtman et al., 2001, Takagi et al., 2006, Bergmeister 
et al., 2008). Once implanted in animal models, decellularised xenografts have been shown to 
develop deposits of immunoglobulin, IgM and IgG, with the presence of macrophages (Allaire 
et al., 1997, Courtman et al., 2001, Cai et al., 2009). The monocytes have been shown to cause 
damage to the elastin and release factors that promote SMC proliferation causing intimal 
hyperplasia (Courtman et al., 2001, Cai et al., 2009). An immune response to decellularised 
xenografts in animals has also been shown to result in the formation of mural thrombus and 
lead to vessel occlusion (Courtman et al., 2001). 
It has been reported that the immune response to decellularised xenogeneic tissue can be 
overcome by cross-linking (Bayrak et al., 2010). Others report a lowering of immune response 
but attribute it to the cross-linking preventing the penetration of macrophages and other 
inflammatory cells into the tissue and preventing the degradation (Chang et al., 2005, 
Bergmeister et al., 2008). It has also been reported that decellularised xenogenic grafts in 
animal models elicit no immune response (Conklin et al., 2002, Wang et al., 2007b, 
Bergmeister et al., 2008). Whilst there are reported interspecies differences in the primary 
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structure of the ECM components, it is also reported that major ECM components such as 
collagen and elastin are highly conserved in higher species and so should not cause an immune 
response (Conklin et al., 2002, Wang et al., 2007b).  
The range of results obtained in the analysis of decellularised allogenic and xenogenic grafts 
can be explained by the different efficiencies of the decellularisation protocols used. An 
inability to remove cellular debris can lead to an immune response and inflammation 
associated with the danger signals released by the dead cells remaining in the scaffold 
(Badylak, 2004). Some decellularisation protocols will remove more cellular debris than others, 
and different species will have slightly different vessel sizes and structures. A vessel harvested 
from one location will have a different ECM structure and composition compared to a vessel 
from a different location (Ketchedjian et al., 2005, Rieder et al., 2006, Williams et al., 2009). 
Calcification is also a problem associated with inadequately decellularised scaffolds as lipid and 
cellular remnants provide nucleation sites for the formation of calcium crystals (Courtman et 
al., 1994). Developments made in tissue engineering have presented an alternative method of 
producing a decellularised scaffold.  Natural vessel like structures can be formed by growing 
cells on biodegradable polymer scaffolds or by using rolled cell sheets in vitro (Quint et al., 
2012). This artificially produced scaffold may then be decellularised to leave the extracellular 
matrix produced by the cells behind (Quint et al., 2012). The artificial scaffolds have the 
advantage of being produced using human cells to result in allogeneic tissue and so eliminate 
the problems associated with sourcing allografts.  
When implanted into animal models, decellularised scaffolds have been shown to exhibit ECM 
turnover and the formation of endothelial-like structures on the implant surface (Dahan et al., 
2012). Reported attempts to overcome thrombogenesis have involved the re-cellularisation of 
the grafts in vitro and the use of anti-clotting factors to prevent clot formation, growth factors 
and adhesion ligands to improve cell migration and proliferation, and use of antibodies to 
catch and bind progenitor cells from the blood stream, all with the aim to improve re-
endothelialisation of the scaffold (Patel et al., 2007, Wang et al., 2007b, Cai et al., 2009, Zhou 
et al., 2009b).  
The use of decellularised scaffolds seeded with cells before implantation has been 
demonstrated in several animal and preclinical studies. The patency and lifetime of the grafts 
have been significantly improved by the pre-formation of an endothelium (Zhao et al., 2010, 
Heine et al., 2011). Cell seeding has also been shown to reduce the problem of calcification in 
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decellularised grafts known to calcify (Koenneker et al., 2010). Anti-clotting agents such as 
heparin have been added to decellularised grafts and this has the observed effect of lowering 
the level of platelet adhesion to the graft and slowing the onset of thrombosis formation (Zhou 
et al., 2011). A major problem facing vascular grafts is post-surgical infection. Decellularised 
grafts perform well here, having been shown to be more resistant to infection than synthetic 
materials such as Dacron and ePTFE (Jernigan et al., 2004, Yow et al., 2006). 
 
1.4.8 Advantages and limitations to current approaches to vascular tissue 
engineering 
 
The search for a viable replacement for small diameter blood vessels has been compared to 
the search for the “holy grail”. None of the above methods have been successful in producing 
a graft that is able to match all the requirements of a small diameter vascular graft. Autografts 
remain the gold standard for blood vessel replacements. However, their limited availability 
and associated complications has lead to the need to develop other sources of graft material. 
Allografts are the next logical choice but, due to the immune response associated with foreign 
tissues and the unjustifiable costs and risks of immuno-suppression, are severally limited. 
Synthetic materials have potential as materials for future use in vascular tissue engineering; 
however, there remain significant obstacles that need addressing before any future 
application. A synthetic material that allows for cell attachment and growth that maintains 
patency and sterility and has the required mechanical properties is needed but is currently 
unavailable.  
A lack of processability, mechanical strength and tailorability limit any potential use of natural 
biomaterials. Natural biomaterials have potential when used in conjunction with synthetic 
materials to provide a composite scaffold for tissue engineering a replacement blood vessel, 
but problems with thrombus formation and platelet activation still need to be addressed. 
Cellular derived scaffolds can be made to closely resemble natural blood vessels; the problem 
is the sourcing of the cells and the time required to construct the artificial blood vessel.  
A decellularised scaffold has the required biocompatibility and mechanical properties for a 
blood vessel replacement, but the lack of an endothelium has been shown to lead to 
hyperplasia and thrombosis. 
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Allogeneic sourcing of tissues for decellularisation could pose a problem due to limited 
availability. This could be overcome by the use of xenogeneic tissue which results suggest, with 
the correct decellularisation technique, could provide a scaffold that does not elicit an immune 
reaction. There are also problems to overcome with the use of xenogeneic tissue. Failure to 
correctly decellularise the scaffold could result in severe immune rejection and interspecies 
disease transmission is still a concern. As long as a method for preventing thrombus formation 
and intimal hyperplasia can be found, decellularised scaffolds have the potential to provide 
“off the shelf” vascular grafts that will maintain functionality and long term patency.  
 
1.5 Development of decellularised small diameter blood vessel grafts 
 
Decellularised grafts are a promising candidate for a viable long-term small diameter blood 
vessel graft. There are a wide range of decellularisation methods that could be used to develop 
decellularised small diameter blood vessel grafts. The major problems associated with 
decellularised materials are disease transmission, sterilisation and thrombosis formation.  
 
1.5.1 Decellularisation methods 
 
Physical, chemical and enzymatic techniques can be used to decellularise a tissue. Physical 
techniques include sonication and agitation, mechanical compression, high pressure 
environments and freezing. These techniques are designed to physically cause the lysis of the 
cells within the natural tissue. Freezing creates ice crystals within the cells to rupture the cell 
membrane. High pressure and compression cause cell deformation and cell death (Gilbert et 
al., 2006). Sonication and agitation have been demonstrated to aid and improve the 
decellularisation of tissues. Chemical and enzymatic techniques rely upon the use of a 
chemical reaction or enzymatic cleavage that acts to disrupt cell membranes. 
Early attempts at decellularisation concentrated on the use of freezing techniques and 
enzymatic washes. Freezing techniques were shown to be limited as the rate of temperature 
change had to be very carefully controlled to rupture the cells but not cause extensive damage 
to the ECM (Gilbert et al., 2006). A number of studies have investigated the use of enzymes 
such as trypsin for the removal of cells from tissues; whilst the enzymes have been shown to 
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successfully remove cells, considerable damage to the ECM has been reported (Yang et al., 
2005). 
One of the most successful techniques uses hypotonic and hypertonic solutions to change the 
osmotic pressure within the cell, disrupting the cell membrane and killing the cell (Meyer et al., 
2006, Wilshaw et al., 2008a). Hypotonic and hypertonic washes are however unable to remove 
cellular debris and so other washing steps are needed to remove all cell remnants. There are a 
range of detergents that can be used to aid in the removal of cellular debris; Triton X-100 and 
sodium dodecyl sulphate (SDS) are common choices for use; Triton X-100 and SDS are used to 
remove lipids, proteins and DNA (Schaner et al., 2004, Chang et al., 2005, Martin et al., 2005, 
Roy et al., 2005, Meyer et al., 2006, Rieder et al., 2006, Wilshaw et al., 2008a, Bergmeister et 
al., 2008, Gui et al., 2009, Williams et al., 2009) other detergents such as N-lauroyl sarcosinate 
and 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) have also been 
used to remove cellular debris (Ketchedjian et al., 2005, Gilbert et al., 2006).  
Triton X-100 is a non ionic detergent that will disrupt lipid-lipid and lipid-protein interactions 
but not affect protein-protein interactions as such that the ECM should not be affected by its 
use. Triton X-100 has been used with differing degrees of success in cellular removal 
dependent upon the tissue being decellularised. Studies have shown that the use of Triton X-
100 did not result in a fully decellularised blood vessel even after prolonged treatment (Gilbert 
et al., 2006).  
Ionic detergents, such as SDS, are known to disrupt protein-protein interactions and have been 
shown to successfully solubilise nuclear and cytoplasmic membranes (Gilbert et al., 2006). This 
use of SDS has the potential to disrupt and damage the ECM. The action of SDS has been 
shown to be concentration dependent: damage to the ECM increased as the concentration 
and time period over which SDS was used increased (Courtman et al., 1994, Grauss et al., 
2005). Low concentrations of SDS have been reported to successfully remove cellular debris 
(Rieder et al., 2004, Gilbert et al., 2006, Koenneker et al., 2010). There are however concerns 
over residual detergent left in the decellularised material causing cytotoxicity effects 
(Ketchedjian et al., 2005, Wilshaw et al., 2008a). It has also been argued that damage to the 
ECM is responsible for poor cell in growth and toxic effects as opposed to detergent toxicity 
(Gratzer et al., 2006). 
Many early stage attempts at decellularisation resulted in damage to the ECM as the solutions 
used did not contain protease inhibitors. The ECM has the potential to be degraded during 
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decellularisation by the proteases released from the lysed cells. To overcome protease 
degradation of the ECM it has been suggested that protease inhibitors such as disodium 
ethylenediaminetetra acetic acid (EDTA) should be added to the wash solutions used during 
decellularisation. 
 
1.5.2 Sterilisation & Disease transmission 
 
Transmission of infectious agents is a major risk in the use of any naturally derived biomaterial. 
The risks can be reduced by screening the tissue source, but the transmission of undetected 
agents or any contamination from processing requires a terminal sterilisation step and the 
removal of all coding DNA. There are a number of different techniques that can be used for the 
sterilisation of soft tissues; gamma-irradiation, ethylene oxide and peracetic acid have been 
shown to be effective in removing bacteria, viruses, spores and fungi. 
Gamma-irradiation has been shown to produce structural damage to biological tissues, causing 
cross-linking of collagen fibres and a reduction in mechanical properties (Badylak et al., 2009). 
Ethylene oxide has been observed to cause structural damage, but there are major concerns 
about the safety of its reportedly mutagenic reaction products (Lucas et al., 2003, Badylak et 
al., 2009). Both gamma-irradiation and ethylene oxide have been widely used in the 
sterilisation of medical products and devices. 
Peracetic acid, also known as peroxyacetic acid, is a colourless liquid that has the chemical 
formula CH3CO3H. Peracetic acid is ideal for use as an antimicrobial agent as it has a high 
oxidising potential (Fraise, 1999, Lomas et al., 2003, Freytes et al., 2004, Kitis, 2004, Hodde et 
al., 2007, Zanetti et al., 2007). Microorganisms are killed by oxidation and the subsequent 
disruption of their cell membrane, via the hydroxyl radical (•OH). The radical will react with 
any oxidisable compound in its vicinity and can damage virtually all types of macromolecules: 
carbohydrates, nucleic acids, lipids and amino acids (Fraise, 1999, Hodde et al., 2007, 
Vandekinderen et al., 2009a). This means that peracetic acid has the potential to damage the 
ECM. It has been reported that peracetic acid will not remove or affect collagen; it has also 
been reported that peracetic acid will affect or remove collagen in particular collagen IV, and 
elastin in the ECM (Huang et al., 2004, Derham et al., 2008). 
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The antimicrobial properties of peracetic acid have been known for some time, but recently 
there has been an increasing interest in the potential for peracetic acid as a sterilising agent. 
This is due to its potential for easy use with limited residual contamination. Peracetic acid 
breaks-down into hydrogen peroxide and acetic acid both of which are non-toxic and can be 
metabolised by the body (Fraise, 1999, Kitis, 2004). This makes peracetic acid a preferred 
choice over other sterilising agents that have toxic break-down products (Cowan et al., 1993, 
Maffei et al., 2005, Vandekinderen et al., 2009a, Vandekinderen et al., 2009b).  
One major concern in the use of decellularised tissue is the potential for the transmission of 
diseases , such as HIV, or cross species transmission of viruses such as porcine endogenous 
retro viruses (PERVs)(Kallenbach et al., 2004). Some studies have shown that up to 2 % of 
vascular DNA can survive some decellularisation processes (Kallenbach et al., 2004, Gilbert et 
al., 2009).To prevent the transmission of viruses or the risks associated with leaving encoding 
DNA and RNA behind, DNAse and RNAse enzymes are used in decellularisation processes to 
breakdown and destroy any coding DNA or RNA (Brody and Pandit, 2007).  The removal of RNA 
and DNA also removes a potential nucleation point that can lead to calcification. 
 
1.6  Thrombus formation  
 
Thrombosis can be caused by the composition of the blood, changes to the blood vessel wall 
or by changes to the flow of blood. Hypercoagulability or thrombophilia is caused by 
congenital/genetic disorders or by acquired disorders such as or in the case of autoimmune 
conditions that change the composition of the blood and cause increased blood clotting. 
Disturbances in the flow of blood, particularly at points of injury and vessel compression, can 
cause stagnant blood to coagulate. Damage or dysfunction of the endothelium is the major 
cause of thrombus formation following injury or surgical interventions and is associated with 
several disease states (Kroll and Schafer, 1989, Wu and Thiagarajan, 1996, McNicol and Israels, 
2003). 
Blood clotting is one of the most complex events in nature with a careful balance needing to 
be found between the prevention of blood clotting in healthy blood vessels and the need to 
trigger rapid haemostasis in the result of injury or trauma. Blood coagulation is a highly 
conserved process throughout biology. Mammals all have a blood coagulation pathway that 
involves both a cellular (platelet) and protein (coagulation factor) component. Blood clotting 
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involves a wide range of cellular, protein and enzymatic actions to result in the formation and 
maintenance of a blood clot: the human blood clotting pathway is one of the most widely 
studied in biology and yet is still not fully understood. 
In a healthy individual, the main concern regarding the implantation of any foreign material is 
the formation of a thrombus. Thrombosis is also the major concern regarding those with CVD. 
There are two independent pathways to platelet activation that can work together or 
separately to result in thrombus formation. The main trigger for haemostatic thrombus is the 
loss or dysfunction of the endothelial cell barrier. Platelets also become activated by minimal 
stimulation from the sub-endothelium and artificial surfaces (Ruggeri, 2002, Gorbet and 
Sefton, 2004).  
Coagulation begins almost immediately at the site of platelet activation where platelets come 
into contact with different ECM components or associated secreted molecules; von Willebrand 
factor (vWF), laminin, collagen and fibulin (Ruggeri, 2002). Platelets tend to bind directly to 
collagen with collagen-specific glycoprotein Ia/IIa surface receptors which are further 
strengthened by binding to vWF. The vWF is an adhesive glycoprotein synthesised by 
endothelial cells, it is secreted and stored in -granules of platelets and in the ECM (Andrews 
et al., 1997). The glycoprotein Ib-IX-V complex on the platelet plasma membrane mediates the 
initial deposition of platelets on the sub-endothelium via the binding of the glycoprotein with 
vWF on the ECM or in high shear stress with vWF in the plasma (Andrews et al., 1997). There 
are many different platelet adhesion receptors, glycoprotein Ib and IIb/IIIa have the highest 
densities; glycoprotein Ib binds to immobilized vWF where glycoprotein IIb will bind to both 
mobile and immobilized vWF (Gorbet and Sefton, 2004). Platelets respond to an antagonist in 
three integrated phases that involve adhesion, activation and aggregation (Andrews et al., 
1997, Ruggeri, 2002, Gorbet and Sefton, 2004, Mackman, 2008).  
Platelet activation results in the release of intracellular granules that contain platelet factor 4, 
thrombospondin, -thromboglobulin, ADP and serotonin. P-selectin, a glycoprotein that 
mediates adhesion of platelets with neutrophils, monocytes and lymphocytes, is expressed on 
the membrane after  granule secretion, and platelet micro-particles form that are rich in 
factor Va and platelet factor 3 (Gorbet and Sefton, 2004). This initial primary binding state is 
then accelerated to form a plug at the site of activation.  
Activation changes the shape of the platelets through the release of ADP, a weak antagonist 
that directly induces only shape changes and reversible platelet aggregation (Ruggeri, 2002, 
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Gorbet and Sefton, 2004, Mackman, 2008). This shape change promotes platelet-platelet 
contact and adhesion and releases prothrombinase complexes on phospholipids; additional 
platelets then bind through receptor mediated binding to the attached platelets resulting in 
platelet aggregation (Ruggeri, 2002, Gorbet and Sefton, 2004, Mackman, 2008).  
Platelet aggregation in the secondary state is caused by ADP induced synthesis of 
thromboxane A2 and acts as the amplification step that within minutes leads to the 
accumulation of platelets into a thrombus (Ruggeri, 2002). Platelet activation involves the 
cleavage and activity of G protein-linked platelet receptor PAR1, thrombin receptor, by the 
protease -thrombin generated on the membrane of stimulated platelets (Ruggeri, 2002). 
These newly activated platelets then release the contents of granules that further promote 
platelet recruitment, adhesion, aggregation and activation (Mackman, 2008). Platelet binding 
to adhesive ligands causes enhanced adhesive and pro-coagulant properties through signalling 
pathways (Ruggeri, 2002). The binding of vWF to platelets triggers an intracellular signalling 
pathway and a calcium flux that activates a calcium dependent membrane aggregation 
receptor for fibrinogen (Andrews et al., 1997). The cross-linking with fibrinogen aids in platelet 
aggregation and completes the primary stage of haemostasis. 
The secondary stage of haemostasis occurs simultaneously with the primary stage and has two 
protein based pathways that lead to the formation of fibrin strands that strengthen and help 
maintain the platelet plug. The intrinsic, contact activation pathway, and extrinsic, tissue factor 
pathway, are activated in different ways and involve different proteins found in the serum. 
The intrinsic pathway is a series of stepwise reactions that convert proteins in the plasma into 
serine proteases by proteolysis and is involved in the growth and formation of fibrin in the 
coagulation cascade (Figure 1.11) (Davie et al., 1991). The intrinsic or contact activation 
pathway is activated by contact with negatively charged surfaces and the formation of primary 
complexes on collagen types I and III and other ECM components or artificial materials. Factor 
XII is auto-activated and undergoes a conformational change due to cleavage and binding upon 
auto-activation (Colman and Schmaier, 1997). Contact with negatively charged surfaces and 
ECM also results in the activation of prekallikrein and the cleavage of kininogen (Gailani and 
Rennè, 2007). 
These processes are involved in the activation of several plasma host-defences, in fibrin 
formation, complement activation and thrombus stability (Gailani and Rennè, 2007). Factor XII 
becomes factor XIIa that acts on factor XI to convert it into factor Xia. Factor XIa then acts on 
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factor IX and produces factor IXa (Davie et al., 1991, Colman and Schmaier, 1997, Gailani and 
Rennè, 2007). Factor IXa and its cofactor factor VIIIa form a tenase complex that binds to 
factor X and in the presence of Ca2+ ions and converts factor X into factor Xa as shown in Figure 
1.11 (Davie et al., 1991, Colman and Schmaier, 1997, Gailani and Rennè, 2007). 
The physiological and pathological importance of the intrinsic coagulation pathway is not fully 
understood with no evidence of factor XII deficiencies being related to bleeding disorders. 
However, other studies have shown that the intrinsic pathway is involved in several vascular 
diseases (Gailani and Rennè, 2007). Deficiencies in factor XI in mice does not cause a loss of 
haemostasis whereas factor IX deficiency does. Still, comparisons of factor XI null mice and IX 
null mice in arterial injury show similar protection from thrombus formation. This finding 
suggests that the intrinsic pathway is not critically involved with haemostasis but is critical to 
thrombus formation (Gailani and Rennè, 2007).  
The main role of the extrinsic pathway or tissue factor pathway is to rapidly form large 
amounts of thrombin that is important for the initial activation of blood clotting and is used as 
a feedback mechanism in coagulation activation (Davie et al., 1991, Gorbet and Sefton, 2004, 
Gailani and Rennè, 2007). Tissue factor (TF) forms the other pathway of platelet activation and 
involves thrombin generated by the action of tissue factor found in the vessel wall or free in 
the blood. The release of tissue factor is one of the ways atherosclerotic plaque rupture is 
believed to trigger thrombosis (Epstein and Ross, 1999, Libby et al., 2002, Furie and Furie, 
2008).  
The extrinsic pathway involves the formation of a tenase complex that converts factor X into 
factor Xa (Figure 1.11). The tenase complex is produced when factor VIIa, from the circulation, 
comes in contact with and forms a complex with TF as shown in Figure 1.11. TF is found on the 
membrane of cells in the subendothelial layers of blood vessels, is expressed on the surface of 
damaged cells at the site of vascular injury and can be found free in the blood (Gorbet and 
Sefton, 2004, Gailani and Rennè, 2007). TF activates clotting when blood vessels are damaged 
and the underlying cells are exposed to blood flow (Gailani and Rennè, 2007). The extrinsic 
pathway is believed to be short lived due to the presence of a lipo-protein-associated 
coagulation inhibitor or extrinsic pathway inhibitor that inactivates the factor VIIa-tissue factor 
complex (Davie et al., 1991, Gailani and Rennè, 2007). The short lived nature of the extrinsic 
pathway means that the intrinsic pathway becomes the primary mode for the continued 
growth of fibrin clots (Davie et al., 1991, Gailani and Rennè, 2007). 
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The intrinsic and extrinsic pathways converge at the common pathway where factor X is 
activated and is converted to factor Xa. Factor Xa activates pro-thrombin conversion to 
thrombin in the presence of cofactor Va and subsequently the conversion of fibrinogen into 
fibrin by thrombin (Gailani and Rennè, 2007). The fibrin that is formed in the common pathway 
is then cross-linked by factor XIII to stabilise the clot (Figure 1.11) (Gorbet and Sefton, 2004). 
 
 
Figure 1.11; Schematic of intrinsic and extrinsic pathways in blood clot formation 
 
There are a number of cofactors that are involved in several of the blood clotting cascades. 
Calcium is a key cofactor and is involved in the binding of several factors to platelets and the 
action of the tenase complexes formed by the extrinsic and intrinsic pathways (Mann et al., 
1990, Gorbet and Sefton, 2004, Gailani and Rennè, 2007). Removal of calcium from collected 
blood by the addition of citrate is a widely used method to prevent blood coagulation. Blood 
coagulation can be restored to citrated blood by the addition of excess calcium. Vitamin K is an 
important cofactor involved in many different metabolic pathways. Several of the complexes 
involved in the blood coagulation pathway, most notably the tenase complexes from the 
intrinsic and extrinsic pathways, involve vitamin K-dependent enzymes to create the 
appropriate serine proteases (Mann et al., 1990). Warfarin, an anti-clotting agent, works by 
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reducing the level of available vitamin K and its effects can be reversed by the addition of 
excess vitamin K to treated blood.  
There are many different mechanisms that are used to regulate blood coagulation. Protein C is 
a major physiological anticoagulant that degrades factor Va and VIIIa (Esmon, 1989). Protein C 
is activated by the binding of Protein C and thrombin to a thrombomodulin receptor; the 
receptor vastly accelerates the activation of Protein C (Esmon, 1989). Activated Protein C 
forms a complex with Protein S and several lipids to form a serine protease that inactivates 
factors Va and VIIIa by proteolysis of several peptide bonds in activated factor Va and VIIIa 
(Esmon, 1989).  
The majority of coagulation factors are serine proteases. Plasma contains several protease 
inhibitors, 1-protease inhibitor, 2-macroglobulin, heparin cofactor II and antithrombin III, 
which are involved in the modulation and inhibition of coagulation in healthy vasculature in 
vivo (Gorbet and Sefton, 2004). Antithrombin is the most common serine protease inhibitor 
that inhibits the action of thrombin and the factors involved in the intrinsic pathway, factors 
Xa, IXa, XIa and XIIa (Davie et al., 1991). Antithrombin forms a one-to-one complex with these 
factors and blocks the site of enzymatic activity. In the presence of heparin or similar 
sulphated glycosaminoglycans, the inhibitory effect of antithrombin is greatly increased (Davie 
et al., 1991). Antithrombin plays an important part in preventing thrombosis. Deficiency in 
antithrombin can be inherited or acquired but leads to hypercoagulable diseases and often 
death from thrombophilia if not carefully treated (Van Boven and Lane, 1997).  
The main regulator of the extrinsic or tissue factor pathway is the tissue factor pathway 
inhibitor (TFPI). TFPI inhibits the activity of the factor VIIa-TF complex towards factor X and, to 
a lesser extent, to factor IX in what is believed to be a two step mechanism (Broze Jr, 1995, 
Panteleev et al., 2002). TFPI binds to factor Xa near or on the active site of the enzyme and 
inhibits further progression through the common pathway. It is believed that the TFPI-Xa 
complex then binds to the factor VIIa-TF complex and blocks its activity rapidly deactivating 
the extrinsic pathway (Broze Jr, 1995, Panteleev et al., 2002). Platelets carry around 10 % of 
the total TFPI in the blood and release it following stimulation by antagonists such as thrombin 
(Broze Jr, 1995).  
Several of the regulatory mechanisms target platelet activity. Prostacyclin is released from 
platelets upon activation and is involved in the negative feedback regulation of platelet activity 
(Ruggeri, 2002). Prostacyclin is a potent stimulator of cyclic adenosine monophosphate (cAMP) 
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accumulation in platelet rich serum. cAMP inhibits platelet activation in many different ways; 
preventing granule release, preventing the exposure of a pro-coagulant phospholipid surface 
and preventing platelet adhesion and aggregation (Krishnamurthi et al., 1984, Zwaal et al., 
1984). It is believed that this is brought about by the lowering of cytoplasmic calcium in the 
platelets that has been shown to be critically involved, directly or indirectly, with platelet 
activation (Krishnamurthi et al., 1984). 
 Fibrinolysis is one of the key maintenance mechanisms involved in blood clotting and starts to 
degrade a clot within a few hours. In the presence of newly generated fibrin tissue, 
plasminogen activators catalyze plasminogen into plasmin, which breaks down fibrin (Davie et 
al., 1991). Slow fibrin turnover allows for tissue remodelling and repair and the intrinsic 
pathway likely acts as an antagonist against fibrinolysis to create a slow rate of fibrin turnover 
(Davie et al., 1991). This adds to the belief that the intrinsic pathway is more closely involved 
with thrombus formation.  
Thrombi formed in arteries and veins differ in their composition. Venous thrombi tend to be 
fibrin and red blood cell rich and relatively poor in platelets where arterial thrombi tend to 
have high levels of platelets. The intrinsic pathway is involved in fibrin formation in venous 
thrombosis. The role of the intrinsic pathway in arterial thrombosis is not as clear (Gailani and 
Rennè, 2007). As such arterial thrombi differ from venous thrombi in their target of action, 
anti-arterial thrombosis treatments target platelets and anti-venous thrombosis treatments 
target the proteins of the coagulation cascade (Mackman, 2008). 
 
1.6.1 Thrombus prevention  
 
There are two main ways by which to prevent thrombus formation. In a healthy blood vessel, 
thrombus formation is prevented by a layer of endothelial cells that form an anti-
thrombogenic layer (Nerem, 2000, Rémy-Zolghadri et al., 2004, Williamson et al., 2007, Yin et 
al., 2009). In the case of medical intervention, blood clot formation is often prevented by 
treatment with anti-clotting agents such as heparin, dipyridamole and warfarin, or by the use 
of anti-fouling surfaces (Uyama et al., 1998, Aldenhoff et al., 2001, Liem et al., 2001, Crowther 
et al., 2002, Knetsch et al., 2004, Fittkau et al., 2005, Wang et al., 2007b).  
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1.6.2 Non-fouling surfaces  
 
There are a wide range of non-fouling materials, mainly synthetic polymers, which have been 
produced for use in biomedical applications. Polyacrylamide has been shown to have a low 
level of platelet interaction. Polyvinylpyrrolidone has been used to coat surfaces to reduce the 
adsorption of fibronectin and poly N, N-dimethylacrylamide has been shown to work as a 
coating that will remain unfouled for extended periods of time (Uyama et al., 1998). Poly 
ethylene glycol (PEG) has been the main focus of anti-fouling surfaces in vascular graft 
replacements. PEG has been incorporated into a wide range of materials and extensive testing 
has revealed a short, four subunit long PEG that has been found to be the most inert form in 
interactions with blood; PEG has also been modified with RGD and other ligands to allow for 
the attachment of cells to the surface (Uyama et al., 1998, Fittkau et al., 2005). 
The use of anti-fouling surfaces works but is not an ideal solution for preventing thrombus 
formation since the modification of the surfaces can lead to changes in chemical and 
mechanical properties. Degradation of the surface will naturally occur in the long-term use of a 
vascular replacement and the loss of the anti-fouling coating will allow for the formation of 
blood clots if a fully functional endothelial layer has not formed. Natural extracellular matrix 
regulates the binding and release of proteins and various factors from the blood. The loss of 
this function could negatively impact on cellular interactions and negate one of the reasons for 
using naturally derived scaffolds as vascular grafts. 
 
1.6.3 Anti-clotting agents  
 
In thrombotic disorders such as deep vein thrombosis, blood clots are formed and lead to 
thrombus that occlude the blood vessel and cause serious problems. Blood clotting disorders 
are treated with anti-clotting agents to prevent the initial blood clot formation. In the same 
manner, anti-clotting agents could be used to prevent thrombus formation in vascular grafts. 
There has been much interest in the use of anti-coagulants that are released from or attached 
to vascular replacements. Anti-clotting agents that are used systemically can often lead to 
complications, especially as patients requiring vascular grafts often have some form of vascular 
disease making long term treatment with anti-clotting agents undesirable (Saltzman and 
Olbricht, 2002, Nagai et al., 2006). 
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Controlled delivery or immobilisation is a preferable method of treatment as it is more 
efficient, being able to directly deliver to the required site means that lower overall doses are 
needed and there are lower potential risks (Wissink et al., 2000, Fattori and Piva, 2003, Luong-
Van et al., 2006). Heparin is a highly-sulphated glycosaminoglycan that is a naturally occurring 
anti-clotting agent. Commercially available heparin has a molecular weight of around 12 kDa – 
15 kDa (native heparin is between 3 kDa and 50 kDa) and is highly negatively charged. 
 
 
Figure 1.12, Schematic of the action of heparin on the formation of thrombin-anti-thrombin complex; 
Heparin binds to anti-thrombin and catalyses the reaction with thrombin, the affinity of anti-thrombin 
for heparin is reduced and heparin is released. 
 
It has been demonstrated that heparin works by accelerating the action of anti-thrombin, an 
inhibitor that neutralizes thrombin, by increasing the rate at which thrombin and anti-
thrombin complex (Rosenberg, 1974, Bjork and Lindahl, 1982). Once the thrombin-anti-
thrombin complex has been created, the heparin is released from the complex as it is not 
consumed in the reaction (Figure 1.12) (Bjork and Lindahl, 1982). 
The use of heparin on Dacron has been extensively explored as a method of improving 
patency. Heparin has been shown to increase the lifetime of vascular grafts by reducing the 
rate of thrombus formation without affecting mechanical properties (Wang et al., 2007b). The 
use of heparin has been shown to have no effect on the attachment of endothelial cells and 
has also been demonstrated to significantly increase endothelial cell density (Knetsch et al., 
2004). This could be caused by direct stimulation of endothelial cell growth or by the 
potentiation of growth factors, where under the right conditions heparin binds such growth 
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factors as vascular endothelial growth factor or basic fibroblast growth factor, increasing the 
proliferation of the endothelial cells (Knetsch et al., 2004). 
Heparin increases the time a graft remains patent, but the loss of heparin as this is released or 
lost from the surface of the graft eventually leads to thrombus formation (Xue and Greisler, 
2003, Venkatraman et al., 2008). Dipyridamole is an anti-platelet drug. Dipyridamole is 
believed to act in two possible ways. One way is blocking the uptake of adenosine into 
platelets. The other mechanism is by inhibiting the enzyme phosphodiesterase, that breaks 
down cAMP, leading to higher levels of cAMP, so preventing platelet coagulation (Moncada 
and Korbut, 1978, Gresele et al., 1986). Dipyridamole has been shown to reduce thrombus 
formation and platelet activation, increasing the lifetime of vascular grafts (Aldenhoff et al., 
2001). An endothelial cell layer can attach and survive on dipyridamole, but dipyridamole has 
been shown to significantly slow cell growth by reducing the rate of DNA synthesis which could 
cause problems with re-endothelialisation and long term patency (Aldenhoff et al., 2001, Liem 
et al., 2001). 
Warfarin has been used for the treatment of thrombus formation. For this purpose, low levels 
of warfarin are used as it has been shown to carry a high risk of haemorrhage (Crowther et al., 
2002). Warfarin works by inhibiting peroxide reductase that diminishes the level of vitamin K  
and therefore prevents the synthesis of vitamin K dependent clotting factors (Bell et al., 2002). 
Warfarin has been shown to increase the lifetime of grafts but does not prevent eventual 
failure due to thrombosis (Crowther et al., 2002). It has been shown that the presence of 
warfarin  has no significant effect upon the attachment and normal function of endothelial 
cells (Liem et al., 2001).  
Recently, there has been increased interest in the use of DNA aptamers in the prevention of 
thrombus formation. On screening a collection of randomly synthesized DNA segments, it was 
found that a single strand of DNA will bind to thrombin with high affinity (Raviv et al., 2008). 
The DNA segment GGTTGGTGTGGTTGG is able to bind to exosite 1, the fibrin binding site, of 
thrombin and prevent thrombin catalyzed fibrin clot formation (Bock et al., 1992, Dougan et 
al., 2003). The DNA aptamer has been shown to fully displace pre-bound thrombin from 
preformed clots and aid in, but not directly cause, the breaking up and removal of blood clots 
(Raviv et al., 2008). The aptamer has also been shown to prevent the binding of thrombin to 
protease-activated receptors and so prevent platelet activation (Raviv et al., 2008). The main 
problem concerning the use of DNA aptamers is the lifetime of free DNA in the blood due to 
serum nucleases that will destroy the aptamer within a matter of minutes (Dougan et al., 
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2000). The lifetime of the aptamers can be extended by adding caps to the end of the DNA 
sequence to prevent enzymatic degradation (Dougan et al., 2000). 
The use of slow release anti-coagulants and anti-coagulant coatings allows for the prevention 
of clot formation and platelet activation. The problem with using anti-clotting agents is that 
they do not replace the natural endothelial layer. Additionally, if the anti-coagulant is fully 
released or removed from the surface of a scaffold by degradation and a fully formed 
endothelial layer has not formed, platelets will become activated and blood clots will form. 
This is the reason for the number of reported cases in which anti-clotting agents were able to 
increase the lifetime of the vascular graft, but unable to prevent eventual thrombus formation 
and failure. 
 
1.6.4 Endothelium formation 
 
Another approach to deal with thrombus formation is the creation of an endothelial layer. This 
is the approach taken when scaffolds are cellularised in vitro and the presence of a fully 
formed endothelium is used to prevent platelet activation and thrombus formation. In situ 
cellularisation attempts to increase the speed and efficiency at which a fully formed and 
functional endothelial layer is created in order to prevent thrombus formation. This can be 
achieved by the use of cell attachment ligands and growth factors. 
 
1.6.4.1 Growth factors  
 
There are a range of different growth factors that have been identified to be involved with 
endothelial cell maintenance. Basic fibroblast growth factor (bFGF) belongs to the family of 
fibroblast growth factors and is involved in angiogenesis and wound healing. bFGF is found in a 
membrane bound form on the basement membrane and subendothelial layers of blood 
vessels (Thomas, 1987, Ornitz and Itoh, 2001). It has been reported that bFGF is a mitogen for 
fibroblasts, endothelial and smooth muscle cells (Asahara et al., 1995, Dixit et al., 2001). An 
increase in the penetration of cells into scaffolds and in endothelial cell proliferation has been 
observed with the use of bFGF, and it has been demonstrated to work in a dose dependent 
manner (Chen et al., 1997, Wissink et al., 2000, Simionescu et al., 2006).The lifetime of 
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fibroblast growth factors have been shown to be increased by the introduction of heparin 
which increases resistance of fibroblast growth factors to thermal degradation (Thomas, 1987, 
Wissink et al., 2000, Ornitz and Itoh, 2001).  
Vascular endothelial growth factor (VEGF) is a subset of the platelet derived growth factor 
family; it is a key regulator of angiogenesis and vasculogenesis and has been implicated in 
wound healing, endothelium maintenance and endothelial cell survival (Zachary, 1998, Luo et 
al., 1998, Dorafshar et al., 2003, Ferrara et al., 2003, Matsuno et al., 2003, Cursiefen et al., 
2004, Zhou et al., 2009b). VEGF has been reported to be a powerful mitogen and chemo-
attractant of endothelial cells, working on endothelial cells to increasing their rates of 
proliferation and migration (Asahara et al., 1995, Zachary, 1998, Luo et al., 1998, Matsuno et 
al., 2003, Zhou et al., 2009b).  
There are different forms of VEGF: factor A has been associated with migration and 
proliferation of endothelial cells and linked to the creation of the blood vessel lumen; factor B 
has been shown to be involved with embryonic angiogenesis; factor C has been reported to be 
linked to lymphangiogenesis; and factor D has been linked to angiogenesis (Zachary, 1998, 
Ferrara et al., 2003, Matsuno et al., 2003, Cursiefen et al., 2004, Bhardwaj et al., 2005).  
VEGF is highly specific to endothelial cells and acts by promoting the expression of 
plasminogen activators, metalloproteinase and interstitial collagenase which provide the 
environment needed for cell migration and proliferation (Dvorak et al., 1995, Asahara et al., 
1995, Luo et al., 1998, Ferrara et al., 2003, Matsuno et al., 2003). Cellular invasion and vascular 
remodelling is also promoted by the expression of urokinase receptors triggered by VEGF 
(Ferrara et al., 2003). VEGF has been shown to accelerate the re-endothelialisation of vascular 
scaffolds and prevent thrombus formation (Asahara et al., 1995, Lemstrom et al., 2002, Drury 
and Mooney, 2003, Ferrara et al., 2003, Zhou et al., 2009b). 
A variant of VEGF, VEGF165, has been found to have the highest mitogenic activity and to 
promote faster re-endothelialisation (Zhou et al., 2009b). High local levels of VEGF are needed 
to promote re-endothelialisation because of the short lifetime of VEGF in the blood. The 
lifetime of VEGF can be increased by the presence of heparin which improves stability and 
bioactivity (Drury and Mooney, 2003, Matsuno et al., 2003, Zhou et al., 2009b). 
The use of growth factors has been shown to greatly improve the re-endothelialisation of 
vascular grafts. However, there are several problems associated with the use of growth 
factors. Fibroblast growth factors are able to promote the proliferation of endothelial cells but, 
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as they are not cell specific, they also promote the proliferation of smooth muscle cells which 
is linked to intimal hyperplasia. VEGF is cell specific but is reported to be closely linked with 
tumour pathogenicity and spreading (Zachary, 1998, Dorafshar et al., 2003, Ferrara et al., 
2003, Cursiefen et al., 2004). 
 
1.6.4.2 Attachment ligands  
 
For in situ re-endothelialisation, it is important not only to stimulate cell proliferation but also 
cell migration and attachment. Migration can be triggered by growth factors, but this is heavily 
dependent upon the presence of attachment ligands to facilitate attachment and retention; 
this is of particular importance in flow conditions. 
RGD (Arginine-Glycine-Aspartic acid) is a naturally occurring attachment motif; it is often in the 
form of RGD, PRGDS or YRGDS and is known to enhance cell attachment to a surface (Drury 
and Mooney, 2003, Chen and Hunt, 2007, Wang et al., 2008). The inclusion of RGD on vascular 
scaffolds such as Dacron and POSS-PCU, has been shown to enhance cell migration, 
attachment and retention; it has been suggested that RGD could have catch and hold 
characteristics (Patel et al., 2007, Wang et al., 2008, de Mel et al., 2009). RGD sequences are 
reported to be easily incorporated into scaffolds either by direct binding of the amino acid 
groups, the physical adsorption of the RGD peptide sequence onto the scaffold or the 
incorporation of RGD into the structure of synthetic grafts (Walluscheck et al., 1996, Fittkau et 
al., 2005, Patel et al., 2007). 
Studies using RGD motifs have highlighted the importance of distribution and density on cell 
function. It has been demonstrated that the presence and density of attachment ligands can 
control cell growth and function. Low concentrations of RGD result in poor cell migration, 
retention and function. High levels of RGD have been shown to significantly increase cell 
attachment but have been reported to have a detrimental effect upon cell migration and 
proliferation. At the appropriate concentrations RGD has been shown to enhance cell 
attachment and retention whilst stimulating cell migration and proliferation; it has also been 
shown to increase the cells resistance to shear stresses (Walluscheck et al., 1996, Chen and 
Hunt, 2007, Norman et al., 2008). 
Other naturally derived attachment ligands have been investigated, such as YIGSR and 
RYVVLPR from laminin and TAGSCLRKFSTM from collagen. All have been shown to improve the 
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attachment and migration of endothelial cell to scaffolds, but not as well as RGD (Drury and 
Mooney, 2003, Genové et al., 2005). YIGSR has been found to increase cell migration whilst 
not causing blood clotting (Jun and West, 2004). A mixture of RGD and YIGSR has been 
reported to have a higher rate of cell adhesion and retention, than either of the two ligands 
individually, without affecting the cell spreading behaviour (Fittkau et al., 2005). This indicates 
that a combination of different attachment ligands may yield the best results.  
There has been interest in the possible use of antibodies for the selective capture and 
retention of cells from the blood stream. Endothelial progenitor cells are a bone-marrow 
derived subset of CD34+ cells that can differentiate into endothelial type cells (Urbich and 
Dimmeler, 2004, Aoki et al., 2005, Rotmans et al., 2005, Patel et al., 2007, Yin et al., 2009). In 
normal vascular biology, endothelial progenitor cells contribute to re-endothelialisation, but 
only to a small extent (Urbich and Dimmeler, 2004). It has been reported that antibodies 
against CD34+ cells may be used to capture and attach endothelial progenitor cells from the 
blood stream. Using antibodies the number of progenitor cells attached to the scaffold has 
been increased; the progenitor cells then contribute to, and accelerate, re-endothelialisation 
(Aoki et al., 2005, Patel et al., 2007, Yin et al., 2009). This technique has been used to attach 
cells and form a layer of cells on the surface of a replacement blood vessel. The antibodies 
have been shown not to adversely affect the metabolic activity of the endothelial cells, and 
normal growth and differentiation has been observed (Aoki et al., 2005, Yin et al., 2009). 
There are possible problems with the use of antibodies against CD34+ cells; endothelial 
progenitor cells are just one subset of CD34+ cells. Because of this, the attached cell has the 
potential to differentiate into other cells rather than endothelial cells, such as smooth muscle 
cells (Urbich and Dimmeler, 2004, Rotmans et al., 2005). As the antibodies used must be anti-
human CD34+ antibodies, they could elicit an immune response if they have been developed in 
animals, as in the case of mice (Aoki et al., 2005). 
Due to the immune response and range of cells that can be attached to antibodies against 
CD34+ cell markers there is research into the development of aptamers that are specifically 
targeted to one cell type. An example is a DNA aptamer developed by Hoffman et al. that binds 
endothelial progenitor cells. Similarly, Veleva et al. have developed a peptide aptamer, with 
amino acid sequence of TPSLEQRTVYAR, that selectively binds to blood outgrowth endothelial 
cells (Hoffmann et al., 2008, Veleva et al., 2008). Cell ligand interactions are complex and the 
function of the ligand is dependent upon the ligand environment (Barker, 2011).  
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Proteolysis and mechanical stimulation of the ECM has been shown to potentially expose or 
alter conformationally-sensitive ligand domains that have different effects in different 
conformations (Barker, 2011). Proteolytic fragments of the ECM have been shown to have an 
enhanced mitogenic activity; this effect results in a new class of bio-molecules called 
“matrikines” (Barker, 2011). The inclusion of cell attachment ligands has the potential to aid 
and accelerate the formation of an endothelial cell layer to aid in the prevention of thrombus 
formation. It is worth noting that, even though the addition of the attachment ligands will 
accelerate endothelialisation, there is a time period before the fully functional endothelial 
layer is formed where the vessel will be prone to blood clot formation and thrombosis.  
 
1.6.5 Advantages and limitations of current methods associated with thrombus 
prevention 
 
There are many different ways of preventing thrombosis that have been researched, yet no 
ideal approach has been found. The use of non-fouling surfaces has been well explored for the 
creation of a range of medical devices. Non-fouling surfaces have been shown to successfully 
prevent thrombus formation, but, due to the properties of the materials that make them non-
fouling, these materials are unable to facilitate normal cellular function. The controlled release 
of anti-clotting drugs and their coating of surfaces has been shown to increase the life-time 
and patency of vascular grafts. The use of anti-clotting drugs should allow for normal cellular 
attachment and function; however, coatings and controlled release devices have a limited 
lifetime until the drug has worn off the surface or has been fully released. If a fully formed and 
functional endothelium is not present then thrombosis can occur. It is also not desirable to use 
anti-clotting agents unless necessary as their use can lead to complications. The idea of 
forming a fully functional endothelium on a scaffold in vitro should mimic the natural method 
of thrombosis prevention.  The sourcing of the patient’s own cells, the time and cost of 
growing the endothelium and the risks of infection limit the potential application of this 
technique. 
The idea of forming an endothelium in vivo is very attractive and, if successful, it should 
provide a natural anti-thrombogenic barrier which will allow for long-term graft patency and 
lifetime. The problem with in vivo recellularisation is that the endothelium will take time to 
form and before the endothelium is fully formed the graft will be highly susceptible to 
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thrombosis formation. To prevent thrombogenesis, it is desirable to have an endothelium that 
can interact and regulate blood clotting. 
Because of the issues with in vitro recellularisation, it is preferable to use in situ 
recellularisation to form the endothelium. To prevent thrombosis formation before the 
endothelium can be grown in situ, some form of anti-clotting function is needed. As non-
fouling surfaces tend to disrupt or prevent cell attachment and migration, their use would be 
counterproductive to the formation of an endothelium layer. The use of anti-clotting agents is 
one possible method of preventing thrombogenesis; however, their use is not ideal due to the 
possibility of associated complications. The ideal situation would be the addition of a material 
or coating to the decellularised vessel that acts to passivate the surface and aids in cell 
attachment and migration.  
 
1.7 Self-assembled peptides as biomaterials for tissue engineering 
1.7.1 Self-assembly  
 
Self-assembly is the spontaneous organisation of molecules into well ordered and structurally 
defined arrangements that are stabilised through non-covalent interactions. Self-assembly is a 
major field of research in nanotechnology and is the basis of bottom-up nanotechnology. The 
best examples of self-assembly can be found in biology. The cell membrane is a double layer of 
lipid molecules that self-assemble into a membrane due to hydrophobic interactions. Similarly, 
the proteins that constitute the capsid of a virus are synthesised by the host cell and then self-
assemble around the viral nucleic acids. Self-assembly is possible with a wide range of 
polymers, lipids, DNA, peptides and proteins; the structures of these molecules can be 
rationally designed to control the structures that are formed and the conditions that will 
trigger self-assembly (de Loos et al., 2005). The most basic form of self-assembly is self-
complementary; where two identical molecules, designed to have alternating charges, align 
alongside each other in a parallel or anti-parallel arrangement and are joined by hydrogen 
bonds (Aggeli et al., 2001). 
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1.7.2 Nucleated and non-nucleated 1D self-assembly  
 
The most basic form of self-assembly is the organisation of molecules in one 
direction/dimension into an ordered structure. Self-assembly can either be nucleated or non-
nucleated. Non-nucleated self-assembly otherwise known as isodesmic equilibrium is where 
monomers are added together in a step-wise fashion and the addition of every monomer is 
governed by a single equilibrium (Smulders et al., 2009). Nucleated or cooperative self-
assembly has an unfavourable activation step requiring the formation of a nucleus from which 
chain elongation and growth happens (Chen, 2005, Smulders et al., 2009). The formation of a 
nucleus occurs by self-association and will only happen above a critical concentration. Below 
this concentration, the molecules will be monomeric with the presence of unstable seeds 
(Chen, 2005). Isodesmic self-assembly is a slow and gradual process with an increase in 
concentration resulting in an increase in chain length and number. Nucleated self-assembly 
has a bimodal distribution of monomer and elongated chains, this can be seen as a steady 
increase in chain length with concentration (Smulders et al., 2009). 
 
1.7.3 Complementary self-assembly  
 
Complementary self-assembly happens when two different molecules combine together to 
create an ordered structure. Two molecules that have the opposite electrostatic charge that 
self-assemble when mixed are an example of complementary self-assembly. The molecules 
that will self-assemble complementarily have a 1:1 stoichiometric ratio and will only self-
assemble if they are correctly charged under the same conditions (Aggeli et al., 2003a). 
Complementary self-assembly most commonly happens due to Coulombic attraction between 
the two oppositely charged monomers; when mixed, the monomers will spontaneously self-
assemble. Complementary self-assembly is attractive due to the ease of triggering self-
assembly and the increased stability of the structures formed. Self-complementary self-
assembled structures are mainly held together by hydrogen bonding; complementary self-
assembled structures are held together by electrostatic interactions as well as hydrogen bonds 
increasing the stability (Aggeli et al., 2003a).  
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1.7.4 Peptide self-assembly  
 
Peptides have great potential as biomaterials for tissue engineering. The use of the natural 
material, amino acids, in peptide design should allow for the creation of a biocompatible, 
biodegradable and non-immunogenic biomaterial. As with natural protein folding, the two 
main conformations that peptides can assume are -helix and -sheet. Peptides can self-
assemble to form a wide range of different structures including -sheets, -hairpins, -helices, 
monolayers, nanotubes (vesicles) and there are peptides that can switch between a -sheet 
and -helix conformation (Zhang and Altman, 1999, Zhang, 2002). The wide range of amino 
acids that can be used to make a peptide sequence mean that a range of material properties 
can be achieved by varying the peptide sequence and length. It has been found that the most 
important factor when designing a peptide to be either -helix or -sheet is periodicity; an 
alternating sequence of polar and non-polar amino acids will preferentially form a -sheet 
structure (Xiong et al., 1995).  
 
1.7.4.1 -Sheet 
 
Due to their biological relevance, peptides that form -sheets are of particular interest for the 
formation of biomaterials, but also for their pathological significance in the misfolding of 
proteins and the formation of amyloid plaques. -sheet forming peptides can be considered as 
chiral rods that self-assemble in one dimension to create elongated peptide -sheet tapes 
(Aggeli et al., 2001, Aggeli et al., 2003b, Carrick et al., 2007).  
The surfaces of a -sheet forming peptide have differences in hydrophobicity. This causes 
tapes to stack, one on top of the other, above a certain concentration to create a range of 
higher ordered structures (Zhang and Altman, 1999, Aggeli et al., 2001). The concentration 
dependence of peptide self-assembly results in a hierarchy of structures being formed (Aggeli 
et al., 2001, Carrick et al., 2007). As the peptides are chiral, a twist is induced in the peptide 
tape. As the concentration is increased the ribbons stack to create a fibril, the fibril size is 
limited by the twisting of the ribbons (Figure 1.13). Fibrils then interact edge to edge and twist 
together to create fibres (Aggeli et al., 2001, Aggeli et al., 2003b, Carrick et al., 2007). Fibril size 
and width is related to the competition between the free energy gain and the elastic cost of 
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untwisting, since a fibril has to untwist slightly to permit further stacking (Aggeli et al., 2001, 
Carrick et al., 2007). 
 
 
Figure 1.13; Hierarchy of-sheet self-assembly 
 
1.7.4.2 -Hairpin 
 
-Hairpin peptides are formed from two -sheet strands joined together by a -turn. The 
strands are made of alternating hydrophobic and hydrophilic amino acids, such as lysine and 
valine. The formed peptide will fold into an amphiphilic -hairpin when the electrostatic 
repulsion between strands is reduced. The amphiphilic hairpin will then self-assemble via 
hydrophobic interactions to form a fibrillar structure that excludes the hydrophobic amino 
acids from aqueous solution (Figure 1.14). The lessening of the electrostatic repulsive forces on 
hydrophilic amino acids can be achieved in basic conditions, deprotonating and neutralising 
the charged side chains (Schneider et al., 2002, Ozbas et al., 2004). The electrostatic charge on 
the hydrophilic amino acids can also be screened by the presence of salt, as in physiological 
conditions (Ozbas et al., 2004, Haines-Butterick et al., 2007). The amphiphilic -hairpins 
naturally form non-covalent cross-links between fibrils. These cross-links are semi-permanent 
and are formed by both hydrogen bonding and hydrophobic interactions (Ozbas et al., 2004). 
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Figure 1.14; (A) Schematic of folding and subsequent self-assembly when MAX1 and MAX8 peptides 
are placed in physiological solution. (B) Peptide sequences of MAX1 and MAX8. Reproduced from 
Haines-Butterick et al (Haines-Butterick et al., 2007). 
 
1.7.4.3  Stabilised -sheet 
 
Fmoc-dipeptides have been demonstrated to self-assemble and form stable self-supporting 
gels with a reduction of solution pH. Fmoc-dipeptides self-assemble in two ways; Fmoc-
dipeptides form anti-parallel -sheets but also form anti-parallel π – π stacks. The only 
conformation that allows for both states to exist is the formation of cylindrical structures 
formed by the interlocking of anti-parallel -sheets through lateral π – π interactions with 
aromatic groups on adjacent sheets (Figure 1.15); these cylindrical structures then align to 
form a flat ribbon (Smith et al., 2008). Work on Fmoc-AA peptides has shown that Fmoc-group 
π – π stacking plays the key role in stabilizing the fibril structure of the self-assembled peptides 
(Mu et al., 2012). 
 
 
Figure 1.15, Left: Fmoc-FF -sheets, binding through π-π-stacked phenyl (orange) and Fmoc groups 
(purple); Right: side view of Fmoc-FF aggregate. Adapted from Smith et al (Smith et al., 2008). 
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1.7.4.4 -Helix coiled coils 
 
A coiled coil is made up of two or more supercoiled -helices. These comprise two or more 
peptide chains designed to co-assemble resulting in an offset -helix dimer with 
complementary ends (Figure 1.16). The complementary ends allow dimers to assemble 
longitudinally into a fibril. Through careful design, the fibrils are made to align by hydrophobic 
and hydrogen bonding interactions into thick fibres.  The use of hydrophobic interactions 
favours the hydrogelation of these peptides when mixed. As long as these peptide are mixed in 
the correct conditions, self-assembly follows the complementary self-assembly pathway and 
no additional trigger is needed except for the mixing of the peptides (Banwell et al., 2009). 
 
 
Figure 1.16, Schematic of Alpha helix forming peptide coiled coil architecture. Reproduced from 
Banwell et al (Banwell et al., 2009). 
 
1.7.5 Peptide biocompatibility 
1.7.5.1 RAD-based peptides 
 
At the time of writing RAD-based peptides, developed by Zhang and co-workers, are the 
subject of the majority of the literature on peptide self-assembly. The RAD-based peptides are 
modelled on a peptide sequence from a yeast protein and undergo hydrophobic stacking into 
-sheets. These -sheets then stack further into ribbons and fibrils (Zhang et al., 1993). Whilst 
several variations of the RAD-based peptide have been developed, the main interests lies in 
RAD16-1, Ac-(RADA)4-CONH2, which has been commercialised under the name PuraMatrix. 
Several applications for RAD16-1 have been investigated. RAD16-1 has been shown to support 
the growth of neural cells and the formation of new functional synapses (Holmes et al., 2000, 
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Ellis-Behnke et al., 2006). RAD-based peptides have been demonstrated to support the growth 
of endothelial and myocardial cells, and have been shown to be better for recellularisation 
than Matrigel (Davis et al., 2005). It is reported that RAD16-1 has immediate haemostatic 
properties and has been shown to support favourable tissue growth and repair in a wound site 
due to the 3-dimentional matrix formed as the peptides self-assembles (Meng et al., 2009). 
RAD16-1 has also been shown to increase tissue repair by lowering the number of 
macrophages and astrocytes at the wound, cells known to be causes of secondary injury (Guo 
et al., 2009).  
The immunological properties of RAD16-1 have been tested. When injected into rats, rabbits 
and goats RAD16-1 showed no inflammatory or immune response even having been 
conjugated with a carrier protein (Holmes et al., 2000). Attempts have been made to enhance 
the biological properties of RAD16-1 by the addition of functional groups YIGSR and RYVVLPR. 
Attachment ligands shown to promote cell adhesion, migration and tubular formation have 
been added onto the end of RAD16-1 and have been shown to increase the number of 
attached cells and increase cell growth (Genové et al., 2005).  
 
1.7.5.2 P11 series of peptides 
 
The P11 peptides are a range of around 30 peptides developed by Aggeli and co-workers at the 
University of Leeds. This series of peptides are all 11 amino acids in length and are designed to 
form anti-parallel -sheet structures following the hierarchy of nucleated self-assembly (Figure 
1.13). Some of these peptides have been designed to self-assemble by a change in pH or ionic 
concentration (Aggeli et al., 2003b, Carrick et al., 2007). Several of the peptides have also been 
designed to remain monomeric and self-assemble by complementary self-assembly (Aggeli et 
al., 2003a).  
The main focus of the work around the P11 series of peptides has been on the development of 
design criteria to produce superior peptides for the purpose of tissue engineering and 
regenerative medicine. It has been found that for this class of peptides a ±2 charge is need for 
self-assembly in physiological solutions (Maude et al., 2011a) (Personal communication from 
Dr D. Miles, University of Leeds). It has been shown that serine and threonine based P11 
peptides interact with model cell membranes and that amino acid sequence is important to 
peptide/phospholipid membrane interactions (Protopapa et al., 2009). It has been reported 
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that the positively charged peptides P11-8, P11-12, P11-16 and P11-18 are non cytotoxic to L929 
murine fibroblasts. However, only P11-8 supports cell growth and proliferation in 3-dimentional 
culture (Maude et al., 2011a). It is believed that this is due to the stability of the different 
peptide gels as P11-8 remains stable where the other peptides degrade preventing cell 
attachment and normal cell function (Maude et al., 2011a). All of the positively charged 
peptides show inferior levels of cell growth and proliferation when compared to a collagen gel 
(Maude et al., 2011a). This could be due to the higher levels of trifluoro acetic acid (TFA) in the 
positively charged peptides.  
It has been shown that the negatively charged peptides P11-4, P11-9, P11-15, P11-17 and P11-20 
are non cytotoxic to L929 murine fibroblasts (Personal communication from Dr D. Miles, 
University of Leeds). Peptides P11-4, P11-15, P11-17 and P11-20 appeared to have supported the 
growth and proliferation of the cells: most noticeably, P11-4 supported similar levels of growth 
to the collagen control. Testing with primary human fibroblasts has been reported to show no 
cytotoxic effect for P11-4 and P11-8 (Wilshaw et al., 2008b). It has been shown that lymphocytes 
from mice immunised with peptide showed no response to P11-4 or P11-8, however, when the 
peptides were conjugated with keyhole limpet hemocyanin an antibody titre of 1/64 was 
measured against both peptides (Wilshaw et al., 2008b). 
 
1.7.5.3 -Hairpin 
 
Several self-assembling -hairpin peptides have been developed by Schneider and co-workers. 
Most widely reported in the literature at the time of writing are MAX1 and MAX8.  MAX1 and 
MAX8 are very similar with one of the lysine residues in MAX1 being replaced with glutamic 
acid to reduce the gelation time (Haines-Butterick et al., 2007). MAX1 and MAX8 are both 
designed to self-assemble in cell culture medium (Haines-Butterick et al., 2007).  
It has been reported that MAX1 is non-cytotoxic to fibroblasts, and allows for cell attachment 
and proliferation whilst maintaining its mechanical properties (Kretsinger et al., 2005). The 
capacity for a pro-inflammatory response has been assessed; it is reported that macrophages 
will grow on MAX1 and MAX8 gels and show no significant secretion of pro-inflammatory 
cytokine TNF- indicating that the peptide gels are non-inflammatory (Haines-Butterick et al., 
2008). It has been suggested that MAX1 may be of increased interest as it shows antibacterial 
properties against both Gram positive and negative bacteria (Salick et al., 2007). MAX1 has 
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been shown to inhibit the growth and proliferation of E.coli below a certain concentration, 
above this concentration the surface of the gel is covered and the cell remnants allow for the 
shielding and attachment of other microorganisms (Salick et al., 2007).  
MAX1 and MAX8 have been reported as possible cell encapsulation gels for cell delivery. With 
a reduced gelation time, MAX8 has been reported to be able to entrap cells throughout the gel 
without the cells settling to the bottom (Haines-Butterick et al., 2007). 
 
1.7.5.4 Fmoc-dipeptides 
 
There are a range of Fmoc-dipeptides that will form self-assembled structures. Of particular 
interest is Fmoc-diphenylalanine (Fmoc-FF) as it will form gels at low concentrations at a 
physiological relevant pH (Zhou et al., 2009a). The first reported use of Fmoc-FF was by Gazit 
and co-workers; the majority of the work on biological use of Fmoc-FF has been reported by 
Ulijn and co-workers.  
Fmoc-FF has been reported to have a wide range of mechanical properties. It is believed that 
these observed differences are due to different preparation methods and solution pH used to 
achieve a gel (Helen et al., 2011). A number of different cells have been grown in and on Fmoc-
FF peptide gels. It has been reported that chondrocytes grow and proliferate on the surface of 
Fmoc-FF gels and can be encapsulated in a 3D gel (Jayawarna et al., 2009, Zhou et al., 2009a, 
Yan et al., 2010). It has been shown that other cells, 3T3 and human dermal fibroblasts, die 
when grown on the surface of Fmoc-FF peptide gels (Jayawarna et al., 2009). It was reported 
that when Fmoc-FF was mixed with other Fmoc-protected peptides these problems could be 
overcome. The addition of other Fmoc-amino acids and Fmoc-RGD can allow growth of 3T3 
and human dermal fibroblasts (Jayawarna et al., 2009, Zhou et al., 2009a). Fmoc-FF has been 
suggested as a possible drug delivery mechanism; konjac glucomannan (KGM) has reportedly 
been mixed with Fmoc-FF in solution and self-assembly triggered to form an Fmoc-FF-KGM 
peptide-polysaccharide composite that is able to be tailored to give different release profiles 
(Huang et al., 2011).   
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1.7.5.5 -Helix 
 
An example of coiled coils reported by Woolfson and co-workers uses a pair of 28 amino acids 
long peptides, hSAF AAA-W, to form -helix coiled coils. This pair of peptides can be used to form 
hydrogels that are stable in physiological solutions (Banwell et al., 2009). Neural cells grown in 
hSAF AAA-W peptide gel have been reported to show cell growth, proliferation, differentiation 
and neurite outgrowth but cells grown on Matrigel showed better results (Banwell et al., 
2009).  
Other peptides that self-assemble into coiled coils have been developed, modified and 
explored for biological use. It has been reported that adding an RGD containing region into the 
helix destabilises the peptide gel; when the peptide was used to coat other materials the RGD 
containing peptide was able to increase cell adhesion (Villard et al., 2006). However, RGD 
containing -helices in solution were shown to bind to RGD receptors and inhibit the binding 
of other ligands to the receptor (Villard et al., 2006). This binding could prove problematic as 
the peptide gel breaks down; the binding could also be used as a potential method for slow 
release, targeted drug delivery (Villard et al., 2006). This has implications in the development 
of -helix functionalised peptide gels. 
 
1.7.5.6 Peptide amyloidogenicity 
 
One of the major concerns about fibrillar forming peptides is their similarity to pathological 
amyloid fibrils. Fibrillation of amyloid proteins is associated with the pathogenicity of amyloid 
diseases. Fibrillation is a two-step process involving a slow initial lag phase where nucleation 
seeds are formed followed by comparatively rapid fibril propagation from the seeds (Wu et al., 
2008). The same as what is observed in peptide nucleated self-assembly. There is an increased 
risk that self-assembling peptides could cause increased amyloid deposition by acting as 
nucleating seeds. There are a number of tests for amyloid deposition; basic in vitro tests use 
Congo red and thioflavin staining which can be tested for using microscopy or spectroscopic 
techniques, while animal models of amyloidosis have also been developed for in vivo testing. 
A mouse model of AA-amyloidosis which is triggered by the injection of silver nitrate has been 
used to study the deposition of amyloid fibers in the presence of a range of peptide gels 
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(Westermark et al., 2009). Testing of RAD16-1 in the mouse model showed the potential for 
these peptides to reduce the time taken for amyloid development; it should however, be 
noted that not all the mice in the test developed amyloid formations (Westermark et al., 
2009). 
A wide range of materials have been shown to reduce amyloid deposition time; natural 
amyloid-like fibrillar materials such as Bombyx mori silk, curli from E.coli and artificial materials 
such as nano-particles have all been shown to reduce the lag time of amyloid fibrillar 
formation (Linse et al., 2007, Wu et al., 2008, Westermark et al., 2009). It should also be noted 
that stains such as thioflavin and Congo red not only bind to amyloid like structures but also 
bind to connective tissues such as elastic fibers, mucopolysaccharides and RNA and DNA, an 
increased detection of these stains does not necessarily indicate amyloidogenicity (Khurana et 
al., 2005). 
 
1.7.6 Rational design and modification of peptides 
 
The design of a peptide will be dependent upon the desired properties and responsiveness. 
Peptides can be designed to be responsive to different stimuli. An example is a peptide that 
has side-chains that are able to be protonated and de-protonated: the peptide will respond to 
changes in the pH as the side chains are protonated and de-protonated, such that self-
assembly can be triggered and reversed by changing the pH (Figure 1.17) (Aggeli et al., 2003b, 
Carrick et al., 2007, Maude et al., 2011b). A peptide can be designed that responds to ionic 
concentration; a peptide designed not to self-assemble at neutral pH due to repulsive charge 
interactions will self-assemble when the ionic concentration is changed as the ions shield the 
repulsive charges (Chen, 2005, Carrick et al., 2007, Maude et al., 2011b). 
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Figure 1.17, Left) Schematic modle of pH control over P11-4 self-assembly. Right) Self-assembly of 6.3 
mol.m
-3
 of P11-4 under different conditions. (a) Percentage -sheet of P11-4 as a function of pD in D2O 
(by FTIR). (b) Percentage -sheet of P11-4 as a function of pD in 130 mol.m
-3
 NaCl in D2O (by FTIR). 
Modified from (Aggeli et al., 2003b, Carrick et al., 2007) 
 
Varying the length of the peptide and the amino-acid sequence allows for control over the 
energetics and dynamics of the peptide; this control allows the tailoring of a peptide to have 
specific physical and chemical properties (Aggeli et al., 1997, Chen, 2005). 
Peptides can be obtained in a number of different ways. They can be cleaved from naturally 
obtained proteins, synthesised chemically or can be recombinantly expressed. The advantage 
of peptide self-assembly is the ease with which functional groups can be added to the peptide 
sequence. As -sheet peptides self-assemble face to face the C and N termini are exposed on 
the outside of the peptide tape and make the ideal location for modification (Genové et al., 
2005, Gelain et al., 2006, Gelain et al., 2007, Jung et al., 2009). Other peptide conformations 
can be modified by the inclusion of functional groups into the peptide sequence, as they are 
found in nature, or by modification of exposed side chains. 
The addition of the motif can impact upon the self-assembly and mechanical properties of the 
peptide (Jung et al., 2009), in some cases there is no noticeable effect (Gelain et al., 2006) and 
in others the self-assembly of the peptide is affected (Genové et al., 2005, Villard et al., 2006). 
The modified peptide can then be mixed with unmodified peptide and self-assembled; as long 
as the addition of the motif does not interfere with the self-assembly the modified peptide will 
be incorporated into the self-assembled structure and will not leach out (Jung et al., 2009). 
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This ability to mix modified peptide and unmodified peptide allows for the inclusion of multiple 
functional groups. 
 
1.7.7 Advantages and limitations of peptides as biomaterials for tissue 
engineering 
 
There are a wide range of different self-assembling peptides that have potential as scaffolds 
for tissue engineering. The most widely used peptide in tissue engineering is RAD16-1 with 
results showing good cellular growth and function for a range of different cell types. One 
possible complication with the use of RAD16-1 is the reported haemostatic properties of the 
peptide. An effect upon the blood clotting pathway will make a peptide unsuitable for use in 
contact with blood, especially in the development of a tissue engineered blood vessel. 
Fmoc-FF is attractive due to it being cheap to make. However, difficulty with controlling 
gelation and material properties coupled with the mixed results for the growth of different cell 
types on and in Fmoc-FF gels severally limits the potential applications and raise concerns over 
long term toxicity and peptide-cell interactions. Alpha helix coiled coils show good 
compatibility but are not as good at supporting cell growth and function as commercial 
products like Matrigel. The cost and difficulty of synthesising two 28 amino acid long peptides 
also makes coiled coils less commercially desirable.  
The antibacterial properties of -hairpin peptides MAX1 and MAX8 make them very attractive 
peptide for tissue engineering applications, especially with problems associated with post-
operative infection. The mechanism of this antibacterial activity needs to be better 
understood. Testing is needed on the antibacterial properties as several possible mechanisms 
could impair normal cellular function. The size and associated cost of the -hairpin peptides 
could potentially limit their application. 
The P11 series of peptides have a wide range of potential due to the different material 
properties expressed by the range of peptide sequences. The shorter size of the P11 series 
compared to the -hairpin and -helix peptides makes them more desirable commercially but 
less so than the cheaper/shorter Fmoc-FF. The limited data on the immuno-compatibility of 
some of the P11 series of peptides and the results showing good cell growth and proliferation 
show the potential of some of these peptides. A large amount of work is needed on self-
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assembled peptides to develop peptides that are optimised for specific tissue engineering 
applications. Whilst the majority of peptides have demonstrated potential, more detailed work 
is needed with comparisons to biologically and commercially relevant controls to truly assess 
self-assembling peptides for potential application.   
 
1.8 Hypothesis  
 
A fully decellularised vascular graft will be free from problems of infection, immune response, 
calcification, mechanical mismatch and aneurysm, but will still suffer from thrombus 
formation. A self-assembling peptide could be self-assembled within the decellularised tissue 
to passivate the surface and prevent initial thrombus formation. The re-endothelialisation of 
the decellularised graft could be aided and enhanced by the addition of functionalised 
peptides designed to aid in cell attachment and retention. 
 
1.9 Aims and objectives 
 
The aim of the work undertaken in this thesis is to test the hypothesis that decellularised 
vascular tissue and self-assembling peptides can be combined to overcome the limitations of 
both materials in the application of blood vessel tissue engineering. 
Objectives 
 Investigate the possible self-assembly of peptide with a decellularised vascular 
conduit 
 Assuming that self-assembly in decellularised vessel works, develop a protocol 
for the production of vessel peptide hybrid materials 
 Test a range of peptides for biocompatibility 
 Test a range of peptides for haemocompatibility 
 Analyse results of biocompatibility and haemocompatibility testing to assess 
for any design criteria for biocompatible peptides 
 Test anti-thrombogenic properties of self-assembled peptide 
 Test attachment of cells to functionalised self-assembled peptide  
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2 Materials and methods 
 
2.1 Materials 
2.1.1 Equipment 
 
A list of laboratory equipment used throughout the study and UK suppliers is presented in 
Appendix Table A-1. 
 
2.1.2 Glassware 
 
All laboratory glassware was obtained from Fisher Scientific (Loughbourgh, UK) unless 
otherwise stated. Glassware was cleaned by immersion in a 1 % (v/v) solution of Neutracon® 
for one hour and was then rinsed with tap water and dried or sterilised using dry heat. 
 
2.1.3 Plastic ware 
 
All sterile and non-sterile disposable plastic ware was purchased from Scientific Laboratory 
Supplies Ltd. (Nottingham, UK) unless otherwise stated. All plastic ware was stored as per 
suppliers’ instruction. 
 
2.1.4 Chemicals  
 
A list of all Chemicals and reagents used in this study can be found in Appendix Table A-2. 
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2.1.5 Cell biology reagents and solutions 
2.1.5.1 Dulbecco’s phosphate buffered saline (DPBSa) 
 
One tablet of DPBS per 100 ml was dissolved in distilled water and the pH adjusted to pH 7.6. 
The DPBSa was sterilised by autoclaving and stored at room temperature for up to one month.  
 
2.1.5.2 Ringer’s solution 
 
Four Ringer’s tablets were dissolved in 500 ml of distilled water and the pH adjusted to pH 7.6. 
The Ringer’s solution was sterilised by autoclaving and stored at room temperature for up to 
one month. 
 
2.1.5.3 Tris buffered saline (TBS)  
 
Trizma base, 6.05 g to achieve a final concentration of 50 mol.m-3, and 8.76 g of sodium 
chloride to achieve a final concentration of 150 mol.m-3 were dissolved in 1 L of distilled water 
and the pH adjusted to pH 7.6. The TBS was sterilised by autoclaving and stored at room 
temperature for up to one month. 
 
2.1.5.4 Tryptone phosphate broth 50 % stock solution (TPB) 
 
Tryptone phosphate, 50 mg, was dissolved in 100 ml of distilled water and filter sterilised in a 
class II safety cabinet and stored in aliquots of 10 ml at -20°C. 
 
2.1.5.5 3T3 culture medium 
 
Foetal bovine serum, 20 ml, 2 ml of L-glutamine to achieve a final concentration of 200 mol.m-3 
and 4 ml of penicillin/streptomycin to achieve a final concentration of 100 U.ml-1 were added 
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to 174 ml of Dulbecco’s modified Eagles medium (DMEM) and mixed. Once prepared the 
medium was stored for up to one week at 4°C. 
 
2.1.5.6 2X 3T3 culture medium 
 
Foetal bovine serum, 20 ml, 2 ml of L-glutamine to achieve a final concentration of 400 mol.m-3 
and 4 ml of penicillin/streptomycin to achieve a final concentration of 200 U.ml-1 were added 
to 74 ml of DMEM and mixed. Once prepared the medium was stored for up to one week at 
4°C. 
 
2.1.5.7 BHK culture medium 
 
Foetal bovine serum, 10 ml, 10 ml of tryptone phosphate broth stock solution to achieve a final 
concentration of 2.5 % TPS, 2 ml of L-glutamine to achieve a final concentration of 200 mol.m-3 
and 4 ml of penicillin/streptomycin to achieve a final concentration of 100 U.ml-1 were added 
to 174 ml of Glasgow minimum essential medium (GMEM) and mixed. Once prepared the 
medium was stored for up to one week at 4°C. 
 
2.1.5.8 2X BHK culture medium 
 
Foetal bovine serum, 10 ml, 10 ml of tryptone phosphate broth stock solution to achieve a final 
concentration of 5 % TPB, 2 ml of L-glutamine to achieve a final concentration of 400 mol.m-3 
and 4 ml of penicillin/streptomycin to achieve a final concentration of 200 U.ml-1 were added 
to 74 ml of GMEM and mixed. Once prepared the medium was stored for up to one week at 
4°C. 
 
2.1.5.9 Endothelial cell culture medium 
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Foetal bovine serum, 40 ml, 4 ml of penicillin/streptomycin to achieve a final concentration of 
100 U.ml-1, 30 U.ml-1of heparin sulphate and 75 µg.ml-1 of endothelial cell growth factor (ECGF) 
were added to 156 ml of Medium-199 (M-199) and mixed. Once prepared the medium was 
stored for up to one week at 4°C. 
 
2.1.6 Cells and biological tissues 
2.1.6.1 Cells 
 
All mammalian cell lines used in biocompatibility assays are shown below in Table 2-1 and 
were received as frozen cultures. Cells were expanded, subcultured and cryopreserved in 
liquid nitrogen until use unless otherwise stated. 
 
Cell Type Origin Isolation method Supplier 
3T3 Fibroblast Swiss Mouse 
Embryo Tissue 
Trypsin digestion Health Protection 
Agency Culture 
Collections 
BHK-21 Epithelial Baby Syrian 
Hamster Kidneys 
Trypsin digestion Health Protection 
Agency Culture 
Collections 
Table 2-1; Cells used throughout the study including supplier 
 
2.1.6.2 Biological tissue 
 
Porcine internal carotid arteries were procured from Graystone Ltd (Hull). Vessels arrived 
frozen and were defrosted, dissected and washed in DPBSa. DPBSa was passed through the 
vessels using a syringe to remove remaining blood before use. Vessels not used immediately 
were wrapped in tissue soaked in DPBSa and stored at -80°C. 
Ovine legs were procured from John Penny and Sons abattoir (West Yorkshire). All legs arrived 
fresh having been slaughtered that morning. All procedures involving the ovine legs were 
carried out on the day of arrival.  
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Citrated sheep blood was obtained from Harlan Laboratories. Blood was mixed with trisodium 
citrate 10% (w/v) upon harvesting and shipped under refrigerated conditions. Blood was 
received, stored at 4°C and used within 5 days.  
Normal human serum from pooled normal clotted human blood, tested for Hepatitis 
associated antigen and HIV, was purchased from MP Biomedicals Europe. Serum arrived as a 
frozen sample, was stored at -20°C and was defrosted at room temperature before use. 
All animal tissue and biological fluids were disposed of following established procedures in 
place at the time of experimentation. 
 
2.1.7 Antibodies 
 
A list of antibodies used throughout the study and suppliers information is presented in Table 
2-2,Table 2-3 and Table 2-4. 
 
Antigen Type Clone number Isotype Dilution Supplier 
Red Blood Cell 
Stroma 
Rabbit anti-
sheep 
- IgG1 1:200 Sigma Aldrich 
Von Willebrand 
Factor 
Rabbit anti-
human 
- Polyclonal 1:200 Dako UK Ltd 
 Smooth 
Muscle Actin 
Mouse anti-
human 
1A4 IgG2a 1:400 Sigma Aldrich 
Smooth Muscle 
Myosin Heavy 
Chain 
Mouse anti-
human 
N1/5 1gG1 1:100 Chemicon 
International 
Endothelial Cell 
CD31:FITC 
Mouse anti-
sheep 
CO.3E1D4 1gG2a 1:100 AbD Serotec 
Table 2-2; Primary antibodies used throughout the study 
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Antigen Type Conjugate Dilution Supplier 
Mouse Whole 
antibody 
Goat anti-
Mouse 
Alexa Fluor 488 1:200 Invitrogen Ltd 
Rabbit F(ab’)2 
fragment 
Goat anti-
rabbit 
Alexa Fluor 488 1:200 Invitrogen Ltd 
Table 2-3; Secondary antibodies used throughout the study 
 
Antigen Host Isotype Dilution Supplier 
Aspergillus niger 
glucose oxidase 
Mouse IgG2a As Primary Dako UK Ltd 
Aspergillus niger 
glucose oxidase 
Mouse IgG1 As Primary Dako UK Ltd 
- Rabbit Immunoglobulin 
fraction 
As Primary Dako UK Ltd 
Aspergillus niger 
glucose oxidase 
Mouse IgG2a-FITC As Primary MBL international 
Table 2-4; Isotype control antibodies used throughout the study 
 
2.1.8 Peptides 
 
All P11 series peptides and peptides hSAF AAA-W P1 and P2 were purchased from Polypeptide 
group, Fmoc-diphenylalanine was purchased from BACHEM and the homo-polypeptides were 
purchased from Sigma Aldrich; all peptides were tested for purity on arrival using elemental 
analysis and were over 95 % pure. 
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2.2 General Methods 
2.2.1 Sterilisation 
2.2.1.1 Dry heat sterilisation 
 
Items to be sterilised were placed in suitable containers or wrapped in tinfoil and placed into a 
hot air oven at a temperature of 190°C for 4 hours. Items were allowed to cool and then 
removed from the oven taking care to maintain sterile conditions. 
 
2.2.1.2 Moist heat/ autoclave sterilisation 
 
Solutions and items not suitable for dry heat sterilisation were sterilised using an autoclave. 
Items were placed into suitable containers or placed into autoclave bags and labelled with 
autoclave tape. Items were autoclaved at 15 psi at 121°C for 20 minutes. Items were allowed 
to cool and were then removed from the autoclave taking care to maintain sterility. 
 
2.2.1.3 Gamma irradiation sterilisation 
 
The peptides used in biological experiments were weighed out into glass vials and sterilised as 
a dry powder as the peptides could not be autoclaved or sterilised using dry heat. Gamma 
sterilisation at 25 kGy was carried out by Synergy Health using standard methods developed 
for the sterilisation of medical products. 
 
2.2.2 Measurement of pH 
 
The pH meter was calibrated using purchased solutions of pH 4, 7, and 10. The pH of solutions 
was measured at room temperature using temperature compensation. The pH of solutions 
was changed by the drop-wise addition of 6 M hydrochloric acid (HCl) or 6 M sodium 
hydroxide (NaOH) whilst stirring unless otherwise stated. 
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2.2.3 Decellularisation of porcine arterial conduits 
 
Reagents 
Disinfection 
solution 
Vancomycin hydrochloride, 50 mg to achieve a final concentration of 0.05 
mg.ml-1, 500 mg Gentamicin sulphate to achieve a final concentration of 0.5 
mg.ml-1 and 200 mg polymyxin B to achieve a final concentration of 0.2 
mg.ml-1 were added to 100 ml of DPBSa and the pH adjusted to pH 7.4. The 
solution was passed through a 0.2 µm pore size filter and made up to 1 L 
using sterile DPBSa. 
EDTA solution Disodium ethylenediaminetetra acetic acid (EDTA), 74.4 g to achieve a final 
concentration of 200 mol.m-3, was dissolved in 1L of distilled water and the 
pH adjusted to pH 7.4. The EDTA solution was sterilised by autoclaving and 
stored at room temperature for up to one month. 
Hypotonic 
buffer 
Trizma base, 1.21 g to achieve a final concentration of 10 mol.m-3 and 1 g of 
EDTA to achieve a final concentration of 2.7 mol.m-3 were added to 1 L of 
distilled water and the pH adjusted to pH 8.2. The hypotonic buffer was 
sterilised by autoclaving and stored at room temperature for up to one 
month. Aprotinin, 1 ml to achieve a final concentration of 10 KIU.ml-1, was 
added before use. 
SDS solution Sodium dodecyl sulphate, 10 g to achieve a final concentration of 10 % 
(w/v), was dissolved in 100 ml of distilled water and was passed through a 
0.2 µm pore size filter. The solution was stored at room temperature for up 
to six months. 
SDS hypotonic 
buffer 
SDS solution, 10 ml to achieve a final concentration of 0.1 % (w/v), was 
added to 990 ml of autoclaved hypotonic buffer and stored for one week at 
4°C if opened aseptically. 
Washing buffer Ten Oxoid Dulbecco’s PBS tablets and 1 g of EDTA to achieve a final 
concentration of 2.7 mol.m-3 were dissolved in 1 L of distilled water and the 
pH adjusted to pH 7.4. The wash buffer was sterilised by autoclaving and 
stored at room temperature for up to one month. 
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Nuclease 
solution 
Trizma base, 6.1 g to achieve a final concentration of 50 mol.m-3 and 2 g 
magnesium chloride to achieve a final concentration of 20 mol.m-3 were 
dissolved in 990 ml of distilled water and the pH adjusted to pH 7.6. The 
nuclease solution was sterilised by autoclaving and stored at room 
temperature for up to one month. Bovine serum albumin, to achieve 50 
µg.ml-1, DNAase to achieve 50 U.ml-1 and RNAase to achieve 1 U.ml-1 were 
added and the solution used within 10 minutes. 
Hypertonic 
solution 
Trizma base, 6.06 g to achieve a final concentration of 50 mol.m-3 and 87.66 
g sodium chloride to achieve a final concentration of 1.5 X103 mol.m-3 were 
dissolved in 1 L of distilled water and the pH adjusted to pH 7.6. The 
hypertonic solution was sterilised by autoclaving and stored at room 
temperature for up to one month. 
Sterilising 
solution 
Peracetic acid, 3.14 ml to achieve a final concentration of 0.1 % (v/v), was 
added to 1 L of autoclaved DPBSa and the pH adjusted to pH 7.4. The 
solution was used within one hour of production. 
 
Procedure 
Following dissection of the vessel from surrounding tissue or defrosting, 15 cm lengths of the 
porcine arteries were placed in plastic pots and washed using 150 ml of the disinfection 
solution for 30 minutes at 37°C. All washes were carried out with agitation on a shaking table 
at 110 rpm. Following disinfection the vessels were washed in 150 ml of EDTA solution at 4°C 
for 24 hours. The arteries were then removed and washed in 150 ml of hypotonic buffer at 4°C 
for 24 hours. To further remove cells and cellular debris the arteries were washed in 150 ml of 
SDS hypotonic solution at 37°C for 24 hours then washed in 150 ml of hypotonic buffer at 4°C 
for 24 hours. The vessels were washed in 150 ml of washing buffer containing 10 KIU.ml-1 of 
aprotinin over the weekend (48-56 hours) at 4°C followed by a further wash in 150 ml SDS 
hypotonic buffer at 37°C for 24 hours. The vessels were washed three times using 150 ml of 
DPBSa at 37°C for 30 minutes each and then washed using 150 ml of the nuclease solution at 
37°C for 3 hours. The vessels were washed three times in 150 ml of washing buffer containing 
10 KIU.ml-1 of aprotinin at 37°C for 30 minutes each. The vessels were added to 150 ml of the 
hypertonic solution at 37°C for 24 hours then washed three times in 150 ml of the washing 
buffer containing 10 KIU.ml-1 of aprotinin for 30 minutes each. The vessels were sterilised using 
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150 ml of the sterilising solution at 27°C for 3 hours; further manipulations were carried out 
aseptically in a class II safety cabinet. The vessels were washed using 150 ml of the washing 
buffer containing 10 KIU.ml-1 of aprotinin at 37°C for 30 minutes each then washed with 150 
ml of DPBSa at 4°C for 24 hours. The decellularisation of the vessels was assessed using 
histological techniques described in Section 2.2.4 and the vessels were stored in 150 ml of 
DPBSa at 4°C for up to three months. 
 
2.2.4 Analysis of decellularisation  
2.2.4.1 Paraffin wax embedding of tissue samples 
 
Samples were placed into small plastic cassettes (Histosette®) and dehydrated using an 
automated tissue processor. The automated tissue processor sequentially immersed the 
samples in 70% (v/v) alcohol for 1 hour, 90% (v/v) alcohol for 1 hour and three changes of 
100% (v/v) alcohol for 1 hour each. The samples were then immersed in two changes of xylene 
for 1 hour each. The cassettes were then immersed in molten paraffin wax for 1 hour then 
transferred to fresh paraffin wax for a further hour. Once the processor had finished the 
samples were kept in molten paraffin wax until removed. Wax block moulds were filed with 
molten paraffin wax and the samples quickly removed from the cassettes and orientated in the 
wax block moulds using heated forceps. The molten paraffin wax was allowed to cool and once 
fully hardened the moulds were removed and the excess wax trimmed. 
 
2.2.4.2 Sectioning of paraffin wax embedded samples 
 
The paraffin wax blocks were sectioned at 5 – 10 µM using a microtome. The sections were 
floated in a water bath at 40°C for mounting on a glass slide. The glass slide with three sections 
on was placed on a rack to dry. The slides were then placed on a hot plate for 20 minutes to 
further dry and melt the wax, fixing the sections to the slide. After drying the slides were left to 
cool and then placed in a slide holder for storage.  
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2.2.4.3 De-waxing and rehydration of sectioned paraffin wax embedded samples 
 
The slides were de-waxed by submersion in two changes of xylene for ten minutes each to 
remove all the wax. The slides were then placed in three changes of 100 % (v/v) ethanol for 
three, two and two minutes respectively. The slides were then submerged in 70 % (v/v) 
ethanol for two minutes and washed under running water for three minutes. 
 
2.2.4.4 Haematoxylin and Eosin staining 
 
Haematoxylin stains cell nuclei and eosin is used to stain cytoplasm, collagen and muscle 
fibres. The de-waxed and rehydrated sections on slides were placed into a metal slide holder 
and immersed in haematoxylin for one minute. The slides were then removed and washed 
under running water until it ran clear and all excess stain had been removed.  The sections 
were then immersed in eosin stain for three minutes. Sections were then immediately 
mounted as is Section 2.2.4.6.1. 
 
2.2.4.5 DAPI staining 
 
Reagents 
Dye Buffer Trizma base, 1.211g to achieve a final concentration of 10 mol.m-3, 0.3724 g 
of EDTA to achieve a final concentration of 1 mol.m-3 and 5.8 mg of sodium 
chloride to achieve a final concentration of 1 mol.m-3 were dissolved in 1 L of 
distilled water and sterilised by autoclaving. The solution was stored at room 
temperature in the dark for up to six months the pH was adjusted to pH 7.4 
before use. 
DAPI dye stock DAPI, 10 mg, was added to 10 ml of nuclease free water and stored in 20 µl 
aliquots at -25°C for up to six months 
Working dye DAPI dye stock solution, 40 µl to achieve a final concentration of 0.1 µg.ml-1, 
was mixed with 400 ml of Dye buffer in a dark bottle and used immediately. 
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Procedure 
DAPI or 4’, 6-diamidino-2-phenylindole forms fluorescent complexes that bind strongly with A-
T base rich regions within DNA. The sections having been de-waxed and rehydrated (Section 
2.2.4.3) were placed in a metal slide holder and immersed in DAPI solution for ten minutes in 
the dark then washed three times using DPBSa for ten minutes each in the dark. The sections 
were mounted using DABCO:glycerol (Section 2.2.5), then imaged under a fluorescent 
microscope using a DAPI filter. 
 
2.2.4.6 Mounting of sections 
2.2.4.6.1 Mounting of stained sections using DPX mountant 
 
Following staining sections were submerged in 70 % (v/v) ethanol for five seconds and taken 
through three changes of 100 % (v/v) ethanol for one, two and three minutes respectively. The 
slides were then submerged in two changes of clean xylene for ten minutes each and the 
sections mounted using DPX mountant and glass cover slips. Slides were left to dry for a 
minimum of four hours and imaged using an upright microscope and images captured using a 
digital camera and Image-Pro Plus v 5.1.  
 
2.2.5 Mounting of sections using DABCO:glycerol 
 
Reagents 
Mounting 
solution 
DABCO (1,4-diazabicyclo octane) 2.5 % (w/v), 10 ml, was added to 90 ml of 
glycerol and mixed. The solution was stored in the dark at 4°C for up to 3 
months. 
 
Procedure 
Following cryostat sectioning or staining the sections were mounted using the mounting 
solution. A small drop of mounting solution was placed in proximity to each section and a glass 
cover slip placed on top. Slides could be immediately imaged or left on the dark for a 
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maximum of 24 hours. Samples were imaged using an upright microscope and images 
captured using a digital camera and Image-Pro Plus v 5.1. 
 
2.2.6 Triggering peptide self-assembly 
 
Rationale 
Peptide self-assembly can be triggered in a number of different ways. One dimensional 
nucleated self-assembly is a concentration dependent reaction thus self-assembly can be 
triggered by changing the concentration of peptide in solution, however, it is difficult to 
control concentration when switching between a monomeric and self-assembled state. By 
using peptides that are charged and can be protonated and de-protonated it is possible to 
trigger self-assembly by a pH change or change in ionic concentration. Dependent upon the 
amino acids used in the peptide sequence and their associated pKa values high or low pH can 
trigger self-assembly or disassembly. A concentration of 18.8 mol.m-3, approximately 30 mg.ml-
1 of P11 peptide, was used as a standard concentration for the formation of a self-supporting 
peptide gel. 
 
2.2.6.1 Peptide monomer solution 
 
To ensure the peptide formed a uniform gel upon self-assembly the peptide first had to be 
monomeric in solution to ensure an even distribution of peptide. A monomeric/soluble 
aggregate solution of peptide was made by increasing the pH of the solution to pH 8 using 1 M 
NaOH or by decreasing the pH to pH 5 using concentrated HCl dependent upon the designed 
responsiveness of the peptide. For example P11-4 was monomeric at pH 8 and self-assembled 
at pH 5 where P11-8 was designed for the opposite response and was monomeric at pH 5 and 
self-assembled at pH 8. The peptide solution was vortexed after each addition. The pH of the 
solution was then changed to pH 7.6 using concentrated HCl or 1M NaOH, vortexing after each 
addition. A new pH reading was taken using a pH meter after every acid or base addition. 
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2.2.6.2 Self-assembly triggers 
2.2.6.2.1 pH trigger 
 
As the pH is changed amino acids are protonated or de-protonated removing or restoring the 
repulsive forces between the peptide monomers triggering self-assembly or disassembly. A 
monomeric solution of peptide was made in water as in Section 2.2.6.1. To use pH as a trigger 
for self-assembly the pH of the solution was decreased using concentrated HCl to pH 5 or 
increased to pH 8 using 1M NaOH, dependent upon the designed responsiveness of the 
peptide, vortexing after each addition. The peptide solution was left overnight to allow for self-
assembly to fully occur.  
 
2.2.6.2.2 Ionic trigger 
 
As the ionic concentration is increased a screening effect removes the repulsive forces 
between the peptide monomers triggering self-assembly. There are a number of biologically 
relevant salt solutions in which peptide should self-assemble. PBS is a very common salt 
solution that was chosen for use as it is widely used in biological applications, another solution 
that was chosen for use is Ringer’s solution, since it is a physiological solution.  
Water, 0.9 ml (9/10 final volume) was added to peptide to make a monomeric solution as in 
Section 2.2.6.1. Self-assembly was triggered by the addition of 0.1 ml (1/10 final volume) of a 
10X solution of PBS or Ringer’s solution to create 1 ml of peptide in standard PBS or Ringer’s 
solution. The peptide solution was left overnight to allow for self-assembly to fully occur. 
 
2.2.7 Peptide self-assembly in decellularised porcine internal carotid artery 
 
Rationale 
The self-assembly of peptide within the decellularised porcine internal carotid artery first 
required that the peptide was able to penetrate the material. The artery was naturally porous, 
however, to ensure that the peptide penetrated into the acellular vessel the peptide was 
added to the decellularised artery in a monomeric from unless otherwise stated. This was the 
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same whether the self-assembly was triggered by a pH change or by an increase in ionic 
concentration.  
 
Procedure 
A monomer solution of peptide was made (Section 2.2.6.1) the acellular vessel was added to 
the solution and left overnight to allow the peptide to fully penetrate into the vessel. Self-
assembly was then triggered as described in Section 2.2.6.2 or in Section 2.2.6.2.2 dependent 
upon which trigger was being used. The vessel was left in the peptide solution overnight to 
allow for self-assembly to occur.  
 
2.2.8 Inclusion of fluorescently labelled peptide for fluorescent microscopy 
 
Peptide P11-4 was labelled with a fluorescein tag using a -alanine spacer to show the presence 
of the peptide within the decellularised vessel (Fluorescein-A-Q-Q-R-F-E-W-E-F-E-Q-Q-NH2). It 
was found that a ratio of 1:30 of fluorescein tagged P11-4 to untagged P11-4 gave strong high 
quality fluorescent images. Following self-assembly within decellularised vessel as described in 
Section 2.2.7 the samples were left in the dark until use.  
 
2.2.9 Fourier transform infrared (FTIR) spectroscopy 
 
Rationale 
The Born-Oppenheimer approximation allows molecular rotational, translational and 
vibrational motion to be considered separately (Hollas, 2004, Griffiths and De Haseth, 2007). 
FTIR spectroscopy works on the principle that the differences between vibrational energy 
levels are in the range of infra-red radiation (IR). The IR frequency absorbed by a bond is 
influenced by the vibrational frequency of the bond; the vibrational frequency of the bond is in 
turn influenced by the mass of the atoms and nature of the bonds. This means that for a 
particular molecule the precise absorbance of a bond is governed by the affect different atoms 
in the molecule have on the bonding and on inter/intra-molecular effects, such as hydrogen 
bonding and π-π stacking. 
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As -sheet and -helix both have different hydrogen bonding patterns the secondary 
structures observed in peptide self-assembly can be identified using FTIR. There are significant 
differences in the hydrogen bonding in a -helix structure compared to a -sheet structure; 
this gives rise to the characteristic amide I (1600 – 1700 cm-1) and the amide II (1500 – 1600 
cm-1) absorption bands (Seshadri et al., 1999). The amide I band is mainly due to C=O 
stretching where amide II is mainly due to N-H bending. 
The key component of an FTIR spectrometer is the interferometer. The interferometer is an 
optical device with a beam splitter used to split and recombine the beams produced by the 
source. After being split the incident radiation hits one of two mirrors; both mirrors are at right 
angles to each other and one is fixed in position and one moves position. As the radiation 
beam hits the mirror it is reflected back and re-enters the beam splitter, part of the beam is 
then reflected back at the source and part is directed towards a detector. As the movable 
mirror is moved an interference pattern is produced as the waves from the fixed and movable 
mirrors are recombined. The recombined beam is then passed through a sample before it 
reaches a detector. An interferogram of the sample is produced as the intensity of the IR 
radiation reaching the detector is measured as the mirror is moved. This interferogram is then 
analysed using Fourier analysis which splits a curve into its component wavelengths, this 
analysis gives a spectrum which is the Fourier transform of the interferogram (Griffiths and De 
Haseth, 2007). 
 
Procedure 
To provide quantitative evidence that the peptide was self-assembling in the acellular vessel 
FTIR analysis was carried out. Decellularised porcine internal carotid artery sections were 
placed in 10 ml of deuterium oxide and left over night. The decellularised vessel was removed 
from the deuterium oxide and placed in 10 ml of new deuterium oxide and left over night. This 
was repeated once more to remove any residual water that could affect the FTIR scan. Peptide 
was self-assembled within half of the decellularised vessel sections using the method 
described in Section 2.2.6.2 replacing water in all solutions with deuterium oxide.  The 
remaining decellularised vessel sections were kept in deuterium oxide and taken through the 
same pH changes as the vessels added to the peptide solutions. The peptide coated vessel 
sections and decellularised vessel sections without peptide as a control were compressed 
between two calcium fluoride optical disks and an FTIR spectrum taken. The sample was then 
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moved between the disks to take a spectrum of a different area of the vessel. The spectra from 
the random locations of the samples were combined into a single spectrum and analysed. 
 
2.2.10 Field emission gun scanning electron microscope (FEGSEM) imaging 
 
Rationale 
A scanning electron microscope (SEM) works by scanning a high intensity beam of electrons 
over the surface of a sample using magnetic coils to control the beam of electrons. When the 
electron beam hits the target secondary electrons, backscattered electrons and X-rays are 
produced. The main imaging in the SEM uses secondary electrons, which are electrons from 
the sample that have been ionised by the interaction with the electron beam. X-rays and 
backscattered electrons are used to gather data on the composition of the sample. FEGSEM 
refers to the method by which the electron beam is produced; a field emission gun uses a large 
potential gradient to pull electrons from a tungsten tip. The field emission gun produces a 
beam of electrons that is smaller in diameter and is more coherent with up to three orders of 
magnitude greater current density (brightness) than a normal SEM.  
ECM will collapse and lose its structure when the water is removed; normally biological tissue 
is dried by changes of organic solvents like methanol and ethanol, however, the use of peptide 
prevents the use of organic solvents as the peptide would be removed in these solvents. 
 
Procedure 
In order to maintain the structure of the ECM sections of vessel decellularised as described in 
Section 2.2.3 were fixed in neutral buffered formalin for 4 hours and washed in three changes 
of 20 ml of sterile PBS. Peptide was then self-assembled within the samples (Section 2.2.7). 
The peptide coated fixed vessels were dried in vacuum overnight to ensure the removal of all 
water before imaging in the FEGSEM. The samples were attached to SEM stubs using double 
sided stick carbon pads and coated in a 5 nm layer of platinum and palladium (50:50) using a 
Cressington 108 sputter coater. The samples were then imaged using a Gemini LEO 1530 
FEGSEM at 3 KeV. 
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2.2.11 Fluorescent microscopy imaging 
2.2.11.1 Sectioning of fluorescent samples 
 
The samples were embedded in cryostat embedding solution (Cryoembed, Bios Europe Ltd) at 
-30°C. Once the embedding solution had fully set the samples were sectioned at 7 µm using a 
cryostat. Three sections were collected on a glass slide, covered and allowed to air dry in the 
dark. Sections were mounted with DABCO:glycerol mountant (Section 2.2.5) and kept in the 
dark until imaged. 
 
2.2.11.2 Fluorescent imaging 
 
Sectioned samples were imaged within 24 hours of sectioning using an inverted fluorescent 
microscope with a FITC filter. Images were captured in black and white using a digital camera 
and colour added using Image-Pro Plus v 5.1. 
 
2.2.12 Confocal laser scanning microscopy (CLSM) and multi-photon laser scanning 
microscopy (MPLSM) 
 
The key feature of both the CLSM and the MPLSM is the ability to acquire in-focus images from 
different depths, a process known as optical sectioning. The CLSM does this by using a laser 
that is focused onto a small area of the sample. The fluorescent and reflected light is 
recollected by the objective lens and part of the light is split off into the photo-detector using a 
light splitter. The light passes through a filter that blocks the reflected light but not the 
fluorescence. After passing through a pinhole aperture the light intensity is measured using a 
photo-detector. The pinhole aperture blocks out light not coming from the focal point; out of 
focus light is suppressed meaning that the CLSM provides sharper images than conventional 
fluorescent microscope techniques and is capable of gathering Z-axis stacks through the 
sample. MPLSM works by using red-shifted excitation light; this means that for a fluorophore 
to emit light, two photons have to be absorbed. The probability of absorbing two photons at 
the focal point of the microscope is significantly higher than for any other area in the sample 
and as single stray photons will not cause fluorescence the area that is imaged in a multi-
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photon microscope has less background noise and higher resolution (Figure 2.1). One 
advantage of the use of MPLSM and CLSM is the imaging of live wet samples. 
 
 
Figure 2.1; Schematic of CLSM and MPLSM excitation 
 
2.2.12.1 Confocal laser scanning microscopy (CLSM) imaging 
 
Decellularised vessel was coated in fluorescein tagged P11-4 as described in Section 2.2.8. Self-
assembly was triggered using an ionic trigger as in Section 2.2.6.2.2. The peptide coated 
decellularised vessel was left in the excess peptide gel in a hydrated state until use. The 
samples were imaged in a wet state and were placed on a glass slide with a cover slip on top. 
To reduce the refractive index mismatch and improve the image quality an oil immersion 
objective lens was used rather than a dry objective lens (Frisken Gibson and Lanni, 1991). The 
samples were imaged using a Zeiss LSM 510 META inverted confocal microscope using a FITC 
filter. Images were collected using the associated image software (Carl Zeiss ZEN) and were 
analysed using LSM image browser. 
 
2.2.12.2 Multi-photon laser scanning microscopy (MPLSM) imaging 
 
Decellularised vessel was coated in fluorescein tagged P11-4 as described in Section 2.2.8. Self-
assembly was triggered using a change in ionic concentration as in Section 2.2.6.2.2. The 
peptide coated decellularised vessel was left in the excess peptide gel in a hydrated sate until 
use. Samples were imaged by technicians at the University of York using a Zeiss LSM 510 NLO 
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on an Axiovert 200M microscope stand with a coherent Chameleon Ultra TiSa tuneable laser. 
Images were taken and analysed using LSM image browser. 
 
2.2.13 Cell culture 
2.2.13.1 Resurrection and culture of primary cells and cell lines 
 
Cells were removed from liquid nitrogen storage and rapidly defrosted at 37°C in a water bath. 
Supplemented cell culture medium (10 ml) pre-warmed to 37°C was added drop wise to the 
cells. The cells were centrifuged at 150 g for ten minutes, the supernatant discarded and the 
cell pellet resuspended in 5 ml of supplemented cell culture medium. The cell suspension was 
transferred to a 25 cm2 tissue culture flask and incubated in 5 % (v/v) CO2 in air at 37°C. The 
medium was removed and replaced with 5 ml of supplemented cell culture medium every 48 
hours until the cells became confluent. 
 
2.2.13.2 Sub-culture of primary cells and cell lines 
 
The culture medium was removed from the flask and the cell layer was washed using 10 ml of 
Hank’s balanced salt solution without calcium and magnesium. After 2 – 5 minutes the Hanks 
balanced salt solution was removed and replaced with trypsin/EDTA solution (1 ml in a 25 cm2 
tissue culture flask, 2.5 ml in a 75 cm2 tissue culture flask and 5 ml in a 175 cm2 tissue culture 
flask) and incubated in 5 % (v/v) CO2 in air at 37°C for no more than five minutes. The cells 
were dislodged from the surface of the flask by gently tapping the surface. The trypsin was 
neutralised by the addition of 5 ml of supplemented medium, containing at least 10 % (v/v) 
foetal calf serum. The cell suspension was transferred to a sterile universal tube and 
centrifuged at 150 g for ten minutes. The supernatant was removed and the cells resuspended 
in 5 ml of supplemented medium. The total number of viable cells was determined using the 
trypan blue method (Section 2.2.13.3). The cells were seeded into a larger tissue culture flask 
or split 1:3 into the same size tissue culture flasks with 5ml of supplemented cell culture 
medium for a 25 cm2 tissue culture flask, 10 ml of medium in a 75 cm2 tissue culture flask and 
15 ml of medium in a 175 cm2 tissue culture flask. The cells were incubated in 5 % (v/v) CO2 in 
air at 37°C with the medium changed every 48 hours. 
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2.2.13.3 Trypan blue estimation of cell viability and number 
 
Rationale 
The trypan blue exclusion test works on the principle that a viable cell will have an intact 
membrane and is there for not permeable to the dye. When cell death occurs the membrane 
begins to lose integrity and becomes permeable to the dye. The cells that remain unstained 
are viable whilst unviable cells are stained blue. 
 
Procedure 
The cell suspension (90 µl) was mixed with the trypan blue dye (10 µl). The stained suspension 
was loaded onto a haemocytometer (Figure 2.2) and was observed under an inverted 
microscope. The number of unstained cells was counted and in order to make the counts 
accurate the cell suspension was diluted such that the total number of cells in each chamber 
was between 30 and 300 cells.  
 
 
Figure 2.2; Schematic of area cells are counted on a haemocytometer 
 
The mean cell count was calculated by dividing the number of cells counted by the number of 
1 mm2 squares counted. The total number of viable cells per ml was calculated using the 
following: 
Number of cells.ml-1 = Mean cell count x 104 x Original dilution (10/9) 
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2.2.13.4 Cryopreservation of primary cells and cell lines 
 
Cells were harvested from culture as described in Section 2.2.13.2. The cell suspension was 
transferred to a sterile universal tube and centrifuged at 150 g for ten minutes. The 
supernatant was removed and the cells resuspended in 5 ml of supplemented medium. The 
total number of viable cells was determined and the cell suspension was transferred to a 
sterile universal tube and centrifuged at 150 g for ten minutes. The supernatant was removed 
and the cells resuspended in medium containing 20 % (v/v) foetal calf serum and 10 % (v/v) 
dimethyl sulfoxide (DMSO), which was filtered before use, at a density appropriate for the 
growth of the cell type in a 25 cm2 tissue culture flask. Aliquots of 1 ml the cell suspension 
were placed into cryovials then placed in a Mr Freezy pot containing isopropanol. The Mr 
Freezy pot was placed in a -80°C freezer overnight and the vials then transferred to liquid 
nitrogen for long-term storage.  
 
2.2.14 Biocompatibility testing 
 
Rationale 
Cells will not grow in a toxic environment; hence by growing cells in contact with a material or 
in an extract of a material, the material may be tested for any potential toxic effects. Cell 
growth is easily measured in a number of ways. A simple method, used here, was the ATPLite-
M® assay. When the level of ATP from the cells grown in the presence of the extract was 
compared to the negative and positive controls it was possible to asses for any toxic effects. 
Toxic effects would be shown by a reduction in the level of ATP produced by the cells in 
comparison with the negative control. As not all the peptides could be tested by contact 
cytotoxicity testing, the assessment of biocompatibility was based on extract cytotoxicity 
testing.  
 
Procedure 
Each peptide was weighed and following sterilisation was added to GMEM and DMEM to 
create test solutions that would give a final concentration of 0.3 mol.m-3 of each peptide 
during the cytotoxicity testing. 
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Two cell lines, 3T3 and BHK cells, were sub-cultured and resuspended in cell culture medium; 
DMEM based medium for 3T3 cells (Section 2.1.5.5) and GMEM based medium for BHK cells 
(Section 2.1.5.7). Cells were seeded at an appropriate cell density to achieve 80 % confluence 
in a 96 well plate. The cell suspension (200 µl) was added to the wells of a 96 well plate and 
incubated for 48 hours at 37°C in 5 % (v/v) CO2 in air. The cell culture medium was aspirated 
from the cells and replaced with 100 µl of fresh 3T3 and BHK cell culture medium with double 
the concentration of additives (Sections 2.1.5.6 and 2.1.5.8). To this, 100 µl of test solution or 
control (positive, standard cell culture medium with 40 % DMSO; negative, standard cell 
culture medium) was added and incubated at 37°C in 5 % (v/v) CO2 in air for 72 hours. Six 
samples of each peptide were tested. The level of ATP was then measured using the ATPLite-
M® assay described in Section 2.2.14.1. The results were collected and graphed as the mean 
value with 95 % confidence limits (Section 2.2.21.1). Data was analysed for significant 
difference by one-way ANOVA. 
 
2.2.14.1 ATPLite-M® assay 
 
Rationale 
Adenosine triphosphate plays a key role in energy exchanges in all living cells; cell injury or 
nutrient depletion results in a rapid decrease in cytoplasmic ATP (Crouch et al., 1993). ATP can 
be measured using a luminescence assay. The ATPLite-M® assay uses the luciferase enzyme 
from fireflies that reacts with luciferin to produce light. MgATP2- converts the luciferin into a 
form that is oxidised by luciferase in a high yield chemiluminescent reaction (Crouch et al., 
1993). Cellular ATP can be measured by lysis of the cells and reaction with luciferin-luciferase 
leading to luminescence emission (Crouch et al., 1993). 
 
Procedure 
ATPLite-M® assay reagents, lyophilised substrate solution, substrate buffer and mammalian 
cell lysis solution, were allowed to equilibrate to room temperature. The vial of lyophilised 
substrate solution was reconstituted by the addition of 5 ml of substrate buffer.  
The medium was aspirated from each well of the 96 well plate and replaced with 100 µl of 
fresh cell culture medium. To each well 50 µl of mammalian cell lysis solution was added and 
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shaken at 500 rpm for five minutes. To each well 50 µl of substrate solution was added; the 
wells were covered to prevent photo-bleaching and shaken at 500 rpm for five minutes. The 
luminescence was determined using TopCount™. A printed copy of the data was taken, 
recorded and the results transcribed into Microsoft® Excel 2007. 
 
2.2.15 Chandler loop thrombosis model 
 
Rationale 
The Chandler loop model was developed to create a model thrombus in vitro that could be 
used to understand thrombus formation and test “clot busting” drugs for their action 
(Chandler and Jacobsen, 1967, Mutch et al., 2009). There are many different variations on the 
Chandler loop model but the basic model uses a loop of plastic tubing to model a blood vessel. 
Whole blood is added to the loop and rotated at a rate to model normal blood flow in a vessel. 
This produces a standardised thrombus that can easily be removed from the plastic tubing and 
analysed. The Chandler loop forms thrombi that are very similar in morphology to arterial 
thrombi formed in vivo comprising dense platelet and leukocyte rich upstream sections, white 
heads, and red blood cell and fibrin rich downstream sections, red tails (Stringer et al., 1994, 
Robbie et al., 1997). It has been shown by electron microscopy that the platelets in thrombi 
formed in the Chandler loop contained only mitochondria, indicating that platelet de-
granulation had occurred and that there was a polarised distribution of leukocytes 
predominantly in the white heads of the thrombi similar to the distribution seen in arterial 
thrombi (Stringer et al., 1994). Thrombosis in the Chandler loop model is characterised by the 
formation of small platelet aggregates followed by the formation of fibrin and larger platelet 
aggregates that eventually will occlude the loop (McClung et al., 2007b). Thrombogenesis in 
the Chandler loop model has been attributed to the formation of thrombin in the loop 
(Hornstra, 2009). This model can also be modified to test the interactions of materials with 
blood and the effect this has upon thrombus formation. The modified Chandler loop model is 
widely used to test stents and bypass grafts by introducing the stents to the tubing or by 
adding in a graft material as part of the loop (Christensen et al., 2001, Weber et al., 2002, Tepe 
et al., 2006, McClung et al., 2007a).  
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2.2.15.1 Chandler loop model for testing addition of material to blood 
 
Rationale 
In this study the Chandler loop model was modified to test the effect of a solution containing 
peptide monomer or soluble aggregate on thrombus formation. The Chandler loop model 
creates a thrombus of uniform size but normally does not involve total clotting of all the blood 
added to the loop. Adding a clotting agent such as -thrombin will cause total clotting of the 
blood and produce a significantly larger thrombus. As the thrombus normally produced is 
uniform in size the effect of a material on thrombus formation can be observed by a difference 
in the mass of the thrombus produced. If a material has an anti-clotting effect no thrombus or 
a smaller thrombus will be produced. If a material is thrombogenic the size of the thrombus 
will be larger and similar to the thrombus produced with the clotting agent. If the material has 
no to little effect on thrombus formation then no difference in the size of the thrombus 
produced will be observed. 
 
Reagents 
Calcium chloride 
solution 
Calcium chloride dihydrate, 3.68 g to achieve a final concentration of 
250 mol.m-3, was dissolved in 100 ml of distilled water and the pH 
adjusted to pH 7.4. The calcium chloride solution was sterilised by 
autoclaving and stored at room temperature for up to one month. 
Dilute-thrombin 
solution 
Human -thrombin, 20 µl, was added to 980 µl of distilled water and 
mixed by inversion. 
 
Procedure 
Medical grade polyvinyl chloride (PVC) tubing with an internal diameter of 3 mm and an 
external diameter of 4mm was cut to 33 cm lengths. The tubing was cut at both ends using a 
scalpel to leave straight cut edges which joined together leaving no visible gaps. Lengths, 2 cm, 
of medical grade PVC tubing with an internal diameter of 4 mm and an external diameter of 5 
mm were cut and used to connect the ends of the 3 mm tubing together. Peptide was 
dissolved in distilled water at a concentration to achieve a final concentration of 0.3 mol.m-3 
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when added to the blood. Distilled water was used as the negative control and diluted human 
α-thrombin as the positive control. TBS, 0.6 ml, (Section 2.1.5.3) and 50 µl of calcium chloride 
solution were mixed together with 0.9 ml of citrated sheep blood and 100 µl of the peptide 
test solution or controls. The blood mixture was then added by syringe, using a large gauge 
needle to prevent damage to the blood cells, to the loop of PVC tubing. The tubing was then 
placed on a rotator and spun at room temperature (27°C) at 30 rpm to achieve a sheer rate of 
428s-1 (Figure 2.3).  
 
 
Figure 2.3; Schematic of Chandler loop model set up 
 
This sheer rate modelled flow in a blood vessel; the loop was spun for 90 minutes. Six samples 
of each peptide were tested. At the end of 90 minutes the loops were immediately emptied 
and the thrombus removed using smooth tipped forceps and weighed on a 7 figure balance. 
The results were recorded in Microsoft® Excel 2007, averaged and graphed as the mean value 
with 95% confidence limits (Section 2.2.21.1). Data was analysed for significant difference by 
one-way ANOVA. 
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2.2.15.2 Modified Chandler loop model for testing the thrombogenicity of the 
decellularised artery 
 
Rationale 
The modified Chandler loop model is widely used to test stents and bypass grafts by 
introducing the stents to the tubing or by adding in a graft material as part of the loop 
(Christensen et al., 2001, Weber et al., 2002, Tepe et al., 2006, McClung et al., 2007a). The 
Chandler loop model was used to test the ability of the peptide coating to passivate the 
surface of the decellularised vessel and reduce or prevent thrombus formation. 
 
Procedure 
Porcine internal carotid artery with an internal diameter of 5 mm was decellularised (Section 
2.2.3). The decellularised vessel was cut into 5 cm lengths and 18.8 mol.m-3 of peptide was 
self-assembled within the vessel (Section 2.2.6.2.2). A loop of PVC tubing with an internal 
diameter of 3 mm and an external diameter of 4 mm was cut to 33 cm lengths; 5 cm was 
removed from the middle of each loop. The tubing was cut at both ends using a scalpel to 
leave straight cut edges which joined together leaving no visible gaps. Decellularised vessel 
controls and peptide coated vessels were placed over the ends where the 5 cm length of 
tubing had been removed and secured in place using silk sutures. Lengths, 7 cm, of medical 
grade PVC tubing with an internal diameter of 4 mm and an external diameter of 5 mm were 
cut and split down the middle so that they could be opened out. The larger tubing was placed 
over the decellularised vessel to maintain the loops shape and secured in place with cable ties. 
Lengths, 2 cm, of medical grade PVC tubing with an internal diameter of 4 mm and an external 
diameter of 5 mm were cut and used to connect the ends of the 3 mm tubing together to form 
the loop. The 5 cm length of PVC tubing removed from the loop was reinserted in the controls 
in place of the decellularised vessel. TBS, 0.6 ml, (Section 2.1.5.3) and 50 µl of calcium chloride 
solution were mixed together with 0.9 ml of citrated sheep blood. Human -thrombin, 2 µl, 
was also added for the positive control. The blood mixture was then added by syringe, using a 
large gauge needle to prevent damage to the blood cells, to the loop of PVC tubing. The tubing 
was then placed on a rotator and spun at room temperature (27°C) at 30 rpm to achieve a 
sheer rate of 428s-1. The loop was spun for 90 minutes. At the end of 90 minutes the loops 
were then immediately emptied and the produced clot removed using smooth tipped forceps 
94 
 
and weighed on a 7 figure balance. The results were recorded in Microsoft® Excel 2007, 
averaged and graphed as the mean value with 95% confidence limits (Section 2.2.21.1). Data 
was analysed for significant difference using one-way ANOVA. 
 
2.2.16 Haemolysis assay 
 
Rationale  
Haemolysis is the rupturing of erythrocytes and the subsequent release of their contents into 
the surrounding environment. Haemolysis can be caused by the interaction of erythrocytes 
with foreign materials. This lysis action is not limited to erythrocytes but can affect different 
cells; erythrocytes are used to test for this destructive membrane interaction as the release of 
haemoglobin into solution is easily detected. The principle behind the haemolysis test is 
simple; the erythrocytes are incubated in contact with a test material. If the materials cause 
haemolysis then high levels of free haemoglobin will be detected in solution; if the material 
has no haemolytic activity then no excess haemoglobin will be detected. 
 
2.2.16.1 Washed erythrocytes 
 
Erythrocytes were obtained from citrated sheep blood which was washed with Ringer’s 
solution at a ratio of 2 parts blood to 3 parts Ringer’s solution. The blood was mixed by 
inversion and centrifuged at 600 g for 10 minutes. The supernatant was discarded and the 
erythrocytes washed a further two times. After the final wash the erythrocyte mixture was 
centrifuged at 900 g for 10 minutes to pack the cells. The erythrocytes were resuspended in 
Ringer’s solution to make a 10 % (v/v) solution of washed erythrocytes, i.e. 5 ml of packed 
erythrocytes resuspended in 45 ml of Ringers solution. Washed erythrocytes were kept at 4°C 
for a maximum of 24 hours.  
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2.2.16.2 Haemolysis assay 
 
Peptide was dissolved in Ringer’s solution at a concentration to achieve a final concentration 
of 0.3 mol.m-3 of peptide in each test. Test solutions, 500 µl, of peptide solution, Ringer’s 
solution (negative control) and distilled water (positive control) were added to 500 µl of 
washed erythrocytes. The erythrocyte suspensions were mixed by inversion and the mixture 
was incubated at 37°C. Samples, 160 µl, were taken at 6, 12, 24, 48 and 72 hours and 
centrifuged at 1500 g for 5 minutes to pellet any intact erythrocytes. Supernatant, 100 µl, from 
each test sample was added to 100 µl of distilled water in a flat bottomed optical 96 well plate 
and the absorbance of the samples measured at 540 nm using a microplate 
spectrophotometer. Six replicates of each peptide were tested and the results exported to 
Microsoft® Excel 2007 and saved as a worksheet. The results were averaged and graphed as 
the mean value with 95% confidence limits (Section 2.2.21.1). Data was analysed for significant 
difference using one-way ANOVA. 
 
2.2.17 Complement inhibition assay 
 
Rationale 
The principle behind the complement assay is that when complement containing serum is 
incubated in contact with antibody sensitised erythrocytes the classical complement pathway 
is activated and haemolysis occurs. The level of haemolysis is easily detected and is dependent 
upon the concentration of complement present in the serum. A standard test to determine the 
level of complement in serum is the 50 % complement haemolysis (CH50) assay. In the CH50 
assay serum is diluted and incubated with sensitised erythrocytes; as the serum becomes more 
dilute there is less complement present to cause haemolysis. Serial dilution of the serum 
allows the dilution at which 50 % of the erythrocytes are lysed to be determined.  
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2.2.17.1 CH50 assay 
 
Reagents 
Antibody  
solution 
Lyophilized anti-sheep red blood cell stroma antibody was reconstituted with 
2 ml of sterile deionised water. Reconstituted antibody, 2 ml, was added to 18 
ml of sterile Ringer‘s solution (1:10 dilution) and stored at -20°C in 2 ml 
aliquots. 
 
Procedure 
The assay used washed sheep erythrocytes which were prepared as described in Section 
2.2.16.1. Erythrocytes were sensitised by adding, drop-wise, an equal volume of antibody 
solution to washed erythrocytes all the time mixing the solutions together to prevent 
agglutination. The erythrocyte antibody mixture was incubated at 37°C for 30 minutes, mixing 
the cells after 15 minutes. Sensitised erythrocytes were kept at 4°C for a maximum of 24 
hours.  
 
 
Figure 2.4, Schematic of serial dilution of serum for CH50 test 
 
Normal human serum from pooled blood was serially diluted as in Figure 2.4. Diluted serum, 
100 µl, 100 µl of water as a total lysis control (positive control), 100 µl of Ringer’s solution as a 
blank control (negative control) and 100 µl of serum incubated for 180 minutes at 60°C to heat 
inactivate the complement (negative control) were added to test tubes with 100 µl of 
sensitised erythrocytes as in Figure 2.5 and were gently mixed. The samples were incubated at 
97 
 
37°C for 30 minutes gently mixing after 15 minutes. Six samples of each serum dilution and 
control were tested. The samples were then centrifuged at 1500g for 5 minutes to sediment 
the erythrocytes. Supernatant, 100 µl, was added to 100 µl of distilled water in a flat bottomed 
optical 96 well plate and the absorbance of the samples measured at 540 nm using a 
microplate spectrophotometer. The results were imported into Microsoft® Excel 2007 and 
converted into a line graph. From the graph the dilution of serum needed to achieve 50 % lysis 
of the sensitised erythrocytes was calculated. 
 
 
Figure 2.5, Schematic of set up of CH50 assay 
 
2.2.17.2 Modified CH50 complement inhibition assay 
 
Rationale 
The principle of the CH50 assay can be modified in order to test for the inhibition of 
complement activation. When sensitised erythrocytes, serum diluted to give 50 % lysis and a 
test material are mixed together the effect of the material on the complement system can be 
assessed. If the test material has no effect on the complement system then 50 % cell lysis will 
still be observed, however, if the test material inhibits the complement system the level of 
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lysis in the sample will be below 50 %. Since the level of haemolysis observed was dependent 
upon the concentration of complement in the serum it was not possible to test for 
complement activation using this assay. 
 
Procedure 
The assay used washed sheep erythrocytes which were prepared as described in Section 
2.2.16.1. Peptide was dissolved in Ringer’s solution to achieve a final concentration of 0.3 
mol.m-3 in the test mixture. The peptide solution, 1 ml, was added to 1 ml of antibody solution 
and mixed by inversion. Erythrocytes were sensitised by adding, drop-wise, an equal volume of 
antibody-peptide solution to washed erythrocytes all the time mixing the solutions together to 
prevent agglutination. The erythrocyte antibody-peptide mixture was incubated at 37°C for 30 
minutes, mixing the cells after 15 minutes. Sensitised erythrocytes were kept at 4°C for a 
maximum of 24 hours. Sensitised erythrocytes for the controls were prepared as in the CH50 
assay (Section 2.2.17.1). 
 
 
Figure 2.6; Schematic of set up of modified CH50 complement inhibition assay 
 
Normal human serum from pooled blood was serially diluted as in Figure 2.4 to the dilution 
determined using the CH50 assay. Diluted serum, 100 µl, was added to 100 µl of antibody-
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peptide sensitised erythrocytes and gently mixed as in Figure 2.6. Diluted serum (dilution 
determined by CH50 assay), 100 µl, as a 50 % lysis control, 100 µl of water as a total lysis 
control (positive control), 100 µl of Ringer’s solution as a blank control (negative control) and 
100 µl of serum incubated for 180 minutes at 60°C to heat inactivate the complement 
(negative control) were added to test tubes with 100 µl of sensitised erythrocytes as in Figure 
2.6 and were gently mixed. Six replicates of each mixture were made and the samples were 
incubated at 37°C for 30 minutes gently mixing after 15 minutes. The samples were then 
centrifuged at 1500g for 5 minutes to sediment the erythrocytes. Supernatant, 100 µl, was 
added to 100 µl of distilled water in a flat bottomed optical 96 well plate and the absorbance 
of the samples measured at 540 nm using a microplate spectrophotometer. The results were 
imported into Microsoft® Excel 2007 and saved as a worksheet. The results were graphed as 
the mean value with 95% confidence limits (Section 2.2.21.1). Data was analysed for significant 
difference using one-way ANOVA. 
 
2.2.18 Isolation and growth of ovine endothelial cells 
2.2.18.1 Isolation of ovine arterial endothelial cells 
 
Reagents 
Antibiotic solution Penicillin streptomycin, 6 ml to achieve a final concentration of 300 
U.ml-1, was added to 100 ml of sterile PBS with calcium and 
magnesium. The solution was made aseptically and used within 24 
hours of production. 
Collagenase stock 
solution (1%) 
Collagenase type II (2273 U.ml-1), 50 mg, was reconstituted in 5 ml 
sterile PBS without calcium and magnesium. Solution was made 
aseptically and was stored at -20°C. 
Working collagenase 
solution (0.1%) 
Collagenase type II stock solution (1% w/v), 1 ml, was added to 9 ml of 
PBS without Calcium and magnesium. The solution was made 
aseptically and was used immediately 
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Procedure 
All procedures were carried out in a class II safety cabinet to reduce the chance of infection. 
Ovine legs delivered fresh from slaughter that morning were placed in the class II safety 
cabinet. The legs were dissected to find the end of the superficial femoral artery. The ends of 
the vessels were clamped to reduce the chance of infection. The branches of the vessels were 
tied off with sutures or surgical clips as the vessel was removed. Once fully dissected from the 
ovine legs the superficial femoral arteries were placed in antibiotic solution and incubated at 
37°C for one hour. The vessels were washed through with antibiotic solution using a syringe to 
remove any blood or blood clots. One end of the vessel was closed with a clip or silk suture 
and a blunt ended needle was placed in the other end and secured with a silk suture. A syringe 
containing working collagenase solution (0.1% w/v) was attached to the needle and used to fill 
the vessel. The needle was then removed and the suture tightened to contain the collagenase 
solution. The vessel containing the collagenase was then incubated at 37°C for 30 minutes. 
Following incubation the vessel contents were emptied into a sterile universal tube and the 
vessel washed through using 10 ml of sterile PBS without calcium or magnesium added. The 
cell suspension was centrifuged at 250 g for ten minutes. The supernatant was removed and 
the cells washed with 20 ml M-199. The cells were then resuspended in 5 ml of endothelial cell 
culture medium (Section 2.1.5.9) and placed in a 25 cm2 tissue culture flask. The cells were 
incubated at 37°C in 5 % (v/v) CO2 in air changing the culture medium every 48 hours. 
 
2.2.18.2 Subculture of ovine arterial endothelial cells 
 
The culture medium was removed from the flask and the cell layer was washed using Hank’s 
balanced salt solution without calcium and magnesium. After 2 – 5 minutes the Hanks 
balanced salt solution was removed and replaced with trypsin/EDTA solution (1 ml in a 25 cm2 
tissue culture flask, 2.5 ml in a 75 cm2 tissue culture flask and 5 ml in a 175 cm2 tissue culture 
flask) and incubated in 5 % (v/v) CO2 in air at 37°C for no more than three minutes. Having 
isolated the cells there is a need to purify the cell population. It has been observed that after 3 
minutes trypsin digestion small polygonal endothelial cells detached whereas larger flatter 
smooth muscle cells were still attached (Ryan, 1984). Others have reported that endothelial 
cells were subcultured in trypsin for 2-3 minutes as that is all the time endothelial cells needed 
to detach in trypsin (Gimbrone et al., 1974). After three minutes the endothelial cells detached 
but any smooth muscle or fibroblast cells remained attached to the bottom of the tissue 
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culture flask. The trypsin was neutralised by the addition of 5 ml of supplemented medium, 
containing at least 10 % (v/v) foetal calf serum. The cell suspension was transferred to a sterile 
universal tube and centrifuged at 180 g for ten minutes. The supernatant was removed and 
the cells resuspended in 5 ml of supplemented medium. The total number of viable cells was 
determined using the trypan blue method (Section 2.2.13.3). The cells were seeded into a 
larger tissue culture flask or split 1:3 into the same size tissue culture flasks with 5ml of 
supplemented cell culture medium for a 25 cm2 tissue culture flask, 10 ml of medium in a 75 
cm2 tissue culture flask and 15 ml of medium in a 175 cm2 tissue culture flask. The cells were 
incubated in 5 % (v/v) CO2 in air at 37°C changing the medium every 48 hours. Isolated cells 
were purified by successive subculture, taking advantage of the difference in detachment 
times for endothelial cells, short 2 – 3 minutes, and smooth muscle cells, longer 4 -5 minutes 
(Ryan, 1984).  
 
2.2.18.3 Cryopreservation of ovine endothelial cells 
 
Isolated endothelial cells were cryopreserved as described in Section 2.2.13.4 using medium 
M199. 
  
2.2.18.4 Characterisation of ovine arterial endothelial cells 
 
Ovine arterial endothelial cells were subcultured (Section 2.2.18.2). Cell suspension, 20 µl, was 
added to the spots of a multi-spot glass slide and incubated for 4 hours. The medium was then 
aspirated and the slide covered in 5 ml of endothelial cell culture medium and incubated for 48 
hours at 37°C in 5 % (v/v) CO2 in air. Cell culture medium was removed and the cells fixed for 
one minute in 1:1 acetone and methanol. The slides were air dried for five minutes and 
washed in running tap water for 10 minutes. The slides were washed with TBS for five minutes 
and tapped to remove excess saline. 
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2.2.18.4.1 Indirect immunofluorescent antibody method 
 
Reagents 
BSA stock 
solution 
Bovine serum albumin (BSA), 2.5 g, was dissolved into 50 ml sterile PBS. 
The solution was passed through a 0.2 µm pore size filter and stored at -
20°C for up to six months. 
Antibody diluent Sodium azide (1%), 6 ml, 300 µl of BSA stock solution and 40 ml sterile TBS 
were mixed together. The pH of the solution was adjusted to pH 7.6 and 
the volume made up to 60 ml using sterile TBS. The solution was stored at 
4°C for up to three months. 
TBS-Tween 20 Tween 20, 500 µl, was added to 1 L of sterile TBS. The pH of the solution 
was adjusted to pH 7.6. The solution was stored at room temperature for 
up to three months. 
Dye buffer Trizma base, 1.211g to achieve a final concentration of 10 mol.m-3, 0.3724 
g of EDTA to achieve a final concentration of 1 mol.m-3 and 5.8 mg of 
sodium chloride to achieve a final concentration of 1 mol.m-3 were 
dissolved in 1 L of distilled water and sterilised by autoclaving. The pH of 
the solution was adjusted to pH 7.4 before use and stored at room 
temperature in a dark bottle for up to six months. 
DAPI dye stock DAPI (10 mg) was added to 10 ml of nuclease free water and stored in 20 
µl aliquots at -25°C for up to six months 
DAPI working 
solution 
DAPI dye stock solution, 40 µl, to achieve a final concentration of 0.1 
µg.ml-1, was mixed with 400 ml of Dye buffer and was used immediately. 
 
Procedure 
Primary antibody solutions against von Willebrand factor, smooth muscle cell -actin and 
myosin heavy chain were made at the manufacturers recommended dilutions in antibody 
diluent; Anti-vWF 1:200, anti--actin 1:400 and anti-myosin 1:100. Primary antibody, 20 µl, 
was added to each spot of cells on a multi-spot slide and incubated in a moist environment for 
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one hour at room temperature. The slides were washed twice in TBS-Tween 20 for 10 minutes 
each on an orbital shaker at 40 rpm. The slides were then washed in TBS for 10 minutes on an 
orbital shaker at 40 rpm. Secondary fluorescently labelled antibody solutions were made using 
antibodies against the primary antibodies host species. Alexa Fluor 488 labelled goat anti-
mouse antibody (whole antibody) diluted 1:200 against anti-a-actin and anti-myosin primary 
antibodies and Alexa Fluor 488 labelled goat anti-rabbit antibody (F(ab’)2 fragment) diluted 
1:200 against anti-vWF antibody. Fluorescently labelled secondary antibody, 20 µl, was added 
to each spot and incubated in a moist environment for 30 minutes in the dark. The slides were 
washed twice in TBS-Tween 20 for 10 minutes each on an orbital shaker at 40 rpm. The slides 
were then washed in TBS for 10 minutes on an orbital shaker at 40 rpm. Slides were then 
immersed in DAPI working solution and incubated at room temperature for 10 minutes in the 
dark. The slides were washed with DPBSa three times for 10 minutes each in the dark. Slides 
were mounted with a glass slide and DABCO: glycerol mountant (Section 2.2.5) and stored in 
the dark for a maximum of 24 hours then imaged using an upright fluorescent microscope and 
appropriate filters. Images were captured using a digital camera and image-Pro Plus v 5.1.  
 
2.2.18.4.2 Direct immunofluorescent antibody method 
 
Reagents 
Reagents as above in Section 2.2.18.4.1 
 
Procedure 
Primary antibody solution against CD31 was made at the manufacturers recommended 
dilution, 1:100, in antibody diluent. Primary antibody, 20 µl, was added to the each spot of 
cells and incubated in a moist environment for one hour at room temperature. The slides were 
washed twice in TBS-Tween 20 for 10 minutes each on an orbital shaker at 40 rpm. The slides 
were then washed in TBS for 10 minutes on an orbital shaker at 40 rpm. Slides were then 
immersed in DAPI working solution and incubated at room temperature for 10 minutes in the 
dark. The slides were mounted and visualised as above in Section 2.2.18.4.1. 
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2.2.19 Endothelial cell attachment and proliferation 
 
Porcine internal carotid artery was decellularised (Section 2.2.3). Following histological 
assessment (Section 2.2.4) the decellularised vessel was cut into 1.5 cm lengths and cut 
horizontally to open the vessel and create sections of vessel with the intimal layer exposed. 
Peptide P11-4, 60 mg (18.8 mol.m
-3), and 60 mg (18.8 mol.m-3) P11-4 mixed at a ratio of 1:50 
with P11-4-cRGD was weighed and added to 1.8 ml of sterile water and a monomer solution 
made. The sections of decellularised vessel were added to the peptide monomer and left 
overnight. Peptide self-assembly was triggered by the addition of 0.2 ml of 10X Ringer’s 
solution (Section 2.2.6.2.2). Sections of decellularised vessel were added to 1.8 ml of sterile 
water and left overnight, 0.2 ml of 10X Ringer’s solution was added and the vessels left 
overnight as a control. Four samples of the control and each peptide coated vessel sections 
were placed at the bottom of 6 wells of a 12 well plate for each time point and a seeding ring 
placed on the vessel section and pressed down to create a seal. Endothelial cell growth 
medium without ECGF, 300 µl, was added to each seeding ring and incubated for 24 hours at 
37°C. The endothelial cell growth medium without ECGF was aspirated from each seeding ring.  
Endothelial cells were subcultured as described in Section 2.2.18.2. Cell numbers were 
estimated (Section 2.2.13.3) and the cells resuspended in endothelial growth medium at 
25,000 cells per ml. Endothelial cell suspension, 200 µl, was added to each seeding ring to give 
5000 cells per seeding ring and incubated at 37°C in 5 % CO2 (v/v) in air for 4 hours. After 4 
hours the medium was aspirated and the seeding rings removed. Sterile PBS, 1 ml, was added 
to each well and removed after 1 minute to remove any unattached cells. Endothelial cell 
growth medium, 1 ml, was added to each well and incubated at 37°C changing the medium 
every 48 hours. Four samples for each test condition were removed at 4 hours, 24 hours and 
72 hours for analysis. A solution of 1 mol.m-3 calcein AM and 2 mol.m-3 ethidium homodimer-1 
was made in sterile PBS (2 µl of calcein AM and 8 µl of ethidium homodimer-1 in 8 ml of PBS). 
The culture medium was aspirated from each well and replaced with 0.5 ml of PBS containing 
calcein AM and ethidium homodimer-1 and incubated at 27°C in the dark for 40 minutes. The 
PBS containing calcein AM and ethidium homodimer-1 was removed and replaced with 1 ml of 
sterile PBS which was removed after 1 minute. Each sample of decellularised vessel was turned 
over and stored in the dark until imaged. Samples were imaged using an inverted confocal 
fluorescent microscope (Section 2.2.12.1). Six images were taken of each sample at random 
and the number of live and dead cells present counted, recorded and analysed using 
Microsoft® Excel 2007. Results were shown as representative images and graphed as the mean 
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value with 95% confidence limits (2.2.21.1). Data was analysed for significant difference by 
two-way ANOVA. 
 
2.2.20 Flow cell model of flow over luminal surface in small diameter blood vessels 
used to test peptide stability under flow 
 
Rationale 
The peptide stability under flow in a small diameter blood vessel was judged by the design and 
use of a flow cell system that modelled the flow rate of blood over the luminal surface of the 
vessel. A flow cell was designed such that a section of peptide coated vessel could be placed in 
a well with a lamina flow of salt solution being passed over the top of the luminal face of the 
vessel. The flow cell used a reservoir that was the same width as the test well; the reservoir 
filled up with test solution to be level with the surface of the test material and test solution 
flowed over the whole sample surface and down into a second reservoir at the end of the test 
well resulting in lamina flow.  
 
 
Figure 2.7, Cross-section schematic of flow cell 
 
Reagents 
Test solution Ringers solution with 0.02 % (W/V) sodium azide (NaN3) 
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Procedure 
Decellularised vessel was cut in half to expose the luminal face of the vessel and fluorescently 
tagged peptide self-assembled within the vessel as described in Section 2.2.7. The peptide 
coated vessel was placed in the bottom of the flow cell. A peristaltic pump was used to 
circulate test solution through the flow cell. The normal flow rate of blood over the surface of 
the vessel could be modelled in the flow cell by setting the pump to a revolution speed of 65 
rpm and using tubing with an internal diameter of 5 mm. The flow cell system was covered and 
set running in a dark room as not to photo-bleach the fluorescently tagged peptide. A separate 
flow cell was set up for each sample of vessel being tested. After 1, 2, 3, 4, 7 and 14 days the 
vessel was removed from the flow cell, sectioned and imaged as described in Section 2.2.11.1 
and Section 2.2.11.2. The intensity of fluorescence for three different locations for each image 
was determined and recorded in Microsoft® Excel. The fluorescent intensity was averaged for 
each time point at each magnification, 95% confidence limits determined as in Section 2.2.21.1 
and the mean value and 95 % confidence limits graphed. 
 
2.2.21 Statistical analysis 
2.2.21.1 Confidence limits 
 
Confidence limits were calculated at 95 % for all applicable data with a minimum of three 
replicates using the equation; 
 Confidence limit =      
 SE (Standard error) =  
  
  
 
 SD   = Standard deviation of a sample  
 (t)   = t-value  
Confidence limits were determined using statistical package on Microsoft® Excel 2007. 
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2.2.21.2 Statistical analysis 
 
For the comparison of data for one test condition with more than two groups a one way 
analysis of variance (ANOVA) was carried out using data analysis tools. For the comparison of 
data for two test conditions with more than two groups a two way analysis of variance 
(ANOVA) was carried out using data analysis tools. Individual differences between means were 
then determined by calculating the minimum significant difference (MSD) at p=0.05 using the 
T-method.  
 
 MSD  = Critical value x SE 
 SE  =  
                        
 
 
 Critical value = [K,v] from table of studentized range at Q=0.05 
 K  = Number of groups 
 V  = Degrees of freedom of MS within 
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3 Development of methodologies and testing of peptide self-
assembly in decellularised arterial conduits 
 
3.1 Introduction 
 
Peptide -sheet self-assembly and arterial decellularisation have been extensively studied. 
Previous work done within the Institute of Medical and Biological Engineering (iMBE) at the 
University of Leeds has developed and tested a patented method of decellularising tissues that 
has been adapted and applied to blood vessels (Wilshaw et al., 2011, Owen et al., 2012).  The 
peptide group at the University of Leeds has studied the self-assembly properties of a range of 
peptides and has started to apply these peptides in biological applications (Aggeli et al., 2001, 
Kirkham et al., 2007, Maude et al., 2011a). The purpose of this work was to study the self-
assembly of a model peptide within decellularised porcine internal carotid artery, to ascertain 
if the peptide would self-assemble within the acellular scaffold. 
 
3.1.1 Peptide self-assembly 
 
The peptides developed at the University of Leeds are eleven amino acids long and self-
assemble by a one dimensional nucleated process. The effects of the environment upon the 
energetics of the self-assembling process have been explored in depth in order to develop 
design characteristics for the production of self-assembling peptides. Knowledge from protein 
folding has shown that an alternating sequence of hydrophobic and hydrophilic residues will 
create a -sheet structure regardless of the propensity of the amino acids in the chain to form 
-helix or -sheet (Xiong et al., 1995). It has been identified that peptides self-assembled in 
antiparallel -sheet tapes when there were an odd number of amino acids in the peptide 
sequence as this encouraged a more complete register and better spatial positioning of the 
adjacent strands and hydrogen bonds (Maude et al., 2011a).  
The structures formed by the self-assembling peptides have been explored and found to be 
the result of the concentration of peptide in solution forming a hierarchy of self-assembled 
structures which resulted in the formation of peptide hydrogels (Aggeli et al., 2001). The effect 
of changing, pH and ionic concentration on a range of different peptides was studied for the 
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effect on the nucleation, gelation and the hierarchy of the self-assembled structures formed 
(Aggeli et al., 2003b, Carrick et al., 2007). The pKa of the different amino acids in the peptide 
allows for switchable self-assembly as the residues are protonated and de-protonated, this 
behaviour has been well documented (Zhang et al., 1993, Schneider et al., 2002, Carrick et al., 
2007). It has also been reported that the natural repulsive charges between the peptides can 
be overcome by charge screening from an increase in ionic concentration (Carrick et al., 2007, 
Maude et al., 2011a). It was reported that the change in the Debye length when the ionic 
concentration was altered resulted in the self-assembly of the peptide at lower energies and 
did not affect the structure of the peptide aggregates formed (Carrick et al., 2007).  
Design characteristics that have been found for the peptides developed at the University of 
Leeds that showed a net charge was needed to stabilise fibril formation (Aggeli et al., 2003a). It 
was further established that in biological conditions a net charge of +/- 2 produced the most 
stable self-assembled peptide gels (Maude et al., 2011a)(Personal communication, Dr D. Miles, 
University of Leeds). 
 
3.1.2 Peptide P11-4 
 
Self-assembling peptides lie between two material classes, they are not natural proteins such 
as collagen and elastin but are comprised of natural amino acids (Maude et al., 2013). The 
primary difference between a peptide and a protein is size; peptides are typically less than 50 
amino acids long where proteins consist of several polypeptide chains. Unlike proteins that can 
fold to form complex tertiary and quaternary structures the P11 series of peptides are limited 
to secondary structure -sheets; consequently self-assembled peptides are held together, 
predominantly, by hydrogen bonding where the tertiary structured proteins are held together 
by other bonds such as disulphide bridges. The main difference between the -sheets found in 
proteins and self-assembled peptides are the -sheets found in proteins tend to be connected 
together and be part of the same protein chain where the -sheet structures formed by 
peptides are made up of individual monomers. 
The peptide selected to test self-assembly within acellular scaffolds was P11-4 (Figure 3.1). This 
peptide is a rationally designed peptide comprising eleven amino acids (CH3CO-Q-Q-R-F-E-W-E-
F-E-Q-Q-NH2). The P11 series of peptides typically use alternating polar and aromatic residues 
to drive anti-parallel -sheet self-assembly (Maude et al., 2013). It has been shown that 
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peptides of 7 -40 amino acids will have a propensity towards -sheet formation (Bell et al., 
2006). It is believed that an odd number of amino acids allows for maximisation of the 
enthalpy of the peptide subunits aiding in self-assembly (Personal communication from Dr 
Robert Davies University of Leeds). Peptide P11-4 was designed to form fibrils and gels at low 
pH and is converted to a monomeric state at high pH; this material change is driven by the 
protonation and deprotonation of glutamic acid (Carrick et al., 2007). Self-assembly of peptide 
P11-4 can also be triggered by a change in ionic concentration. Repulsive charges interactions 
prevent peptide association and self-assembly, when the ionic concentration is changed self-
assembly occurs as the ions shield the repulsive charges (Chen, 2005, Carrick et al., 2007, 
Maude et al., 2011b). P11-4 was designed to have a resultant charge of -2 in physiological 
conditions; this has been identified as the ideal charge for self-assembly to occur (Personal 
communication, Dr D. Miles, University of Leeds).  
P11-4 was chosen as it has been studied for biological applications and found to be 
biocompatible (Protopapa et al., 2009, Maude et al., 2011a). P11-4 was designed to form fibril 
structures with a left hand twist at low pH and to be monomeric at high pH. In solutions with a 
concentration of 6.3 mol.m-3 of P11-4 self-supporting gels were observed between pH 2.0 and 
pH 3.2, at pH 3.2 to pH 5.0 flocculation occurred and at pH 5.0 to pH 7.0 viscous nematic fluids 
were found. This could be changed by changing the concentration of peptide, for example at 
12.6 mol.m-3, twice the concentration, nematic gels were found at pH 5.0 to pH 7.0 (Aggeli et 
al., 2003a). 
 
 
Figure 3.1; Stick image of peptide P11-4 with amino acids labelled, created using HyperChem 7. 
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3.1.3 Decellularisation 
 
Decellularisation is a logical progression in the development of immunocompatible biological 
scaffolds from allogenic and xenogenic grafts. The idea behind decellularisation is that by 
removing all the cells, cellular debris and coding DNA and RNA the antigens that cause immune 
rejection are removed whilst leaving the ECM. The ECM retains the same biomechanical and 
structural properties as the native tissue. Cellular debris needs to be removed as it maybe 
immunogenic. Cellular debris has also been shown to be a potential site for calcification to 
occur (Courtman et al., 1994). The removal of all coding DNA and RNA is important in the 
prevention of possible disease transmission. If DNA is not removed from a decellularised tissue 
it is possible that coding fragments of retroviruses might be present (Prabha and Verghese, 
2008). The response of a host to a decellularised scaffold has been shown to be largely 
dependent upon the decellularisation method and the decellularised tissue (Badylak, 2004, 
Badylak et al., 2009). Methods that resulted in the removal of the majority of cells and cellular 
debris have shown the best results as there was little to no immune reaction. Where immune 
and detrimental reactions were seen a large amount of debris was present in the tissue 
following less successful decellularisation. Decellularisation has been explored in more detail in 
Section 1.4.7. Blood vessel is a naturally porous material but in theory the vessel is more 
porous following decellularisation as voids will remain where the cells have been removed. 
 
3.1.4 Aims and objectives 
 
The aims of this chapter were to investigate the self-assembly of a model peptide P11-4 within 
decellularised porcine internal carotid artery. 
 Specific objectives: 
a) To determine if P11-4 will self-assemble within the decellularised vessel 
b) Should the peptide self-assemble in the decellularised vessel;  
I. To develop a protocol for the self-assembly of peptides within an 
acellular vessel  
II. To evaluate how P11-4 self-assembles within the acellular vessel 
III. To test the stability of the peptide structures formed 
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3.2 Methods 
3.2.1 Histological evaluation of decellularised porcine internal carotid artery 
 
Porcine internal carotid artery was decellularised as described in Section 2.2.3. After 
decellularisation a 1 cm length sample from the ends and middle of all the vessels were taken 
and processed for standard histological evaluation as described in Section 2.2.4, each sample 
was sectioned at 5 µm, and sections were air dried overnight. Three sections were placed on 
each slide and a minimum of 4 slides were made for each sample. Two slides for each sample 
were stained using haematoxylin and eosin (Section 2.2.4.4) or were stained using DAPI 
(Section 2.2.4.5) and imaged. 
 
3.2.2 Evaluation of peptide self-assembly triggers 
 
The affect of different self-assembly triggers was assessed at 4 different concentrations of 
peptide P11-4. Monomer solutions of peptide, 0.5 ml, were made in deionised water at 30 
mg.ml-1 (18.8 mol.m-3), 15 mg.ml-1 (9.4 mol.m-3), 5 mg.ml-1 (3.13 mol.m-3) and 1 mg.ml-1 (0.63 
mol.m-3), as described in Section 2.2.6.1, for testing the effects of changing the pH. The 
samples were adjusted to pH 8 by the addition of 1 mol.dm-3 NaOH and left overnight before 
making observations and capturing images. The pH of the samples was then lowered to pH 7 
by the addition of concentrated HCl and left overnight before making observations and 
capturing images. The pH of the samples was then lowered to pH 5 by the addition of 
concentrated HCl and left overnight before making observations and capturing images. To test 
the effects of changing ionic concentration monomer solutions of peptide were made in 
deionised water at 9/10 final wanted volume (0.45 ml = 9/10 final volume of 0.5 ml) to achieve 
a final concentration of 30 mg.ml-1 (18.8 mol.m-3), 15 mg.ml-1 (9.4 mol.m-3), 5 mg.ml-1 (3.13 
mol.m-3) and 1 mg.ml-1 (0.63 mol.m-3) as in Section 2.2.6.1. The different concentration 
samples for testing of biological salt solutions were made as described in Section 2.2.6.2.2 
using PBS or Ringer’s solution. The samples were left overnight to allow for self-assembly and 
were then imaged and observations recorded. Inversion of the glass vials allowed for visual 
assessment of the peptide state. Visual inspection of the peptides with a polarised light 
allowed for the assessment of self-assembly by the presence of birefringence.  
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3.2.3 Cross sectioning and imaging of fluorescent peptide penetration into 
decellularised vessel 
 
A monomer solution at 9/10 the final volume was made to achieve a final concentration of 30 
mg.ml-1 (18.8 mol.m-3) of P11-4 at a ratio of 1:30 of fluorescein tagged P11-4 to untagged P11-4 
as described in Section 2.2.8. One end of three 5 cm lengths of decellularised vessel were 
sealed using silk sutures and 0.45 ml of peptide monomer solution was placed inside the 
vessel. The other ends of the vessels were sealed with a silk suture and each vessel was left 
overnight in 15 ml of deionised water to cover the vessel. Observations were made of the 
vessels and the surrounding deionised water. Each vessel was opened at one end and self-
assembly was triggered by the addition of 0.05 ml of 10X Ringer’s solution (Section 2.2.6.2.2). 
The vessels were then sealed again and placed in 15 ml of Ringer’s solution and left overnight 
to allow for self-assembly too occur. The vessels were removed from solution, emptied of 
excess peptide gel and 1 cm length samples were taken from the middle of the vessels and 
sectioned using a cryostat as in Section 2.2.11. The sections were stored in the dark and 
imaged. Controls of decellularised porcine internal carotid artery were put through the same 
pH and solution changes without any peptide present. 
 
3.2.4 FTIR spectroscopy and analysis of peptide presence in decellularised vessel 
 
Decellularised porcine internal carotid artery was cut into three 1 cm2 sections and taken 
through three changes of deuterium oxide (10 ml) as described in Section 2.2.9. Peptide P11-4 
at a concentration of 30 mg.ml-1 (18.8 mol.m-3) in deuterium oxide was self-assembled within 
decellularised vessel using pH as a trigger (Section 2.2.6.2.1). Three sections of decellularised 
vessel were taken through the same pH and solution changes without any peptide present. 
The control vessel and peptide coated vessel sections were compressed between calcium 
fluoride optical lenses and spectra taken of different areas of the control vessels and P11-4 
coated vessels as described in Section 2.2.9. Three samples of each test condition were used 
and the calcium fluoride optical lenses cleaned using methanol in between the collection of 
each spectra. 
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3.2.5 Field emission gun scanning electron microscopy (FEGSEM) imaging of 
peptide in decellularised vessel 
 
Six 1 cm2 sections of decellularised porcine internal carotid artery were fixed in neutral 
buffered formalin for 4 hours. Peptide P11-4 at concentrations of 10 mg.ml
-1 (6.26 mol.m-3), 5 
mg.ml-1 (3.13 mol.m-3) and 1 mg.ml-1 (0.63 mol.m-3) in deionised water were self-assembled in 
samples of the fixed decellularised porcine internal carotid artery, using pH as a trigger 
(Section 2.2.6.2.1). The peptide coated vessel along with uncoated vessel as a control was 
dried under vacuum overnight and processed for imaging as described in Section 2.2.10. 
Samples were placed in the Zeiss LEO 1530 Gemini FEGSEM and imaged using secondary 
electron imaging at 3 KeV. Images were recorded using the associated software and analysed 
using Image J. 
 
3.2.6 Confocal laser scanning microscopy (CLSM) imaging of peptide in 
decellularised vessel 
 
Peptide P11-4 in deionised water at a concentration of 30 mg.ml
-1  (18.8 mol.m-3) at a ratio of 
1:30 of fluorescein tagged P11-4 to untagged P11-4 was self-assembled within three 1 cm
2 
sections of decellularised porcine internal carotid artery using Ringer’s solution as a trigger 
(Section 2.2.6.2.2). Three controls of decellularised porcine internal carotid artery were put 
through the same pH and solution changes without any peptide present. Samples for imaging 
in the CLSM were removed from the peptide gel and placed on a glass slide and a cover slip 
placed on top. An oil emersion objective lens was used as described in Section 2.2.12.1. A 
range of scans were taken of the samples and several z-axis stacks that allowed for images to 
be taken at different depths within the sample. Images were collected and recorded using ZEN 
v7.1 and analysed using LSM image browser. 
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3.2.7 Multi-photon laser scanning microscopy (MPLSM) imaging of peptide in 
decellularised vessel 
 
Peptide P11-4 in deionised water at a concentration of 30 mg.ml
-1 (18.8 mol.m-3) at a ratio of 
1:30 of fluorescein tagged P11-4 to untagged P11-4 was self-assembled within a 1 cm
2 section of 
decellularised porcine internal carotid artery using Ringer’s solution as a trigger (Section 
2.2.6.2.2). A control of decellularised porcine internal carotid artery was put through the same 
pH and solution changes without any peptide present. The samples were stored in the dark 
and transported to the University of York where they were imaged as described in Section 
2.2.12.2. Images were taken using secondary harmonic auto-fluorescence and an FITC filter; 
images were then analysed using LSM image browser. 
 
3.2.8 The effect of concentration on peptide distribution throughout 
decellularised vessel 
 
Three 1 cm2 sections of decellularised vessel were added to monomer solutions of P11-4 at a 
ratio of 1:30 of fluorescein tagged P11-4 to untagged P11-4 in deionised water at concentrations 
of 30 mg.ml-1 (18.8 mol.m-3), 15 mg.ml-1 (9.4 mol.m-3), 7.5 mg.ml-1 (4.7 mol.m-3), 3.75 mg.ml-1 
(2.35 mol.m-3) and 1.87 mg.ml-1 (1.18 mol.m-3) made as described in Section 2.2.6.1. 
Decellularised vessel was left in the monomer solutions overnight and self-assembly triggered 
using Ringer’s solution (Section 2.2.6.2.2). Samples were then stored in the dark until 
sectioning using a cryostat and imaged as described in Section 2.2.11. Three 1 cm2 controls 
sections of decellularised porcine internal carotid artery were put through the same pH and 
solution changes without any peptide present; this control was used to check for vessel auto-
fluorescence.  
 
3.2.9 The effect of self-assembled state on peptide penetration into decellularised 
vessel 
 
Monomer solutions of peptide P11-4 in deionised water at a ratio of 1:30 of fluorescein tagged 
P11-4 to untagged P11-4 were made at concentrations of 30 mg.ml
-1 (18.8 mol.m-3), 15 mg.ml-1 
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(9.4 mol.m-3), 7.5 mg.ml-1 (4.7 mol.m-3), 3.75 mg.ml-1 (2.35 mol.m-3) and 1.87 mg.ml-1 (1.18 
mol.m-3) as described in Section 2.2.6.1. Self-assembly was triggered by the addition of 
Ringer’s solution (Section 2.2.6.2.2). Three 1 cm2 sections of decellularised vessel were added 
to the peptide gel/solutions and left overnight. Samples were then stored in the dark until 
sectioning using a cryostat and imaged as described in Section 2.2.11. Three 1 cm2 sections of 
decellularised porcine internal carotid artery as controls were put through the same pH and 
solution changes without any peptide present; this control was used to check for vessel auto-
fluorescence. 
 
3.2.10 Evaluation of peptide stability in decellularised vessel under flow 
 
Decellularised porcine internal carotid artery was cut into sections to fit the flow cell chamber 
(2 cm by 1.5 cm) and added to a monomeric solution of P11-4 in deionised water at a ratio of 
1:30 of fluorescein tagged P11-4 to untagged P11-4 at a concentration of 30 mg.ml
-1 (18.8 
mol.m-3) made as described in Section 2.2.6.1. Peptide self-assembly was triggered by the 
addition of Ringer’s solution as described in Section 2.2.6.2.2. Peptide stability was tested as 
described in Section 2.2.20 using the flow apparatus. The peristaltic pump was switched on 
and the flow cell experiment covered and placed in a dark room. Vessel was removed from the 
flow cell and sectioned using a cryostat after 1, 2, 3, 4, 7 and 14 days. Sections (7 µm) were 
taken from the middle of the sample to discount any effects due to the edges of the flow cell. 
Decellularised vessel and peptide coated vessel that had not been in the flow cell were used as 
controls of the vessel with and without self-assembled peptide. 
 
3.3 Results 
3.3.1 Histological evaluation of decellularised porcine internal carotid artery 
 
Following staining sections were imaged, recorded and analysed to assess the success of 
decellularisation. Results of histological analysis of decellularised vessel are presented in Figure 
3.2 along with images of control fresh vessel. 
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Figure 3.2; Histology images of fresh and decellularised porcine internal carotid artery, Images 1&2 
stained using H&E, images 3&4 stained using DAPI; 1&3 Fresh porcine internal carotid artery, 2&4 
Decellularised porcine internal carotid artery. S = subendothelial layer, M = medial layer, A = 
adventitial layer. 
 
Imaging of the sections in Figure 3.2 showed the presence of the characteristic three layered 
structure of a blood vessel. An endothelial layer should not be present on the decellularised 
vessel but should be present on the fresh vessel; however, no endothelium could be seen on 
either the fresh or decellularised vessels. The subendothelial layer could be seen on both the 
fresh and decellularised sections in Figure 3.2 images 1 and 2. The presence of a densely 
packed and organised ECM in the medial layer could be seen in the both the fresh and 
decellularised vessel sections. The adventitia can be distinguished from the medial layer by the 
presence of less dense and less organised ECM.   
Haematoxylin and eosin staining of tissue sections showed the presence of cells throughout 
the different layers in the fresh vessel. The DAPI staining in Figure 3.2 image 3 showed the 
presence of DNA in the fresh vessel; the location of the staining suggested that the DNA was 
located in the cell nuclei. The presence of cells or DNA could not be seen in the sections of the 
decellularised vessel suggesting that the removal of all cells and visually detectable DNA had 
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been successful. Haematoxylin and eosin staining showed there had been no visual effect upon 
the structure of the ECM within the subendothelial, medial and adventitial layers following 
successful decellularisation. Having been decellularised the different layers of the vessel could 
still be easily distinguished with no obvious defects present in the ECM. These results showed 
that decellularisation appeared to have been successful with no detrimental effects. 
 
3.3.2 Evaluation of peptide self-assembly triggers 
 
Observations of peptide self-assembly at a range of concentrations at different solution pH 
and in different biological salt solutions were made and images recorded (Appendix Figure A.1 
and Figure A.2). Results and observations are summarised and presented in Table 3-1. 
 
Solution 
Condition 
30 mg.ml-1 
18.8 mol.m-3 
15 mg.ml-1 
9.4 mol.m-3 
5 mg.ml-1 
3.13 mol.m-3 
1 mg.ml-1 
0.63 mol.m-3 
pH 8 Clear fluid Clear fluid Clear fluid Clear fluid 
pH 7 Self-assembled 
gel 
Self-assembled 
gel 
Cloudy fluid Clear fluid 
pH 5 Self-assembled 
gel 
Self-assembled 
gel 
Part assembled 
gel/Cloudy fluid 
Cloudy fluid 
PBS Self-assembled 
gel 
Cloudy fluid Clear fluid Clear fluid 
Ringer’s 
solution 
Self-assembled 
gel 
Self-assembled 
gel 
Part assembled 
gel/Cloudy fluid 
Clear fluid 
Table 3-1; Observed results for self-assembly method for different concentrations of P11-4 
 
The results showed that in deionised water at pH 8 peptide P11-4 was a monomer or soluble 
aggregate at all concentrations tested. At pH 7 in deionised water P11-4 formed a stable self-
supporting gel at concentrations of 30 mg.ml-1 (18.8 mol.m-3) and 15 mg.ml-1 (9.4 mol.m-3). 
Peptide P11-4 at a concentration of 5 mg.ml
-1 (3.13 mol.m-3) in deionised water at pH 7 started 
to form visible aggregates but failed to form a self-assembled gel and at a concentration of 1 
mg.ml-1 (0.63 mol.m-3) P11-4 appeared to be a monomer or soluble aggregate in solution. 
Peptide P11-4 at a concentration of 30 mg.ml
-1 (18.8 mol.m-3) and 15 mg.ml-1 (9.4 mol.m-3) in 
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deionised water at pH 5 formed a stable self-supporting peptide gel; at a concentration of 5 
mg.ml-1 (3.13 mol.m-3) P11-4 formed a viscous flowing peptide gel that was not self-supporting. 
At a concentration of 1 mg.ml-1 (0.63 mol.m-3) at pH 5 P11-4 started to form visible aggregates 
in solution but failed to form a peptide gel.  
At physiological pH peptide P11-4 made in phosphate buffered saline (PBS) formed a self-
supporting gel at 30 mg.ml-1 (18.8 mol.m-3). At 15 mg.ml-1 (9.4 mol.m-3) P11-4 started to from 
visible aggregates in PBS but did not form a gel. P11-4 in PBS at 5 mg.ml
-1 (3.13 mol.m-3) and 1 
mg.ml-1 (0.63 mol.m-3) remained as monomers or soluble aggregates in solution. Peptide P11-4 
at physiological pH made in Ringer’s solution formed self-assembled gels at 30 mg.ml-1 (18.8 
mol.m-3) and 15 mg.ml-1 (9.4 mol.m-3). P11-4 in Ringer’s solution at 5 mg.ml
-1 (3.13 mol.m-3) 
formed a self-assembled viscous fluid/gel which was not self-supporting and remained as 
monomers or soluble aggregates in solution at 1 mg.ml-1 (0.63 mol.m-3)  
These results showed that at high pH P11-4 was a monomer or soluble aggregate in solution at 
all tested concentrations. At low pH peptide P11-4 started to self-assemble in a concentration 
dependent manner and formed a self-supporting peptide gel above a concentration of 15 
mg.ml-1 (9.4 mol.m-3) just below physiological pH. The results showed that ionic concentration 
could be used to trigger self-assembly of model peptide P11-4; the addition of PBS triggered the 
formation of self-supporting gels at 30 mg.ml-1 (18.8 mol.m-3) and the addition of Ringer’s 
solution triggered the formation of self-supporting gels at 30 mg.ml-1 (18.8 mol.m-3) and 15 
mg.ml-1 (9.4 mol.m-3).  
From the results it was decided a standard concentration of 30 mg.ml-1 (18.8 mol.m-3) of 
peptide would be used in further studies unless otherwise stated. At this concentration the 
peptide has been shown to form a stable self-supporting gel when self-assembly is triggered, 
above this concentration the peptide will self-assemble above neutral pH due to the 
concentration dependence of peptide self-assembly and be difficult to make a monomer 
solution (Aggeli et al., 2001, Carrick et al., 2007). As low pH is known to adversely affect the 
components of the ECM it was decided self-assembly would be triggered in further studies by 
the addition of Ringer’s solution. It was decided that pH would be used as a trigger in the 
sample preparation for FTIR and FEGSEM analysis where excess salt had greater potential to 
interfere with the observed results. 
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3.3.3 Cross sectioning and imaging of fluorescent peptide penetration into 
decellularised vessel 
 
Following sectioning images were collected and analysed. For all peptide coated sections there 
was a distinct difference compared to the control decellularised vessel. Results are presented 
as representative images in Figure 3.3 at different magnifications. 
 
 
Figure 3.3; Cross section image of fluorescently tagged peptide P11-4 (ratio 1:30 fluorescein tagged P11-
4 to untagged P11-4) in decellularised porcine internal carotid artery with control decellularised 
porcine internal carotid artery at 10X and 20X magnification. S = subendothelial layer, M = medial 
layer, A = adventitial layer.  
 
Having been left overnight, following the addition of the monomer solution of peptide, the 
deionised water around the outside of the vessel had changed colour taking on a yellow tint. 
The fluorescently tagged peptide solution was optically yellow in appearance suggesting that 
some of the peptide from the inside of the vessel had penetrated through the vessel and out 
into solution. The images in Figure 3.3 showed that the decellularised porcine internal carotid 
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artery was not auto-fluorescent in the same range as the fluorescein tagged P11-4. The images 
of the cross-sections through peptide coated vessels showed that in a monomeric state the 
peptide had fully penetrated through the subendothelial, medial and adventitial layers of the 
vessel and self-assembled. A greater fluorescence was observed at the luminal surface and in 
the adventitia. The peptide on the medial layer appeared to show the fibrous structure of the 
ECM. 
 
3.3.4 FTIR spectroscopy and analysis of peptide in decellularised vessel 
 
Following the collection of spectra from different areas of the samples the spectra were 
combined into a single average spectrum and graphed. Results are presented in Figure 3.4 as 
absorbance against wavelength with selected peaks highlighted and labelled. 
 
 
Figure 3.4; FTIR spectrum in the amide I and II region (1500 – 1900 cm
-1
) showing difference between 
two averaged spectra; Blue) combined spectra of decellularised porcine internal carotid artery, Red) 
combined spectra of decellularised porcine internal carotid artery and 30 mg.ml
-1
 (18.8 mol.m
-3
) of P11-
4. 
 
The average FTIR spectrum for decellularised porcine internal carotid artery is compared to the 
average FTIR spectrum for decellularised porcine internal carotid artery with 30 mg.ml-1 (18.8 
mol.m-3) self-assembled P11-4 in the region of amide I (1600 – 1700 cm
-1) and amide II (1500 – 
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1600 cm-1). As shown in Figure 3.4 a difference can be seen between the two spectra with a 
peak for the peptide coated vessel at 1618 cm-1. This corresponded to the region where -
sheet hydrogen bonds are known to absorb between 1615 and 1642 cm-1. The majority of -
sheet globular proteins absorb between 1625 and 1643 cm-1 in an FTIR spectrum, a lower value 
between 1615 and 1625 cm-1 is believed to represent anti-parallel -strand pairing/self-
assembly as they have shorter hydrogen bonds than typically found in -sheet globular 
proteins (Seshadri 1999).  
The FTIR spectrum shown in Figure 3.4 provided evidence that the peptide was present in the 
decellularised vessel and was forming an anti-parallel -sheet structure that is known to be 
formed by P11-4 when self-assembled. This demonstrated that the peptide was not only in the 
vessel but was also self-assembling in the vessel and not just forming a coating on the vessel 
ECM. 
 
3.3.5 FEGSEM imaging of peptide on the surface of decellularised vessel 
 
Following drying and coating in platinum and palladium (50:50) the uncoated and P11-4 coated 
samples of decellularised vessel were imaged and the secondary electron images recorded and 
analysed. Results are presented as representative images in Figure 3.5 at the same 
magnification. 
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Figure 3.5; FEGSEM images of decellularised porcine internal carotid artery with self-assembled P11-4; A) No peptide, B) 1 mg.ml
-1
 (0.63 mol.m
-3
), C) 5 mg.ml
-1 
(3.13 
mol.m
-3
), D) 10 mg.ml
-1
 (6.26 mol.m
-3
), images taken at 3 KeV at 60,000X magnification.
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Fixed decellularised porcine internal carotid artery without peptide, showed the structure of 
the ECM in the decellularised vessel (Figure 3.5 image A). The collagen fibre bundles could be 
identified by the characteristic banding structure seen in the image. The fibrous nature of the 
ECM could be seen. Fixed decellularised porcine internal carotid artery with 1 mg.ml-1 (0.63 
mol.m-3) of self-assembled peptide P11-4 showed the collagen fibre bundles but the 
characteristic collagen banding was no longer present (Figure 3.5 image B). Fixed decellularised 
porcine internal carotid artery with 5 mg.ml-1 (3.13 mol.m-3) of self-assembled peptide P11-4 
showed fewer collagen fibre bundles on the surface of the vessel (Figure 3.5 image C). Fixed 
decellularised porcine internal carotid artery with 10 mg.ml-1 (6.26 mol.m-3) of self-assembled 
peptide P11-4 showed a relatively thick surface coating (Figure 3.5 image D).  
The different surface coatings that were present on the surface of the vessel formed by the 
different concentrations of peptide P11-4 were clearly evident in Figure 3.5. The fibre 
arrangements present in images A to C were not present in image D. The loss of fibre 
characteristics and definition appeared to be related to peptide concentration; as peptide 
concentration increased a thicker layer of peptide was observed on the surface of the 
decellularised vessel until only the peptide surface coating was seen and none of the fibre 
arrangements underneath.  
 
3.3.6 CLSM imaging of peptide in decellularised vessel 
 
Following peptide self-assembly samples of acellular vessel were removed from the excess 
peptide gel and imaged in the confocal laser microscope. The peptides coated sections were 
distinctly different compared to the control decellularised vessel and control peptide gel. 
Results are presented as representative images in Figure 3.6. 
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Figure 3.6; CLSM images of (A) Peptide gel, 10 mg.ml
-1
 (6.3 mol.m
-3
) of fluorescently tagged P11-4 
mixed with P11-4 at a ratio of 1:50, (B) Decellularised porcine internal carotid artery with 10 mg.ml
-1
 
(6.3 mol.m
-3
) of fluorescently tagged P11-4 mixed 1:50 with P11-4, peptide gel, (C & D) Z-axis stack of 
decellularised porcine carotid artery with 10 mg.ml
-1
 (6.3 mol.m
-3
) of fluorescently tagged P11-4 mixed 
1:50 with P11-4, peptide gel; highlighted region shows peptide coating of a horizontal structure taken 
at different depths (z-axis). Magnification 40X 
 
As shown in Figure 3.6 image A, fluorescently tagged peptide control, the fluorescently tagged 
peptide gel formed a randomly ordered gel that had little visible structure. As shown in image 
B the fluorescently tagged peptide appeared to have self-assembled around the outer surface 
of the ECM coating the bundles of fibres. As shown in the images C and D the fluorescently 
tagged peptide appeared to have coated the ECM, the highlighted region of the image show a 
Z-axis stack through a horizontal bundle of fibres, it was apparent that the peptide had acted 
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to fill the gaps in between the fibres in the bundle and appeared to have then formed a 
coating of similar thickness over the whole surface of the bundle. This coating whilst not 
smooth appeared to be nearly uniform over the surface, it was not possible determine 
whether the coating covered all the fibre bundles or not as the presence of the bundles was 
only inferred by the outline created by the peptide coating. 
 
3.3.7 MPLSM imaging of peptide in decellularised vessel 
 
Following peptide self-assembly samples of decellularised vessel were removed from the 
excess peptide gel and imaged in the multi-photon laser microscope. The peptides coated 
sections were distinctly different compared to the control decellularised vessel. Results are 
presented as representative images in Figure 3.7 and Figure 3.8. 
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Figure 3.7; Multi-photon images of decellularised porcine internal carotid artery coated in 30 mg.ml
-1
 (18.8 mol.m
-3
) of fluorescently tagged P11-4 peptide at a ratio of 
1:50 with untagged P11-4. Images show the same area with the two fluorescent signals separated and combined. Top images are at 63X magnification bottom images 
are at 20X magnification. 
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Figure 3.8; Z-axis stack of multi-photon images of decellularised porcine internal carotid artery coated in 30 mg.ml
-1
 (18.8 mol.m
-3
) of fluorescently tagged P11-4 peptide 
at a ratio of 1:50 with untagged P11-4. Images show fluorescein fluorescence at 2 µm intervals in the same x,y, location. Images taken at 63X magnification.
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The secondary harmonic auto-fluorescence from collagen, the fluorescence from the 
fluorescein labelled P11-4 peptide and the two images combined are seen in Figure 3.7. The 
20X magnification image shows a scan near the surface of the sample that covered a large 
area. The collagen auto-fluorescence showed the characteristic coiled structure associated 
with collagen and showed the fibre bundles were aligned in the same direction as seen in a 
blood vessel. The image of the fluorescein tagged P11-4 showed that the collagen fibre bundles 
appeared to have been coated in self-assembled peptide. The peptide also appeared to have 
coated other extracellular structures in the vessel. A mesh like layer, likely the elastic lamina, 
was seen on top of the collagen fibre bundles. An area of high intensity fluorescence that 
lacked any clear structure was seen on the surface of the vessel, this was most likely excess 
peptide gel on the surface of the vessel. The combined image showed that the majority of the 
collagen auto-fluorescence was covered by the fluorescein fluorescence; however, the 
collagen auto-fluorescence showed through in some areas. The high (63X) magnification 
images from within the vessel showed that the peptide did not form a space filling gel in the 
ECM but rather self-assembled around the ECM structures. The image of the fluorescein 
tagged P11-4 showed the clear coating of the ECM structures with self-assembled peptide and 
provided better evidence that not only the collagen but other extracellular components were 
coated with self-assembled peptide as an ECM structure could be seen coated in peptide but 
showed no collagen auto-fluorescence. The comparison of the two images showed that not all 
of the collagen fibre bundles were coated in self-assembled peptide. 
A Z-axis stack through the vessel is shown in Figure 3.8. The z-axis stack showed the presence 
of an extracellular net-like structure on the surface of the vessel, most likely the elastic lamina. 
As the z-axis went deeper into the vessel the presence of orientated fibre bundles could be 
seen below the net-like structure. 
 
3.3.8 Effect of concentration on peptide distribution throughout decellularised 
vessel 
 
Following peptide self-assembly samples of acellular vessel were sectioned and imaged. The 
images were recorded and analysed. The peptides coated sections were distinctly different 
compared to the control decellularised vessel. Results are presented as representative images 
in Figure 3.9. 
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Figure 3.9; Images showing effects of concentration on peptide self-assembly in decellularised porcine internal carotid artery. Fluorescent cross section images of 
decellularised porcine internal carotid artery and decellularised porcine internal carotid artery coated in 30 mg.ml
-1
 (18.8 mol.m
-3
), 15 mg.ml
-1
 (9.4 mol.m
-3
), 7.5 mg.ml
-1
 
(4.7 mol.m
-3
), 3.75 mg.ml
-1
 (2.35 mol.m
-3
) and 1.87 mg.ml
-1
 (1.18 mol.m
-3
) of fluorescently tagged P11-4 peptide at a ratio of 1:50 with untagged P11-4. 10X magnification. 
S = subendothelial layer, M = medial layer, A = adventitial layer.
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The control image in Figure 3.9 showed that the vessel had little to no auto-fluorescence at the 
wavelengths associated with fluorescein. At all concentrations high fluorescence intensity was 
observed in the adventitial layer of the vessel. A high level of fluorescence was also observed 
on the subendothelium at peptide concentrations between 30 mg.ml-1 (18.8 mol.m-3) and 3.75 
mg.ml-1 (2.35 mol.m-3). At a concentration of 30 mg.ml-1 (18.8 mol.m-3) P11-4 had penetrated 
throughout the vessel and had coated the ECM of the media layer with the structure of the 
coated ECM visible in the fluorescent image. At a concentration of 15 mg.ml-1 (9.4 mol.m-3) and 
7.5 mg.ml-1 (4.7 mol.m-3) peptide P11-4 was seen coating the ECM of the media layer. As the 
concentration was decreased the fluorescent intensity decreased and less of the vessel 
structure could be seen. At a concentration of 3.75 mg.ml-1 (2.35 mol.m-3) P11-4 was seen on 
the outside, subendothelium and adventitia layer, of the vessel but not clearly on the inside of 
the vessel. Peptide P11-4 at a concentration of 1.87 mg.ml
-1 (1.18 mol.m-3) was seen in the 
adventitia but not through the rest of the vessel.   
 
3.3.9 Effect of self-assembled state on peptide penetration into decellularised 
vessel 
 
The state of the peptide when the decellularised porcine internal carotid artery was 
introduced could significantly affect the observed results. The decellularised vessel is porous in 
nature. The penetration of the peptide into the vessel will be dependent upon the size and 
stability of the hierarchy of structures formed when self-assembly is triggered. The stability 
and size of the hierarchy of structures will predominantly be controlled by the concentration of 
peptide present (Aggeli et al., 2001). The energetics of the system will also have an effect such 
that pH and ionic concentration will also affect which structures are formed and there stability 
(Aggeli et al., 2003b, Carrick et al., 2007). The self-assembly of peptide P11-4 is a concentration 
dependent reaction. The effect of different concentrations of self-assembled peptide P11-4 
within decellularised porcine internal carotid artery was explored by adding sections of 
decellularised vessel to self-assembled peptide P11-4. Images were taken, recorded and 
analysed. The peptide coated sections were distinctly different compared to the control 
decellularised vessel. Results are presented as representative images in Figure 3.10. 
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Figure 3.10; Effect of self-assembled state on peptide penetration into decellularised porcine internal carotid artery. Fluorescent cross section images of decellularised 
porcine internal carotid artery and decellularised porcine internal carotid artery coated in 30 mg.ml
-1
 (18.8 mol.m
-3
), 15 mg.ml
-1
 (9.4 mol.m
-3
), 7.5 mg.ml
-1
 (4.7 mol.m
-3
), 
3.75 mg.ml
-1
 (2.35 mol.m
-3
) and 1.87 mg.ml
-1
 (1.18 mol.m
-3
) of fluorescently tagged P11-4 peptide at a ratio of 1:50 with untagged P11-4. 20X magnification. S = 
subendothelial layer, M = medial layer, A = adventitial layer.
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The control image in Figure 3.10 showed that the vessel had little auto-fluorescence at the 
wavelengths associated with fluorescein. It was known that at 30 mg.ml-1 (18.8 mol.m-3) P11-4 
would form a stable self-supporting gel; as the concentration decreased the stability of the gel 
decreased as the length of the -sheet tapes formed decreased. A large amount of peptide 
was observed on the outside of the vessel in the cross-section of the 30 mg.ml-1 (18.8 mol.m-3) 
sample. A relatively small amount of the peptide appeared to have penetrated into the vessel. 
As the concentration of the peptide and as accordingly the size of the self-assembled peptide 
aggregates, decreased more of the vessel structure became clear as more peptide was present 
in the media layer of the vessel. At 15 mg.ml-1 (9.4 mol.m-3) and 7.5 mg.ml-1 (4.7 mol.m-3) of 
P11-4 a large amount of peptide was observed on the outside edges of the vessel with 
significantly less peptide in the media layer. At 3.75 mg.ml-1 (2.35 mol.m-3) and 1.87 mg.ml-1 
(1.18 mol.m-3) of P11-4 the peptide appeared to be evenly distributed throughout the vessel.  
The results in Figure 3.10 showed that when a stable P11-4 peptide gel was formed the peptide 
was unable to fully penetrate the vessel wall. As the peptide concentration was decreased, the 
self-assembled structures became less supported and smaller in size meaning the peptide was 
able to penetrate into the decellularised vessel. 
 
3.3.10 Peptide stability in decellularised vessel under flow 
 
Following removal from the flow cell samples of decellularised vessel were sectioned and 
imaged. The images were recorded and analysed. The peptides coated sections were distinctly 
different compared to the control decellularised vessel. Results are presented as 
representative images in Figure 3.11 and Figure 3.12. The average fluorescent intensity of the 
collected images are shown as a graph for each magnification in Figure 3.13. 
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Figure 3.11; Stability of peptide P11-4  at o, 1, 2, 3, 4, 7 and 14 days in a model of fluid flow in a blood vessel showing peptide stability under flow conditions. 
Fluorescent cross section images of decellularised porcine internal carotid artery and decellularised porcine internal carotid artery coated in 30 mg.ml
-1
 (18.8 mol.m
-3
) of 
fluorescently tagged P11-4 peptide at a ratio of 1:50 with untagged P11-4. 10X magnification. Arrows indicates subendothelium/lumen surface. 
135 
 
 
Figure 3.12; Stability of peptide P11-4  at o, 1, 2, 3, 4, 7 and 14 days in a model of fluid flow in a blood vessel showing peptide stability under flow conditions. 
Fluorescent cross section images of decellularised porcine internal carotid artery and decellularised porcine internal carotid artery coated in 30 mg.ml
-1
 (18.8 mol.m
-3
) of 
fluorescently tagged P11-4 peptide at a ratio of 1:50 with untagged P11-4. 20X magnification. Arrows indicates subendothelium/lumen.
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Figure 3.13; Average fluorescent intensity of sectioned decellularised porcine internal carotid artery 
(DPICA) coated in 30 mg.ml
-1
 P11-4 (fluorescently tagged P11-4 1:50 with P11-4) at 0, 1, 2, 3, 4, 7 and 14 
days. Data is presented as the mean (n=6) ± 95 % confidence intervals. Blue 10X magnification, Red 
20X magnification 
 
The control images of decellularised vessel in Figure 3.11 and Figure 3.12 showed that the 
vessels had no visual auto-fluorescence. In the images in Figure 3.11 and Figure 3.12 the 
subendothelial/luminal surface that was in direct contact with the fluid flow is indicated by 
white arrows. The sections from the vessel are shown at 10X magnification and 20X 
magnification respectively in Figure 3.11 and Figure 3.12. Comparing the images of peptide 
present in the vessel before testing (Figure 3.11; Day 0) and after 1 day (Figure 3.11; Day 1) 
there was a noticeable reduction in peptide present in the vessel yet a large amount of peptide 
was still present as the peptide coated ECM structures could still be seen . Little difference was 
seen between the day 1, day 2 and day 3 images (Figure 3.11). After 4 days there was a 
noticeable reduction in fluorescent intensity, however, the vessel structure could be seen with 
a clear fluorescence from the medial layer. At day 7 there was a further reduction in 
fluorescent intensity, however, peptide was clearly still present throughout the vessel. After 
day 14 there was little fluorescence left in the vessel and the majority of the fluorescence left 
in the vessel came from deeper in the vessel that was further away from the fluid flow. 
The fluorescent cross-sections at day 0 shown in Figure 3.12 indicated that the peptide had 
formed a thick layer of self-assembled peptide around the ECM components in the vessel. It 
was observed that after 1 day in flow conditions a large amount of the peptide had been 
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washed away, however, there was still clearly a coating of peptide present throughout the 
decellularised vessel. At day 2 the peptide was still present on the surface of the ECM. The 
fluorescently tagged P11-4 coating at day 2 looked to be less uniform with clear areas of higher 
intensity fluorescence. At days 3, 4 and 7 the peptide was still present throughout the vessel 
however the fluorescence intensity decreased over time. At day 14 there was little peptide left 
within the vessel however a noticeable fluorescence was observed in the adventitial layer and 
on the luminal surface of the vessel. Comparing the images in Figure 3.11 and Figure 3.12 it 
was clear that the peptide was being removed by the flow of solution over the luminal surface 
over time. This loss of peptide appeared to affect the whole vessel and not just the luminal 
surface.  
The average fluorescence intensity averaged from the images of the cross section samples at 
each time point is presented in Figure 3.13. The graphs showed that there was a steady 
reduction in the fluorescent intensity over time even when the images shown in Figure 3.11 
and Figure 3.12 were indistinguishable from each other. The comparison of the intensity at day 
14 with the negative decellularised porcine internal carotid artery control showed that there 
was still peptide left in the vessel after 14 days but around 80 % of the peptide had been 
removed. 
 
3.4 Discussion 
3.4.1 Histological analysis of decellularised porcine internal carotid artery 
 
The results of the haematoxylin & eosin and DAPI staining showed that all visible cells, cellular 
debris and DNA had been removed from the arteries. The results showed the decellularisation 
process developed at the University of Leeds worked on porcine internal carotid artery; this 
result has also been reported by others on different allogenic and xenogenic arterial matrices 
(Wilshaw et al., 2011, Owen et al., 2012). 
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3.4.2 Evaluation of self-assembly triggers 
 
Testing of peptide self-assembly triggers demonstrated that peptide P11-4 responded to 
varying pH; at high pH P11-4 was a monomer or soluble aggregate at the concentrations tested. 
At low pH peptide P11-4 self-assembled in a concentration dependent manner and formed a 
self-supporting peptide gel above a concentration of 15 mg.ml-1 (9.4 mol.m-3) just below 
physiological pH.  
The results showed that ionic concentration could be used to trigger self-assembly. The 
addition of PBS triggered self-assembly and the formation of a self supporting gel at 30 mg.ml-1 
(18.8 mol.m-3). The addition of Ringer’s solution triggered self-assembly and formed a self 
supporting gel at 30 mg.ml-1 (18.8 mol.m-3) and 15 mg.ml-1 (9.4 mol.m-3). The self-assembly of 
peptide P11-4 in solutions of varying pH and ionic concentrations corresponded to previously 
observed results (Aggeli et al., 2003b, Carrick et al., 2007).  
An unusual effect was observed when comparing the use of PBS and Ringer’s solution to 
trigger self-assembly. Ringer’s solution and PBS both had similar concentrations of salts but 
had different compositions. Ringer’s solution contained slightly higher levels of sodium 
chloride and contained calcium; PBS contained phosphate salts. The difference between 
Ringer’s solution and PBS lead to a difference in the efficiency of the ionic trigger. It is possible 
that the slightly higher level of sodium chloride salt in the Ringer’s solution lead to more 
charge screening and so the formation of a self-supporting gel at a lower concentration. The 
presence of the calcium in the Ringer’s solution could also have increased the charge screening 
effect. It is possible that the presence of the phosphate in PBS could have interfered with the 
self-assembly of the peptide. It is also possible that a mixture of these possible effects could 
have happened and so triggered self-assembly at a lower concentration in Ringer’s solution. 
 The concentration, electronic structure, valence and hydration of counter ions have all been 
shown to have a significant effect upon self-assembly (Stendahl et al., 2006, Cui et al., 2010). 
Taking the conditions of the counter ions in both the Ringer’s solution and PBS it is likely that 
the different concentrations and compositions were responsible for the observed difference in 
self-assembly. 
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3.4.3 Peptide penetration into decellularised vessel 
 
The fluorescent cross sectioning of the vessel showed that the peptide had fully penetrated 
throughout the decellularised vessel. The observed colour change in the water surrounding the 
vessel indicated that the peptide was able to diffuse through the decellularised vessel. The 
vessel was naturally porous and the peptide, as a monomeric solution, was very small in 
comparison hence the peptide was free to diffuse through the vessel. The removal of the cells 
from the artery will have increased the permeability of the conduit as the endothelium that 
normally limits and controls vascular permeability had been removed (Fukumura et al., 2001). 
Vessel thickness has to be taken into account when self-assembling peptide into a vessel as the 
diffusion rate will decrease as the vessel thickens increases. 
 
3.4.4 FTIR analysis of peptide self-assembly 
 
An FTIR spectrum of the decellularised vessel showed no discernible peaks in the amide I (1600 
– 1700 cm-1) and the amide II (1500 – 1600 cm-1) absorption bands. As these bands are where 
absorbance peaks associated with the hydrogen bonding, observed in -sheet self-assembly, 
are seen it was possible to use FTIR analysis to assess if the peptide within the decellularised 
vessel was self-assembled (Seshadri et al., 1999). The peak absorbance observed at 1618 cm-1 
in the decellularised vessel with P11-4 has been identified as the peak associated with anti-
parallel -sheet self-assembly. This peak has been observed and reported in FTIR spectra using 
the same and similar peptides (Aggeli et al., 2003a, Aggeli et al., 2003b, Carrick et al., 2007, 
Maude et al., 2011a). This result and previous corresponding results showed that the peptide 
had self-assembled within the decellularised vessel.  
 
3.4.5 FEGSEM imaging of peptide on decellularised vessel surface 
 
The results of the FEGSEM imaging showed the build up of a surface coating on the 
decellularised vessel as the peptide concentration was increased. As the only difference 
between the samples imaged was the concentration of the peptide; it could be assumed that 
the surface coating was made up of self-assembled peptide. The FEGSEM images did not allow 
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for verification that the peptide had self-assembled as the peptide could have dried around the 
ECM. This assumption was based on the excess peptide in solution forming a self-assembled 
gel and the FTIR results. The build up of peptide was first observed on the FEGSEM images at 
low peptide concentrations, seen by the loss of the characteristic banding typically attributed 
to collagen fibres (Ottani et al., 2001).  
As the peptide concentration increased a thicker layer of peptide was observed on the surface 
of the decellularised vessel until only the peptide surface coating could be seen and none of 
the fibre arrangements underneath. The initial loss of fibre definition and structure likely 
resulted from the presence of self-assembled peptide around the ECM; as the peptide 
concentration increased the more peptide was present in the decellularised vessel and so the 
peptide coating became thicker obscuring more and more of the ECM structure. The thick 
surface coatings observed at higher concentrations were likely the result of excess peptide gel 
on the surface of the decellularised vessel that had collapsed down into a thick layer when 
dried in vacuum. 
 
3.4.6 CLSM and MPLSM imaging of peptide within decellularised vessel 
 
Confocal laser scanning microscopy and multi-photon laser scanning microscopy allowed for 
the imaging of the peptide within the decellularised vessel in a wet state. The CLSM and 
MPLSM images showed the ECM had been coated in a layer of peptide. In the CLSM images it 
could be inferred that the ECM fibre bundles had been coated in a layer of peptide. It was not 
possible to see the ECM as there was no observable auto-fluorescence, however, structures 
could clearly be seen in the negative space surrounded by fluorescently tagged peptide. The 
CLSM images demonstrated that the ECM was coated in an evenly distributed peptide layer. 
The peptide coating appeared to have filled the gaps between the ECM fibre bundles and 
formed a coating over the whole surface of the bundles. In the MPLSM images it was possible 
to see that the collagen fibre bundles and other ECM components had been coated in a layer 
of self-assembled peptide gel. The auto-fluorescence of the collagen fibres could clearly be 
seen in the MPLSM images and the corresponding presence of the peptide coating could be 
seen when the fluorescently tagged peptide was imaged. Combing the two images it is possible 
to see that not all the collagen was coated in peptide and that other extracellular structures 
were also present that could not be seen in the auto-fluorescence images.  
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The peptide self-assembled on the ECM forming a peptide coating and not in solution forming 
a space filling gel. It is, however, possible that a self-assembled network of peptide fibres 
formed between the ECM but was too small to be seen in the CLSM and MPLSM images. The 
self-assembled peptide coatings on the ECM were likely due to the difference in the energetics 
of the self-assembling system in solution and at a solid-liquid interface. When the peptide and 
surface could interact and the charge on the peptide and surface was correct self-assembly 
would have started on the surface as the attraction to the surface became larger than the 
repulsive force (Wattenbarger et al., 1990).  
The surface interface could have acted as a template for nucleation by lowering the energy 
barrier that needed to be overcome for self-assembly to start. Thus the peptide would 
preferentially self-assemble at the surface of a material as the energetics of the system are 
lower than in solution (Taylor and Osapay, 1990, Wattenbarger et al., 1990). This would 
explain why the majority of the ECM was coated in self-assembled peptide. The filling of gaps 
between the bundles of fibres seen on the CLSM can also be explained by this as the peptide 
would have preferentially self-assembled between the two surface interfaces rather than in 
solution or on just the one surface interface.  
The presence of uncoated collagen bundles could be explained by the close packed nature of 
the ECM where the surrounding bundles of fibres protected some bundles from being coated 
in peptide. It was also possible that some property of the uncoated ECM was preventing the 
initial association of the peptide with the surface of those fibres. Different collagen types have 
been shown to have different physical and chemical structures with differences in properties, 
functions, structure and composition, for example the distribution of hydrophobic residues in 
the protein sequence (Bornstein and Sage, 1980). These differences could have caused 
differences in the interaction of the peptide with the ECM; this could have prevented the self-
assembly of the peptide on those ECM fibres.  
 
3.4.7 Effect of concentration on peptide distribution in decellularised vessel 
 
The results demonstrated that the concentration of the peptide in solution affected the 
coating of the peptide in the decellularised vessel. High concentrations of peptide, 30 mg.ml-1 
(18.8 mol.m-3), formed a peptide coating throughout the vessel; as the concentration was 
decreased the peptide was observed in the adventitia and luminal surface layers but 
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decreasingly in the medial layer. The adventitia and subendothelium being on the outside of 
the vessel could have come into more contact with the peptide in solution. This could be the 
result of preferential self-assembly on the different surfaces. The adventitia and luminal 
surface were more open structures whereas the medial layer had a more compact and 
organised structure (Bou-Gharios et al., 2004, Zhang et al., 2007). A less dense structure could 
have been surrounded by more of the peptide allowing for preferential self-assembly around 
the adventitial and subendothelial layers. It is also possible that the different ECM components 
of the different layers allowed for preferential peptide self-assembly.  
 
3.4.8 Effect of the self-assembled state of peptide on distribution in the 
decellularised vessel 
 
The need to add the decellularised vessel to monomeric peptide then trigger self-assembly 
was ascertained by studying the effect that the self-assembled state had on the diffusion of 
the peptide throughout the vessel. It was shown that in a self-assembled state the peptide was 
unable to fully penetrate into the decellularised vessel. As the peptide concentration was 
decreased it was observed that the peptide was able to start to penetrate into the vessel and a 
more even distribution of peptide was seen. This was the result of the concentration 
dependence of the hierarchy of structures formed when the peptide self-assembled (Aggeli et 
al., 2001). At high concentrations larger longer peptide structures were formed which were 
unable to penetrate into the decellularised vessel. As the concentration was decreased these 
structures decreased in size and length allowing the peptide to diffuse into the vessel.  
 
3.4.9 Peptide stability in decellularised vessel under flow 
 
Peptide stability will be of key importance to any potential application. Having self-assembled 
the peptide within the decellularised vessel the results showed that the peptide was slowly 
lost from the decellularised vessel over time but that peptide still remained in the vessel after 
14 days in a model system. The results showed that peptide was primarily lost from the 
luminal face of the vessel but peptide was also lost from the whole vessel as well. This suggests 
that whilst peptide removed by the force of the flow of solution over the surface may account 
for some of the peptide loss that this is not the whole picture.  
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The loss of peptide from the whole vessel was likely the result of the way in which the peptide 
self-assembled. In nucleated self-assembly there is a concentration of peptide that remains 
monomer in solution; above the critical concentration for self-assembly the same 
concentration of peptide remains as monomer in solution (Aggeli et al., 2001, Maude et al., 
2011a). As the monomer was removed by the flow the self-assembled peptide disassembled to 
maintain the concentration of monomer in solution and so slowly disassembled throughout 
the vessel. This means that the time the peptide remained in the vessel was dependent upon 
the critical concentration of self-assembly and the concentration of the peptide present in the 
vessel.  
As the peptide self-assembled with preference at the surface interface the critical 
concentration for self-assembly was lower at the interface and therefore the peptide would be 
lost in a staggered manner. Excess peptide would first be lost from the surface of the vessel 
where the critical concentration for self-assembly was lower. Once the peptide started to 
disassemble from around the ECM the only limiting factor would be the diffusion rate of the 
peptide through the vessel and out into the solution. In vivo this effect would undoubtedly 
become more complex with the involvement of serum proteins. 
 
3.4.10 Summary 
 
Peptide P11-4 was shown to self-assemble within decellularised porcine internal carotid artery. 
It was shown that the peptide preferentially self-assembled around the ECM of the vessel. It 
was established that the peptide had to be added to the decellularised vessel as a monomeric 
solution for the peptide to fully penetrate throughout the vessel. It was shown that the 
thickness of the peptide coating on the decellularised vessel could be controlled by varying the 
concentration of peptide introduced into the vessel. It was also established that the peptide 
was still present in the decellularised vessel for over 14 days under flow conditions that 
modelled the situation in a small diameter blood vessel. 
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4 Systematic study of peptide biocompatibility and 
haemocompatibility 
 
4.1 Introduction 
 
Peptide self-assembly has been widely studied and design characteristics have been developed 
enabling peptides to be intelligently designed to have certain materials properties once self-
assembled. Peptides are of great interest as potential materials for use in tissue engineering 
applications and many groups have explored the potential of peptides as tissue engineering 
scaffolds.  Zhang et al, have shown that PuraMatrix (RAD16-1) supports the growth of a range 
of different cell types and Allen et al, demonstrated that PuraMatrix supported blood vessel 
development in vitro (Zhang et al., 2005, Allen et al., 2011). Jayawarna et al presented results 
showing that Fmoc-diphenylalanine (Fmoc-FF) hydrogels supported the growth of 
chondrocytes and Banwell et al have demonstrated that alpha-helix forming peptide hSAFAAA –W 
P1 & 2 will support the growth and differentiation of PC12 cell lines (Banwell et al., 2009, 
Jayawarna et al., 2009). These results show the potential of peptides however there have been 
no reported attempts to define design characteristics for the haemocompatibility and 
biocompatibility of self-assembling peptides.  
If a self-assembling peptide is used in a medical application it will exist in two forms in the 
body. The peptide will exist at the site of implantation as a gel but will also disseminate as a 
monomer or soluble aggregate carried away from the site of implantation in the blood or 
lymph. The monomer or soluble aggregate exists at a concentration below the critical 
concentration for self-assembly in all peptide gels that self-assembly using nucleated self-
assembly (Aggeli et al., 2001). The monomer or soluble aggregate exists at equilibrium with the 
peptide gel and will be removed by the movement of fluids in the body and by diffusion.  
Testing a peptide as a monomer has several advantages; it reduces the cost of the testing as 
less peptide is needed and monomer can be added to standard test solutions with no need to 
modify tests to allow for the testing of gels. Whilst it is possible that both the monomeric form 
and the gel form of the peptide could be toxic it is unlikely that a peptide would be toxic as a 
gel but not as a monomer. In Alzheimer’s disease it is widely accepted that the self-assembled 
fibrils made up of Amyloid (A) peptides are toxic, however, it has also been shown that the 
soluble smaller amyloid aggregates are also toxic and could represent the primary pathological 
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mechanism in amyloid disease (Klein et al., 2001, Lacor et al., 2007, Glabe, 2008). If a peptide 
monomer is toxic and non-haemocompatible the peptide will not be suitable for biomedical 
application. 
 
4.1.1 Biocompatibility 
 
Biocompatibility can be defined as “the ability of a material, device or system to perform 
without a clinically significant host response in a specific application” (Blass, 1999). 
Biocompatible materials should not be toxic nor have an injurious effect on a biological 
system. Biocompatibility is the corner stone of biomedical research; if materials are not 
biocompatible then there is no potential for these materials to be used in any biomedical 
application. The testing of biocompatibility has been standardised in ISO 10933-5, Biological 
evaluation of medical devices Part 5: Tests for in vitro cytotoxicity.  
 
4.1.2 Haemocompatibility 
 
Haemocompatibility is the ability of a material or device to interact with blood and have no 
detrimental effect on blood clotting and the complement system. Haemocompatibility also 
refers to the ability of a material or device to be in contact with blood cells and not cause 
significant damage. Haemocompatibility is of vital interest when attempting to introduce 
artificial materials into the human body. If a material is not haemocompatible then the range 
of potential medical uses for that material will be limited. Materials that are non-
haemocompatible can still be used in medical applications that are non-blood contacting. 
Testing of haemocompatibility has been standardised in ISO 10993-4, Biological evaluation of 
medical devices Part 4: Selection of tests for interactions with blood. 
 
4.1.3 Thrombus formation/blood clotting 
 
A thrombus is formed in flowing blood and differs from a blood clot found in stagnant blood. 
Thrombi formed in flowing blood have a distinct organised structure and constituents; clotted 
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stagnant blood has a more random arrangement and is made up of all the constituents of 
blood in their normal concentrations (Chandler, 1969). Thrombus formation has been explored 
in Section 1.6.  
When considering the haemostatic response to biomaterials it is important to know how these 
materials in general can lead to thrombosis. The presence of a foreign surface in contact with 
blood results in a complex interlinked series of events involving protein adsorption, platelet 
and leukocyte activation and adhesion, activation of complement and coagulation (Gorbet and 
Sefton, 2004). Immediately following contact between the blood and biomaterial a boundary 
layer of proteins from the plasma is formed that is deposited and displaced; the amount of 
bound individual proteins varies on different biomaterials dependent upon the materials 
surface properties (Basmadjian et al., 1997, Hong et al., 1999). Protein adsorption is the first 
event in blood material interactions and may result in the activation of the intrinsic pathway, 
suggesting that the intrinsic pathway plays a role in the thrombotic activity of materials 
(Gorbet and Sefton, 2004). An important protein involved in this is factor XII which binds to the 
surface of the biomaterials and in an active state converts factor XI into factor XIa (Basmadjian 
et al., 1997, Gorbet and Sefton, 2004). No matter how inert a surface is trace amounts of 
bound factor XII will lead to a significant initiation of the intrinsic pathway (Basmadjian et al., 
1997). 
Platelets will bind or “bounce off” a layer of absorbed proteins, adhesion is mediated by 
glycoprotein GPIIb/IIIa interaction with fibrinogen and GPIb/IIa and von Willebrand factor, 
however, absence of adhesion does not preclude platelet activation (Gorbet and Sefton, 2004). 
Adherent platelets generated by contact with biomaterials have been shown to be pro-
coagulant (Gorbet and Sefton, 2004). It is often presumed that platelet activation by 
biomaterials is caused by the generation of thrombin due to the activation of the intrinsic 
pathway, however the inability of thrombin inhibitors to reduce platelet activation suggests 
that activation is in part mediated by other antagonists (Gorbet and Sefton, 2004). The 
thrombogenic consequences of platelet attachment and activation have been explored in 
greater detail in Section 1.6. 
Material characteristics and absorbed proteins modulate the level of leukocyte adhesion and 
activation; as the biomaterial is larger than can be phagocytised the leukocytes release an 
array of oxygen metabolites and proteolytic enzymes (Gorbet and Sefton, 2004). Leukocytes 
are efficient cells in the vasculature that initiate and amplify coagulation through a regulated 
change in disparate membrane proteins and the release of tissue factor (TF) (Altieri, 1993, 
147 
 
Gorbet and Sefton, 2004). Circulating leukocytes will adhere to adherent platelets and further 
contribute to localized thrombogenesis (Gorbet and Sefton, 2004). The presence of leukocytes 
in a thrombus has been shown to significantly contribute to fibrin formation (Altieri, 1993, 
Gorbet and Sefton, 2001). Studies on leukocyte expression of TF in patients with ventricular 
assist devices, in baboon-shunt models and in vitro clotting assays have shown material-
induced TF expression results in fibrin formation enhancing coagulation (Gorbet and Sefton, 
2001).  
In addition to TF leukocytes possess alternative pathways to initiate coagulation and generate 
thrombin; this allows the assembly of co-factors IXa/VIII that form a tenase complex and 
activate the common pathway (Altieri, 1993). Leukocyte activation has been shown to be 
surface area dependent, however, TF expression has been shown to be stimulated by a 
biomaterial regardless of surface area (Gorbet and Sefton, 2001). TF expressed by monocytes 
and platelets has been suggested to represent a possible activation of the extrinsic pathway 
(Gorbet and Sefton, 2004). Results show leukocytes could be required for the activation of the 
coagulation cascade; suggesting the TF dependent extrinsic pathway of activation may apply to 
biomaterials (Hong et al., 1999). Inflammatory conditions have often been linked to fibrin 
deposits, leukocytes and complement proteins. It has been demonstrated that activation of 
complement, in particular C5, causes a marked increase in TF released by activated leukocytes 
(Muhlfelder et al., 1979). As discussed in Section 4.1.4 the presence of foreign materials can 
activate the complement system leading to increased thrombosis.   
Mass transport is important to consider in thrombosis as flow enhances the transport of 
coagulation factors or inhibitors to the surface. As flow increases, the conversion of factor XI 
into XIa increases and conversion then decreases as flow exceeds a critical value (Basmadjian 
et al., 1997). Surface reactivity and flow are intertwined and have to be considered in unison 
when dealing with the intrinsic pathway (Basmadjian et al., 1997). The effects of flow on mass 
transfer and cell phenotype mean that different flow conditions will favour thrombosis by 
either the extrinsic or intrinsic pathway (Basmadjian et al., 1997, Gorbet and Sefton, 2004). 
Protein adsorption occurs within a few seconds/minutes whereas tissue factor synthesis takes 
over one hour (Gorbet and Sefton, 2004). This means the relative roles between extrinsic and 
intrinsic pathways in the thrombogenic activity of a material are likely to depend upon both 
the time frame and flow rate.  
The common pathway takes place at platelet and leukocyte membranes and involves feed-
back loops that act to increase the levels of thrombin; thrombin levels are affected by flow 
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rate as levels of thrombin are increased with increasing flow rate but decrease as flow exceeds 
a critical value (Basmadjian et al., 1997). The dependence of flow rate on thrombus formation 
in contact with biomaterials explains why large diameter grafts with higher flow rates are 
observed not to occlude as fast as small diameter grafts with lower/intermediate flow rates. 
The understanding needed for biomaterial application is limited by a lack of understanding of 
how much of an inflammatory and thrombotic response is tolerable or if any changes in 
normal haemostasis results in harmful consequences. 
There are a number of different ways to test for thrombogenicity. Testing can be done in vivo 
or in vitro with materials being in planted in animal models or blood being extracted from 
animals or humans for lab based testing. Thrombi can be formed in static or dynamic 
conditions; given the distinct structure of thrombi, dynamic conditions such as in the Chandler 
loop model are preferred. Thrombi can be analysed in a number of ways, the simplest method 
is gravimetric analysis in which the thrombi formed are weighed in a wet or dried state.  
Microscopic analysis of thrombi along with the use of immuno-labelling can be used to assess 
the constituents, structure and morphology of the thrombi. Experiments can be set up to 
analyse the effects of reduction in flow, the percentage occlusion and the time taken for 
thrombogenesis. The ideal in vitro test is a dynamic model that does not adversely affect the 
blood constituents and allows for the flow of blood. The Chandler loop model allows for the 
flow of blood through a closed loop of tubing partly filled with air; this limits the possible flow 
rate and potentially introduces artefacts due to the air interface (van Oeveren et al., 2012).  
The roller pump model uses a closed loop of tubing with no air and circulates the blood using a 
roller pump; this compresses the blood and can lead to haemolysis but higher rotation speeds 
can be used (van Oeveren et al., 2012). The Hemobile model uses a ball valve placed in a 
closed loop of tubing filled with blood; this model has high flow rates and does not induce 
damage to the blood but only achieves semi-circular movement (van Oeveren et al., 2012).  
Another method of testing thrombosis is the use of a thromboelastograph (TEG). The TEG 
mimics sluggish venous flow to activate coagulation (Essell et al., 1993). The TEG can test 
coagulation function testing as well as platelet function, clot strength and fibrinolysis (Peng, 
2010). The TEG gives more data than the other methods described, however, it does not 
model arterial flow which is of interest in this study. The most widely used model for the 
generation of thrombi and the testing of bypass grafts is the Chandler loop model. Given the 
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limited flow rates possible the Chandler loop model is more suited to modelling smaller 
diameter blood vessels with lower flow rates. 
 
4.1.4 Complement system 
 
The complement system is a component of the immune system that consists of more than 20 
proteins found in the blood and fluids surrounding tissues; it can be activated by 
microorganisms, a variety of disease states and by contact with medical devices and foreign 
materials. The complement proteins circulate in an inactive form but become activated in 
response to the presence of foreign materials or antigen/antibody complexes. Activation of 
the complement system generates several different molecular pathways, enhancing 
opsonisation, acting as chemotaxins that attract macrophages and neutrophils, being involved 
in the inflammatory response and causing lysis of cell membranes (Ward et al., 1965, Ruddy et 
al., 1972, Ehlenberger and Nussenzweig, 1977, Fearon and Austen, 1980). The complement 
system can be activated by three pathways.  
The classical pathway is antibody dependent; the antibodies bind to an antigen, C1 (C1q, C1r 
and C1s) then binds to the Fc portion of the antibody. Complement C1 is able to cleave C4 into 
C4b, which attaches to the antigen and C4a that is released. Complement C1 cleaves C2 into 
C2a, which attaches to the antigen and C2b that is released. The C4bC2a complex then 
functions as a C3 convertase cleaving C3 into C3a and C3b (Figure 4.1) (Kerr, 1980, Muller-
Eberhard, 1988). In the lectin pathway mannan-binding protein (MBP) binds to mannose 
groups on the membrane of microbes, two proteins called MASP1 and MASP2 bind to MBP 
and function in the same way as C1 to create an C4bC2a convertase causing the cleavage of C3 
in to C3a and C3b (Figure 4.1) (Muller-Eberhard, 1988, Carroll, 2004).  
The alternative pathway is different from the lectin and classical pathways. Complement C3 
undergoes spontaneous hydrolysis into C3a and C3b, C3a and C3b will naturally decay unless 
C3b binds to the surface components of a cell. Once bound Factor B, an alternative pathway 
protein, binds to C3b and is split by Factor D into Bb and Ba. Factor Bb remains bound to C3b 
forming a C3bBb complex, this C3bBb complex is stabilised by Properdin and functions as a C3 
convertase cleaving C3 into C3a and C3b (Figure 4.1) (Fearon and Austen, 1980, Muller-
Eberhard, 1988, Carroll, 2004). As such the alternative pathway can become involved in the 
amplification of the classical and lectin pathways. 
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 After C3 is cleaved the pathway for complement activation is the same as for the classical, 
lectin and alternative pathways. Complement fragment C3b can incorporate as a subunit in the 
existing convertases and form the C5 convertase of the classical/lectin pathway (C4b2b3b) or 
the alternative pathway (C3bBbC3b) (Medicus et al., 1976, Józsi, 2011). Upon activation of the 
complement system C5 is cleaved into C5a and C5b by the C5 convertase; C6 binds to a labile 
binding site on C5b which is followed by association with C7 exposing a hydrophobic site on C7 
that binds to the cell membrane. C8 is then bound and the complex inserts into the cell 
membrane (Hadders et al., 2012). Up to 16 C9 molecules can bind to the complex and form a 
-barrel pore in the membrane (Figure 4.1) (Muller-Eberhard, 1988). The complex of C6 to C9 
is called the membrane attack complex (MAC). 
 
 
Figure 4.1; Schematic of pathways of complement activation 
 
The presence of biomaterials is conventionally believed to activate complement by the 
alternative pathway. The alternative pathway is triggered by the binding of C3b to surfaces 
that do not provide adequate down-regulation of the C3 and C5 convertase; C3b is able to bind 
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to proteins and carbohydrates via free hydroxyl or amino groups (Andersson et al., 2005). 
Complement C3b has been shown to bind to serum proteins, in particular albumin and IgG and 
that these proteins support binding, convertase assembly and amplification of the alternative 
pathway (Andersson et al., 2005).  
Both the classical and alternative pathway are involved in complement activation in the 
presence of biomaterials; at normal complement concentration in serum activation is mainly 
driven by the alternative pathway with little contribution by the classical pathway, as the 
complement concentration levels in serum decrease the contribution of the classical pathway 
increases as the alternative pathway decreases (Andersson et al., 2005). This supports the 
theory that the alternative pathway is being activated on biomaterials by the adsorption of 
serum proteins. This means that in most biological applications complement activation will be 
by the alternative pathway. Hydroxyl rich surfaces have been shown to cause substantial 
complement activation and deposition; amine and carboxyl surfaces have been shown to 
trigger only slight activation of the complement system (Tang et al., 1998). Non-activating 
materials tend to have negatively charged groups such as sulphate, sialic acid and bound 
heparin (Gorbet and Sefton, 2004). However, not all known activators of the complement 
system conform to this observation suggesting that the mechanism is more complex. 
There are numerous reported methods to test for complement activation. 
Immunoelectrophoresis has been used to assess the presence and levels of complement 
fractions C3a and Bb produced by complement activation (Craddock et al., 1977). 
Immunofluorescence and radiolabelling have also been used to assess complement activation 
(Atkinson et al., 2005). ELISA assays and radioimmunoassay using antibodies against specific 
complement fractions or complexes, for example C3a, have been used to test for the levels of 
complement components only produced following complement activation (Rogers et al., 1992, 
Bruins et al., 1997).  
Animal erythrocytes have been used to test for total complement and C1 and C3 activity using 
haemolysis assays (Craddock et al., 1977, Rogers et al., 1992). Complement inhibition can also 
be tested for using these methods by mixing a known trigger and test material together and 
testing for a reduction in the level of detected complement or complexes compared to a 
control of activated complement (Atkinson et al., 2005, Hammel et al., 2007). A modification of 
the CH50 assay described in Section 2.2.17.2 was chosen for testing complement activity over 
the other methods discussed above. This method was chosen as the CH50 assay is less specific 
and includes the whole complement activation pathway where Immunofluorescence, 
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radiolabelling and ELISA assays are more specific and target only part of the pathway; e.g. an 
ELISA assay against C3a uses antibodies only against C3a. This means that if a material has an 
inhibitory effect elsewhere on the complement system this effect may not be noticed using a 
more targeted test.  
 
4.1.5 Animal models 
 
All new medical devices and materials have to be tested in animal models in order to get 
approval for sale and any medical use. Whilst there is no one ideal candidate for comparison to 
human tests dogs, sheep and pigs are the most widely used. Sheep are the favoured animal 
model for vascular research as their blood vessels are similar in size to human vessels, their 
coagulatory system is closer to humans than dogs or pigs and the rate that sheep form an 
endothelium most closely approximates the situation in humans (Narayanaswamy et al., 2000, 
Ueberrueck et al., 2005). Since sheep are the likely animal model for further testing of the 
concepts developed in this study all tests carried out using blood utilised sheep blood. 
 
4.1.6 Peptides 
 
A number of different peptides have been developed at the University of Leeds. These 
peptides were based on an initial design characteristic of 11 amino acids in the peptide 
sequence to ensure an anti-parallel -sheet conformation. The peptides were designed to 
investigate the effect of changing charge, polarity and hydrophobicity of amino acid residues 
upon the self-assembling properties of the peptides under various conditions. The same library 
of developed peptides were utilised to test the effect of charge, polarity and hydrophobicity of 
the amino acid residues on biocompatibility and haemocompatibility. 
 
4.1.7 Peptides from the literature 
 
In order to ascertain if any observed design characteristics were limited to the library of 
peptides developed at the University of Leeds or apply to all peptides it was necessary to 
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include several peptides from the literature. The widest used and reported peptide in the 
literature is PuraMatrix developed by Dr Shuguang Zhang and co-workers at Massachusetts 
Institute of Technology. PuraMatrix is the trade name of peptide RAD16-1 that has the amino 
acid sequence (RADA)4. PuraMatrix forms anti-parallel -sheet structures and has been shown 
to be biocompatible. Fmoc-FF has been explored for tissue engineering applications by Dr Rein 
V. Ulijn and co-workers and comes from a family of simple Fmoc-di-peptides that have been 
shown to self-assemble into hydrogels via  interlocking -sheets (Smith et al., 2008). As the 
peptides developed at the University of Leeds, PuraMatrix and Fmoc-FF all self-assemble via a 
-sheet pathway a peptide that self-assembles using a -helix pattern was chosen. The 
peptides hSAFAAA-W P1 and P2 were developed by Professor Derek Woolfson and co-workers at 
the University of Bristol; the peptides are 28 residues in length and are designed to co-self-
assemble when mixed together. Self-assembly happens longitudinally and forms an -helix 
coiled fibril, fibrils can then bundle together to form fibres (Banwell et al., 2009). A range of 
homo-polypeptides were also chosen as they are larger in size and allow for the demonstration 
of any effects that are due to particular amino acids. 
 
4.1.8 Aims and objectives 
 
The aims of this chapter were to screen a library of self-assembling peptides developed at the 
University of Leeds, self-assembling peptides from the literature and homo-polypeptides for 
haemocompatibility and biocompatibility in order determine suitable candidate peptides for 
use in vascular tissue engineering applications. A secondary aim was to determine design 
characteristics allowing for the intelligent design of peptides for a range of biological 
applications. 
 Specific objectives; 
a) To determine the biocompatibility of a range of peptides 
b) To evaluate the capacity of a range of peptides to induce thrombus formation 
c) To evaluate the haemolytic capacity of a range of peptides 
d) To determine the capacity of the range of peptides for inhibition of the 
complement system 
e) To determine if a set of design characteristics can be found for future design of 
self-assembling peptides for a range of biological applications 
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4.2 Methods 
4.2.1 Peptides 
 
The sequences, charge (at physiological pH) and molecular weights of the peptides used 
throughout these studies are given in Table 4-1. 
Peptide Name Sequence Charge Molecular weight 
P11-1 CH3CO-Q-Q-R-Q-Q-Q-Q-Q-E-Q-Q-NH2 0 1497 
P11-2 CH3CO-Q-Q-R-F-Q-W-Q-F-E-Q-Q- NH2 0 1593 
P11-3 CH3CO-Q-Q-R-F-Q-W-Q-F-Q-Q-Q-NH2 +1 1593 
P11-4 CH3CO-Q-Q-R-F-E-W-E-F-E-Q-Q-NH2 -2 1596 
P11-5 CH3CO-Q-Q-O-F-O-W-O-F-Q-Q-Q-NH2 +3 1522 
P11-7 CH3CO-S-S-R-F-S-W-S-F-E-S-S-NH2 0 1348 
P11-8 CH3CO-Q-Q-R-F-O-W-O-F-E-Q-Q-NH2 +2 1567 
P11-9 CH3CO-S-S-R-F-E-W-E-F-E-S-S-NH2 -2 1432 
P11-10 CH3CO-N-N-R-F-N-W-N-F-E-N-N-NH2 0 1510 
P11-12 CH3CO-S-S-R-F-O-W-O-F-E-S-S- NH2 +2 1401 
P11-13 CH3CO-E-Q-E-F-E-W-E-F-E-Q-E-HN2 -6 1571 
P11-14 CH3CO-Q-Q-O-F-O-W-O-F-O-Q-Q-NH2 +4 1508 
P11-16 CH3CO- N-N-R-F-O-W-O-F-E-N-N- NH2 +2 1511 
P11-17 CH3CO-T-T-R-F-E-W-E-F-E-T-T- NH2 -2 1487.6 
P11-18 CH3CO-T-T-R-F-O-W-O-F-E-T-T- NH2 +2 1457.6 
P11-19 CH3CO- Q-Q-R-Q-O-Q-O-Q-E-Q-Q-NH2 +2 1469.6 
P11-20 CH3CO-Q-Q-R-Q-E-Q-E-Q-E-Q-Q-NH2 -2 1499.5 
P11-22 CH3CO-T-T-R-F-T-W-T-F-E-T-T-NH2 0 1431.6 
P11-24 CH3CO-S-S-R-Q-E-Q-E-Q-E-S-S-NH2 -2 1335.3 
P11-25 CH3CO-S-S-R-S-E-S-E-S-E-S-S-NH2 -2 1212.2 
P11-26 CH3CO-Q-Q-O-Q-O-Q-O-Q-O-Q-Q-NH2 +4 1412.8 
P11-27 CH3CO-Q-Q-E-Q-E-Q-E-Q-E-Q-Q-NH2 -4 1474.4 
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P11-28 CH3CO-O-Q-O-F-O-W-O-F-O-Q-O-NH2 +6 1481.4 
P11-29 CH3CO-Q-Q-E-F-E-W-E-F-E-Q-Q-NH2 -4 1569.6 
P11-30 CH3CO-E-S-E-F-E-W-E-F-E-S-E-NH2 -6 1488.5 
P11-31 CH3CO-S-S-O-F-O-W-O-F-O-S-S-NH2 +4 1344.5 
RAD16-1 CH3CO-(R-A-D-A)4-NH2 0 1712.8 
Fmoc-FF Fmoc-F-F -1 534.21 
hSAF AAA-W P1 K-I-A-A-L-K-A-K-I-A-A-L-K-A-E-I-A-A-L-
E-W-E-N-A-A-L-E-A 
0 2921.5 
hSAF AAA-W P2 K-I-A-A-L-K-A-K-N-A-A-L-K-A-E-I-A-A-L-
E-W-E-I-A-A-L-E-A 
0 2921.5 
Poly-l-Glutamic 
acid 
(E-E-E-E)n Negative 9000 
Poly-l-Lysine (K-K-K-K)n Positive 50000 
Poly-l-Threonine (T-T-T-T)n 0 10000 
Poly-l-
Tryptophan 
(W-W-W-W)n 0 3000 
Poly-l-Aspartic 
acid 
(D-D-D-D)n Negative 10000 
Poly-l-Arginine (R-R-R-R)n Positive 1000 
Poly-l-Ornithine (O-O-O-O)n Positive 1000 
Polyglycine (G-G-G-G)n 0 2750 
Table 4-1; Peptides used in the study; peptide name, structure, charge and molecular weight 
 
Since not all the peptides would form stable gels in physiological conditions for extended 
periods of time the peptides were tested at low concentrations equivalent to the levels of 
monomer /soluble aggregate released from the peptide gel. To ensure that all the peptides 
could be compared a concentration of 0.3 mol.m-3 was chosen, which corresponded to the 
critical concentration for self-assembly of P11-4, the most significant peptide amongst those 
screened for the present project. The same concentration was also used to screen the other 
peptides as this concentration was below the critical concentration for self-assembly for the 
majority of the peptides. 
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4.2.2 Biocompatibility testing 
 
In accordance with ISO standard protocols (ISO 10933-5) two cell lines were used to test for 
cytotoxicity. Baby hamster kidney (BHK) cells, an adhesive epithelial cell line originally obtained 
from 1 day-old hamsters and 3T3 cells originally obtained from primary embryonic mouse 
fibroblasts were used. All peptides solutions were made in DMEM for 3T3 cells and GMEM for 
BHK cells to achieve a final concentration of 0.3 mol.m-3. All samples were mixed by pipetting 
up and down and by vortexing. Peptide samples which proved difficult to dissolve were 
pipetted up and down to create a dispersion of peptide before each addition of peptide 
solution to each test. All difficulties with dissolving peptides were noted. All biocompatibility 
tests were set-up and run as per the protocol described in Section 2.2.14. Six replicates for 
each peptide were carried out with a maximum of six tests per 96 well plate; one positive 
control, one negative control and up to four different peptide samples. Only one cell type was 
grown in each 96 well plate to prevent cross-contamination and all cells were grown in the 
same incubator for the same time period.  Cells were seeded at approximately 2000 BHK cells 
per well and 4000 3T3 cells per well in a 96 well plate. Cells were grown in a clear 96 well plate 
to allow for the monitoring of their growth and to check for any discrepancies before use. 
Following incubation in test solutions the cell numbers were assessed using the ATPLite-M® 
assay; this has the advantage that cell viability can be assessed by the number of live cells 
compared to the control but as a secondary effect increased levels of cell proliferation can be 
detected. 
 
4.2.3 Chandler loop thrombosis model 
 
All peptide solutions were made in deionised water to achieve a final concentration of 0.3 
mol.m-3. All samples were mixed by pipetting up and down and by vortexing. Peptides samples 
which proved difficult to dissolve were pipetted up and down to create a dispersion of peptide 
before each addition of peptide solution to each test. All difficulties with dissolving peptides 
were noted. All Chandler loop tests were set-up and run as per the protocol described in 
Section 2.2.15.1. Six replicates for each peptide were tested. Six samples were tested at a time 
with three loops per rotator. Citrated blood from sheep was used to test for effects upon 
thrombus formation. All blood used was tested for normal clotting behaviour and a response 
to known triggers of blood clotting before use. 
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4.2.4 Haemolysis assay 
 
All peptide solutions were made in Ringer’s solution to achieve a final concentration of 0.3 
mol.m-3. All samples were mixed by pipetting up and down and by vortexing. Peptides samples 
which proved difficult to dissolve were pipetted up and down to create a dispersion of peptide 
before each addition of peptide solution to each test. All difficulties with dissolving peptides 
were noted. All haemolysis tests were set-up and run as per the protocol described in Section 
2.2.16. Six replicates for each test condition were carried out and samples were taken at 6, 12, 
24, 48 and 72 hours. Erythrocytes were obtained from citrated sheep blood harvested and 
shipped the day before use. 
 
4.2.5 Complement inhibition assay 
 
All peptide solutions were made in Ringer’s solution to achieve a final concentration of 0.3 
mol.m-3 as described above (Section 4.2.1). All complement inhibition tests were set-up and 
run as per the protocol described in Section 2.2.17.2. Six replicates for each test condition 
were carried out. Normal pooled human serum was used for the test and the CH50 level 
determined before testing using the method described in Section 2.2.17.1.  
 
4.3 Results 
4.3.1 Effects of peptides on cell growth 
 
Results were collected, graphed and analysed for significant statistical differences by one-way 
ANOVA and post-hoc analysis (Section 2.2.21.2). For all results there was a significant 
difference between the cellular growth observed for both cell types between the positive and 
negative controls. Results are presented in Figure 4.2 to Figure 4.4 as a series of graphs with 4 
test peptides plus the relevant positive and negative controls. 
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Figure 4.2; ATP levels in cells cultured in the presence and absence of peptides; negative control DMEM for 3T3 cells, GMEM for BHK cells, positive control 40 % DMSO 
in, DMEM for 3T3 cells, GMEM for BHK cells. Data is presented as the mean (n=6) ± 95 % confidence intervals. Data was analysed by one way analysis of variance 
followed by determination of the MSD (p < 0.05). * = Significant difference from negative control.
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3T3 cells grown in solutions of peptides P11-1, P11-2, P11-3, P11-7, P11-8, P11-10, P11-13, P11-14, 
P11-26 and P11-27 showed similar levels of growth with no significant difference compared to 
the negative DMEM controls. 3T3 cells grown in solutions of peptides P11-4, P11-5, P11-9, P11-12, 
P11-17 and P11-18 showed a significantly higher level of growth compared to that of 3T3 cells 
grown in the negative DMEM controls. BHK cells grown in solutions of peptides P11-2, P11-3, 
P11-4, P11-5, P11-7, P11-9, P11-12, P11-13, P11-14, P11-17, P11-18, P11-26 and P11-27 showed similar 
levels of growth with no significant difference compared to the negative GMEM controls. BHK 
cells grown in a solution of peptide P11-8 showed a significantly higher level of growth 
compared to that of BHK cells grown in the negative GMEM control. BHK cells grown in 
solutions of peptides P11-1 and P11-10 showed significantly lower levels of growth compared to 
the negative GMEM control. The growth of both BHK and 3T3 cells in the different peptide 
solutions were all significantly higher than the positive, cytotoxic, controls.  
The results presented in Figure 4.2 showed peptides P11-2, P11-3, P11-4, P11-5, P11-7, P11-8, P11-9, 
P11-12, P11-13, P11-14, P11-17, P11-18, P11-26 and P11-27 were all non-cytotoxic. The results 
showed that P11-1 and P11-10 were non-cytotoxic to 3T3 cells and that there was a significantly 
lower level of growth of BHK cells in solutions of P11-1 and P11-10 but that were significantly 
higher than the cytotoxic control suggesting that the peptides are not cytotoxic.  
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Figure 4.3; ATP levels in cells cultured in the presence and absence of peptides; negative control DMEM for 3T3 cells, GMEM for BHK cells, positive control 40 % DMSO 
in, DMEM for 3T3 cells, GMEM for BHK cells. Data is presented as the mean (n=6) ± 95 % confidence intervals. Data was analysed by one way analysis of variance 
followed by determination of the MSD (p < 0.05). * = Significant difference from negative control
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3T3 cells grown in solutions of P11-19, P11-20, P11-22, P11-28, P11-29, RAD16-1 and 
complementary peptides P11-13 & 14, P11-26 & 27, and P11-28 & 29 showed similar levels of 
growth with no significant difference compared to the negative DMEM controls. 3T3 cells 
grown in solutions of P11-16, P11-24, P11-25, P11-30, P11-31 and complementary peptides P11-30 
& 31 showed a significantly higher level of growth compared to that of 3T3 cells grown in the 
negative DMEM controls. BHK cells grown in solutions of P11-22, RAD16-1 and complementary 
peptides P11-13 & 14, P11-28 &29 and P11-30-&31 showed similar levels of growth with no 
significant difference compared to the negative GMEM controls. BHK cells grown in solutions 
of P11-19, P11-20, P11-24, P11-25, P11-28, P11-29, P11-30 and complementary peptide P11-26 & 27 
showed a significantly higher level of growth compared to that of BHK cells grown in the 
negative GMEM controls. BHK cells grown in a solution of P11-16 showed significantly lower 
levels of growth compared to the negative GMEM control. The growth of both BHK and 3T3 
cells in the different peptide solutions were all significantly higher than the positive, cytotoxic, 
controls.  
The results in Figure 4.3 showed peptides P11-19, P11-20, P11-22, P11-24, P11-25, P11-28, P11-29, 
P11-30, P11-31, RAD16-1 and complementary peptides P11-13 & 14, P11-26 & 27, P11-28 & 29 and 
P11-30 & 31 were non-cytotoxic. The results also showed that P11-16 was non-cyotoxic to 3T3 
cells but showed a significant decrease in cell growth for BHK cells suggesting the peptide is 
non-cytotxic. 
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Figure 4.4; ATP levels in cells cultured in the presence and absence of peptides; negative control DMEM for 3T3 cells, GMEM for BHK cells, positive control 40 % DMSO 
in DMEM for 3T3 cells, GMEM for BHK cells. Data is presented as the mean (n=6) ± 95 % confidence intervals. Data was analysed by one way analysis of variance 
followed by determination of the MSD (p < 0.05). * = Significant difference from negative control, **= significant difference from negative control and no significant 
difference from positive control.
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Dificulty was experienced in disolving the peptide Fmoc-FF, poly-l-tryptophan (Trp) and 
polyglycine in DMEM and GMEM. 3T3 cells grown in solutions of poly-l-glutamic acid (Glu) and 
poly-l-threonine (Thr) showed similar levels of growth with no significant difference compared 
to the negative DMEM control. 3T3 cells grown in solutions of peptide hSAFAAA-W P1, hSAFAAA-W 
P2, poly-l-tryptophan (Trp), poly-l-aspartic acid (Asp), polyglycine and the complementary 
hSAFAAA-W P1&2 showed a significantly higher level of growth compared to that of 3T3 cells 
grown in the negative DMEM controls. 3T3 cells grown in solutions of peptide Fmoc-
diphenylalanine (Fmoc-FF), poly-l-lysine (Lys), poly-l-arginine (Arg) and poly-l-ornithine (Orn) 
showed similar levels of growth to the positive cytotoxic controls. BHK cells grown in solutions 
of peptide hSAFAAA-W P2, poly-l-threonine (Thr), polyglycine and complementary peptide 
hSAFAAA-W P1&2 showed similar levels of growth with no significant difference compared to the 
negative GMEM controls. BHK cells grown in solutions of poly-l-glutamic acid (Glu), poly-l-
tryptophan (Trp) and poly-l-aspartic acid (Asp) showed a significantly higher level of growth 
compared to that of BHK cells grown in the negative GMEM controls. BHK cells grown in 
solutions of peptide Fmoc-diphenylalanine (Fmoc-FF) and hSAFAAA-W P2 showed significantly 
lower levels of growth compared to the negative GMEM controls. BHK cells grown in solutions 
of peptide poly-l-lysine (Lys), poly-l-arginine (Arg) and poly-l-ornithine (Orn) showed similar 
levels of growth to the positive cytotoxic controls. 
The results in Figure 4.4 showed peptides hSAFAAA-W P2, poly-l-glutamic acid (Glu), poly-l-
threonine (Thr), poly-l-tryptophan (Trp), poly-l-aspartic acid (Asp), polyglycine and 
complemmntary peptides hSAFAAA-W P1&2 were non-cytotoxic. The result showed peptide 
hSAFAAA-W P1 was non-cytotoxic to 3T3 cells but showed a significant decrease in cell growth 
for BHK cells suggesting that the peptide is non-cytotoxic. The results also showed that peptide 
Fmoc-diphenylalanine (Fmoc-FF) was cytotxic to 3T3 cells and significantly decreased the 
growth of BHK cells sugesting the peptide is cytotoxic. The results in Figure 4.4 showed homo-
polypeptides poly-l-lysine (Lys), poly-l-arginine (Arg) and poly-l-ornithine (Orn) to be cytotoxic. 
 
4.3.2 Effects of peptides on thrombus formation 
 
Results were collected, graphed and analysed for significant statistical differences by one-way 
ANOVA and post hoc analysis (Section 2.2.21.2). For all results there was a significant 
difference between the size of the thrombus observed between the positive and negative 
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controls. Results are presented in Figure 4.5 and Figure 4.6 as a series of graphs with test 
peptides plus the relevant positive and negative controls. 
 
 
Figure 4.5; Weights of thrombus formed in the presence or absence of peptide in the Chandler loop 
model; Negative control 100 µl of water, Positive control 2 µl of human -thrombin in 98 µl of water. 
Data is presented as the mean (n=6) ± 95 % confidence intervals. Data was analysed by one way 
analysis of variance followed by determination of the MSD (p < 0.05). * = Significant increase from 
negative control, **= significant reduction compared to negative control, ***= no significant 
difference from positive control. 
 
All thrombi that were formed in this assay had a similar appearance with a single thrombus 
being formed with a width similar to the PVC tubing and a visible white head at one end of the 
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thrombus and a red tail similar to arterial thrombi formed in vivo. Difficulty was observed 
dissolving peptide Fmoc-diphenylalanine (Fmoc-FF) in deionised water. 
The results in Figure 4.5 showed that peptides P11-2, P11-4, P11-7, P11-8, P11-9, P11-12, P11-13, P11-
14 P11-17, P11-18, P11-20 P11-26, P11-27, P11-28, P11-29, P11-30, P11-31, Fmoc-diphenylalanine 
(Fmoc-FF) and poly-l-glutamic acid (Glu) all resulted in thrombi similar in size with no 
significant difference to the relevant negative controls. The results also showed that the 
thrombi formed in these peptides were significantly smaller than the thrombi formed in the 
relevant positive controls. The results in Figure 4.5 graph A showed that peptide RAD16-1 
formed significantly larger thrombi than the negative control that was also significantly smaller 
than the positive control. The results in Figure 4.5 graph B showed that homo-polypeptide 
poly-l-threonine (Thr) resulted in significantly larger thrombi than the negative control that 
showed no significant difference from the positive control. The results in Figure 4.5 graph B 
showed that poly-l-lysine (Lys) did not form thrombi as the blood was observed to agglutinate. 
The results in Figure 4.5 showed that peptides P11-2, P11-4, P11-7, P11-8, P11-9, P11-12, P11-13, P11-
14 P11-17, P11-18, P11-20 P11-26, P11-27, P11-28, P11-29, P11-30, P11-31, Fmoc-diphenylalanine 
(Fmoc-FF) and poly-l-glutamic acid (Glu) had no significant effect upon thrombus formation. 
The result showed that peptides RAD16-1 and poly-l-threonine (Thr) increased thrombus 
formation. The results also showed that poly-l-lysine (Lys) prevented thrombus formation but 
was not haemocompatible as it was observed to cause blood agglutination. 
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Figure 4.6; Weights of thrombus formed in the presence or absence of peptide in the Chandler loop 
model; Negative control 100 µl of water, Positive control 2 µl of human -thrombin in 98 µl of water. 
Data is presented as the mean (n=6) ± 95 % confidence intervals. Data was analysed by one way 
analysis of variance followed by determination of the MSD (p < 0.05). * = Significant increase from 
negative control, **= significant decrease compared to negative control, ***= no significant difference 
from positive control. 
 
All thrombi that were formed in this assay had a similar appearance with a single thrombus 
being formed with a width similar to the PVC tubing and a visible white head at one end of the 
thrombus and a red tail similar to arterial thrombi formed in vivo. Difficulty was observed 
dissolving peptides poly-l-tryptophan (Trp) and Polyglycine in deionised water. 
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The results in Figure 4.6 showed that peptides P11-1, P11-3, P11-5, P11-10, P11-16, P11-24, P11-25, 
hSAFAAA-W P1, hSAFAAA-W P2, poly-l- aspartic acid (Asp), Polyglycine and complementary peptides 
P11-13&14, P11-26&27, P11-28&29 and P11-30&31 all resulted in thrombi similar in size with no 
significant difference to the relevant negative controls. The results also showed that the 
thrombi formed in these peptides were significantly smaller than the thrombi formed in the 
relevant positive controls. The results in Figure 4.6 graph A showed that complementary 
peptide hSAFAAA-W P1 & P2 resulted in significantly larger thrombi than the relevant negative 
control that showed no significant difference from the relevant positive control. The results in 
Figure 4.6 graph B showed that homo-polypeptide poly-l-tryptophan (Trp) resulted in the 
formation of thrombi that were significantly larger than thrombi formed in the relevant 
negative control and that showed no significant difference from the relevant positive control. 
The results also show that peptides poly-l-arginine (Arg) and poly-l-ornithine (Orn) failed to 
form thrombi as the blood was observed to agglutinate. 
The results in Figure 4.6 showed that peptides P11-1, P11-3, P11-5, P11-10, P11-16, P11-24, P11-25, 
hSAFAAA-W P1, hSAFAAA-W P2, poly-l- aspartic acid (Asp), polyglycine and complementary 
peptides P11-13&14, P11-26&27, P11-28&29 and P11-30&31 had no significant effect upon 
thrombus formation. The result showed that homo-polypeptide poly-l-tryptophan (Trp) and 
complementary peptide hSAFAAA-W P1 & P2 increased thrombus formation. The results also 
showed that poly-l-arginine (Arg) and poly-l-ornithine (Orn) prevented thrombus formation but 
were not haemocompatible as they were observed to cause blood agglutination. 
 
4.3.3 Effects of peptides on the haemolysis of ovine erythrocytes 
 
Results were collected, graphed and analysed for significant statistical difference by one-way 
ANOVA and post hoc analysis (Section 2.2.21.2). For all results at all time points there was a 
significant difference between the positive and negative controls. Results are presented in 
Figure 4.7 to Figure 4.10 as a series of graphs with all peptides tested plus the relevant positive 
and negative controls. 
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Figure 4.7; Haemolytic effects of peptides after A; 6 hours, B; 12 hours. Positive control water, Negative control Ringer’s solution. Data is presented as the mean (n=6) ± 
95 % confidence intervals. Data was analysed by one way analysis of variance followed by determination of the MSD (p < 0.05). *= significant difference from negative 
control, **= significant difference from negative control and no significant difference from positive control. 
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Figure 4.8; Haemolytic effects of peptides after A; 24 hours, B; 28 hours; Positive control water, Negative control Ringer’s solution. Data is presented as the mean (n=6) 
± 95 % confidence intervals. Data was analysed by one way analysis of variance followed by determination of the MSD (p < 0.05). *= significant difference from negative 
control, **= significant difference from negative control and no significant difference from positive control. 
170 
 
 
Figure 4.9; Haemolytic effects of peptides after 72 hours; Positive control water, Negative control Ringer’s solution. Data is presented as the mean (n=6) ± 95 % 
confidence intervals. Data was analysed by one way analysis of variance followed by determination of the MSD (p < 0.05). *= significant difference from negative 
control, **= significant difference from negative control and no significant difference from positive control. 
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Figure 4.10; Haemolytic effects of peptides; Positive control water, Negative control Ringer’s solution; Data is presented as the mean (n=6) ± 95 % confidence intervals. 
Data was analysed by one way analysis of variance followed by determination of the MSD (p < 0.05). Coloured stars denote a significant difference from the negative 
control, Red stars denote no significant difference from the positive control.  
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All peptide solutions formed clear or cloudy white solutions except for poly-l-threonine (Thr) 
which was brown in colour. The samples of erythrocytes mixed with peptide and the controls 
were all red in colour except for poly-l-threonine (Thr) which was brown/gray in colour. 
Difficulty was observed dissolving peptides Fmoc-diphenylalanine (Fmoc-FF), poly-l-tryptophan 
(Trp) and polyglycine in Ringer’s solution. 
The results presented in Figure 4.7, Figure 4.8, Figure 4.9 and Figure 4.10 showed that the level 
of haemoglobin released from sheep erythrocytes in contact with the majority of the peptide 
solutions at various time points was not significantly different from the level of haemoglobin 
detected in the negative, spontaneous lysis, control. This low level of detected haemoglobin 
indicated that there had been little to no lysis of the sheep erythrocytes caused by interaction 
of the peptides with the erythrocyte cell membrane. After 6 and 12 hours incubation at 37°C 
(Figure 4.7 graph A & B) P11-10, P11-18, poly-l-lysine (Lys), poly-l-threonine (Thr), poly-l-arginine 
(Arg) and poly-l-ornithine (Orn) showed a level of haemoglobin in solution that was 
significantly greater than the negative control indicating that haemolysis had occurred. After 
24 hours at 37°C (Figure 4.8 graph A) P11-3 and after 72 hours at 37°C (Figure 4.9) Fmoc-
diphenylalanine (Fmoc-FF) showed a level of haemoglobin in solution that was significantly 
greater than the negative control indicating that haemolysis had occurred.  
The release of haemoglobin into a solution in the presence of poly-l-lysine (Lys) after 12 hours 
(Figure 4.7 graph B) and poly-l-arginine (Arg) after 72 hours (Figure 4.9) showed no significant 
difference from the positive, total lysis control. The level of haemoglobin released into solution 
for all other peptides was significantly lower than the positive control. The results in Figure 
4.10 showed that the level of haemoglobin in all solutions gradually increased over the 
observed time period with the exception of solutions of poly-l-lysine (Lys) and the positive 
control. The haemoglobin released in a solution in the presence of poly-l-arginine (Arg) 
showed the most noticeable increase over time.  
The results from the haemolysis assay showed that the majority of peptides solutions resulted 
in no significant level of haemolysis. The results from the haemolysis assay showed that 
solutions of peptides P11-3, P11-10, P11-18, poly-l-lysine (Lys), poly-l-arginine (Arg) and poly-l-
ornithine (Orn) all interacted destructively with the erythrocyte membrane causing haemolysis 
and the release of haemoglobin into solution. Due to the differences observed for poly-l-
threonine (Thr) it is not possible to say if haemoglobin had been released. 
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4.3.4 Peptide complement inhibition 
 
The haemolytic nature and results of the haemolysis assay indicated that homo-polypeptides 
poly-l-lysine (Lys), poly-l-threonine (Thr), poly-l-arginine (Arg) and poly-l-ornithine (Orn) could 
not be tested for complement inhibition using this method. To determine the dilution of the 
serum needed to achieve 50 % lysis a CH50 assay was performed (Section 2.2.17.1). The results 
of the CH50 assay (Appendix Figure A.4) were used to determine the dilution of serum to be 
used in complement inhibition testing. Complement inhibition testing was performed as 
described in Section 2.2.17.2. Results for inhibition of complement activation (absorbance at 
540 nm) were recorded and an average of the blank control for each peptide was subtracted 
from the each result. Results were collected, graphed and analysed for significant statistical 
difference by one-way ANOVA and post hoc analysis (Section 2.2.21.2). Results are presented 
in Figure 4.11 and Figure 4.12 as a series of graphs with test peptides plus the relevant positive 
and negative controls. 
 
174 
 
 
Figure 4.11; Complement inhibition by peptides; CH50 negative control, HI (heat inactivated) serum 
positive control. Data is presented as the mean (n=6) ± 95 % confidence intervals. Data was analysed 
by one way analysis of variance followed by determination of the MSD (p < 0.05). *= Significant 
difference from negative control. 
 
All peptide solutions formed clear or cloudy white solutions; when mixed with erythrocytes the 
mixtures were all red in colour and no difficulty was experienced dissolving the peptides in 
Ringer’s solution. 
The results in Figure 4.11 showed that the level of free haemoglobin detected in the presence 
of P11-1, P11-2, P11-3, P11-7, P11-8, P11-10, P11-14, P11-17 P11-18 and P11-19 showed no significant 
difference to the negative, CH50, controls. The results presented in Figure 4.11 graph A 
showed there was a significant reduction in the level of free haemoglobin detected in a 
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solution of P11-4 compared to the negative control. The results presented in Figure 4.11 graph 
B showed a significant reduction in the level of free haemoglobin detected in the presence of 
peptides P11-9, P11-12, P11-13 and complementary peptides P11-13 & 14 compared to the 
negative control. The level of free haemoglobin detected in all solutions presented in Figure 
4.11 was significantly higher than the level of free haemoglobin detected in the relevant, heat 
inactivated serum, positive controls. 
The results in Figure 4.11 showed that peptides P11-1, P11-2, P11-3, P11-7, P11-8, P11-10, P11-14, 
P11-17 P11-18 and P11-19 had no inhibitory effect upon the complement system. The results in 
Figure 4.11 also showed peptides P11-4, P11-9, P11-12, P11-13 and complementary peptides P11-
13 & 14 had an inhibitory effect on the complement system, lowering the level of complement 
mediated lysis, but did not fully inhibit the complement system. 
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Figure 4.12; Complement inhibition by peptides; CH50 negative control, HI (heat inactivated) serum 
positive control. Data is presented as the mean (n=6) ± 95 % confidence intervals. Data was analysed 
by one way analysis of variance followed by determination of the MSD (p < 0.05). *= Significant 
difference from negative control. 
 
All peptide solutions formed clear or cloudy white solutions; when mixed with erythrocytes the 
mixtures were all red in colour. Difficulty was experienced dissolving peptides Fmoc-FF and 
homo-polypeptides Poly-l-Trp and polyglycine in Ringer’s solution. 
The results shown in Figure 4.12 indicated that the level of free haemoglobin detected in the 
presence of P11-20, P11-22, P11-24, P11-25, P11-26, P11-27, P11-28, P11-31, RAD16-1, Fmoc-FF, 
hSAFAAA-W P1, hSAFAAA-W P2, poly-l-glutamic acid (Glu), poly-l-tryptophan (Trp), poly-l-aspartic 
acid (Asp), polyglycine and complementary peptides P11-26 & 27, P11-28 & 29 and P11-30 & 31 
showed no significant difference to the negative, CH50, controls. The results in Figure 4.12 
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graph A showed there was a significant reduction in the level of free haemoglobin detected in 
the presence of peptides P11-29 and P11-30 compared to the negative control. The results in 
Figure 4.12 graph B showed there was a significant reduction in the level of free haemoglobin 
detected in solution between complementary peptide hSAFAAA-W P1 & P2 and the negative 
control. The level of free haemoglobin detected in solution for all the peptides was 
significantly higher than the level of haemoglobin detected in the relevant positive, heat 
inactivated serum, controls. 
The results in Figure 4.12 showed that peptides P11-20, P11-22, P11-24, P11-25, P11-26, P11-27, 
P11-28, P11-31, RAD16-1, Fmoc- diphenylalanine (Fmoc-FF), hSAFAAA-W P1, hSAFAAA-W P2, poly-l-
glutamic acid (Glu), poly-l-tryptophan (Trp), poly-l-aspartic acid (Asp), polyglycine and 
complementary peptides P11-26 & 27, P11-28 & 29 and P11-30 & 31 had no inhibitory effect 
upon the complement system. The results in Figure 4.12 showed that peptides P11-29, P11-30 
and complementary peptide hSAFAAA-W P1 & P2 had an inhibitory effect on the complement 
system, lowering the level of complement mediated lysis, but did not fully inhibit the 
complement system. 
 
4.4 Discussion 
 
For biomedical applications, self-assembling peptides must be biocompatible. For many 
applications the peptide will also need to be haemocompatible. The aim of this study was 
twofold; to ascertain which of the many peptides developed at the University of Leeds was 
best suited for application in vascular tissue engineering and to determine any design 
characteristics indicative of peptide bio and haemo compatibility to aid in the future 
development of self-assembling peptides for biomedical applications. There have been 
numerous potential uses of self-assembled peptides reported in the literature however no 
attempts to determine design characteristics for biomedical use have been reported. 
In order to make comparisons between different sized peptides it was desirable to test the 
same concentration of each peptide. The range of structures formed as peptides self-assemble 
are concentration dependent. Thus one peptide can form a self-assembled gel at a particular 
concentration and another peptide can form a monomeric solution at the same concentration. 
This difference in self-assembly would present difficulties in interpreting results of peptides 
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tested therefore all peptide solutions were tested at a concentration of 0.3 mol.m-3 at which 
the majority of peptides in solution were in monomeric or soluble aggregate form. 
 
4.4.1 Effects of peptides on cell growth 
 
In vitro biocompatibility testing was carried out to establish the cytocompatibility of the 
peptides. The peptides were tested in accordance with ISO 10993-5. The peptides were 
evaluated using extract cytotoxicity testing by growing BHK and 3T3 cell lines in peptide 
solutions for 72 hours. Cell viability was determined using the ATPLite-M® assay. The majority 
of peptides were biocompatible with no effect upon BHK and 3T3 cell growth. This was 
probably a result of the peptides being short sequences of natural amino acids; some of which 
were based off natural protein fragments. 
Some of the cells grown in the peptide solutions showed a significant increase in ATP levels; 
suggesting an increase in cell proliferation in some of the peptide solutions. Both BHK and 3T3 
cells proliferated more than the negative controls in solutions of P11-24, P11-25, P11-30, poly-l-
tryptophan and poly-l-aspartic acid. Several of the peptide solutions induced a higher level of 
ATP in one of the two cell lines. There was a significant increase in the level of ATP produced 
by 3T3 cells grown in solutions of peptides P11-4, P11-5, P11-9, P11-12, P11-16, P11-17, P11-18, P11-
31, hSAFAAA-W P1, hSAFAAA-W P2, polyglycine and complementary peptides P11-30&31 and 
hSAFAAA-W P1 & P2. A significant increase in BHK cell growth was also recorded in solutions of 
peptides P11-8, P11-19, P11-20, P11-28, P11-29, poly-l-glutamic acid and complementary peptides 
P11-26&27.  
Since surface area, wetability and charge play an important role in cell attachment and 
proliferation it is possible that the peptides affected the surface of the cell culture plastic in a 
positive manner to allow for increased cell adhesion and proliferation (Webb et al., 1998, 
Arima and Iwata, 2007). Adsorption of peptide onto the tissue culture plastic can change the 
wetability of the surface. Surface wetability changes the ability of cells to attach to a surface 
and different cells respond differently to changes in surface wetability (Tan et al., 2004, Arima 
and Iwata, 2007).  
Differences in the level of ATP could also have been the result of the peptide having effects on 
molecular and regulatory mechanisms in the cells. Amino acid starvation has been shown to 
affect DNA synthesis and it is believed that mechanisms exist in cells that arrest cell growth if 
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nutrients are in poor supply (Holley and Kiernan, 1974, Melvin et al., 1979). It is possible that 
as the cells reached confluence they had depleted the amino acid supply in the serum and that 
the peptides were acting as an extra source of amino acids.  
Cell proliferation involves a balance between positively and negatively acting signals, a change 
to the quiescent state induces metabolic changes that are necessary for cell survival under 
conditions inadequate for proliferation; this is believed to be in part controlled by a set of 
growth arrest-specific (gas) genes whose expression is negatively regulated by serum 
(Manfioletti et al., 1990). The activation of gas genes changes the metabolic activity of a cell. In 
nutrient poor conditions levels of cellular ATP may change in order to protect cell viability. It is 
possible that mechanisms of cell cycle arrest were being activated in the negative control at an 
earlier time point than in cultures with peptide solutions, in which the peptide was acting as a 
source of amino acids expanding the time to cell cycle arrest. This explanation raises the 
question of why not all the peptides act as a source of amino acids. This in turn could be 
explained by the different peptide sequences where the cells may not have been able to use all 
the peptides if they did not contain cleavable sequences.  
ATP levels can also vary depending upon cellular activation (Crouch et al., 1993). It is possible 
that the peptide solutions activated, enhanced, prevented or stabilised some molecular 
pathway in the cells and increased the level of cellular ATP without increasing the number of 
cells present. The presence of the peptide could also have induced phenotypic change in the 
cells. Cells attached to RAD16-1 have been shown not to spread out, as on the more rigid 
tissue culture plastic, but to remain rounded indicating different cell behaviour on the 
different materials that could have an effect upon cellular levels of ATP (Zhang et al., 1995). It 
is not clear which if any of these effects resulted in the higher levels of ATP detected, it is 
possible that one or more of the effects could have combined to give these results. Further 
studies are needed in order to establish how these peptide solutions affect cultured cells and if 
this effect is translatable into higher concentration peptide solutions and peptide gels. 
The results of the extract cytotoxicity testing showed mixed results for some peptides 
solutions. Peptides P11-1, P11-10, P11-16 and hSAFAAA-W P1 supported significantly reduced BHK 
cell growth compared to the negative GMEM control. The growth of 3T3 cells in solutions of 
peptides P11-1, P11-10, P11-16 and hSAFAAA-W P1 showed no significant difference to the negative 
DMEM control. This suggested that these peptides were not toxic  and that the reduced BHK 
cell growth could have been the result of anomalous results or a cell specific effect due to the 
different growth conditions of BHK and 3T3 (O'Neill et al., 1979). The different growth 
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conditions needed for 3T3 and BHK cells could also possibly explain why in some peptide 
extracts one cell type had a significantly higher level of ATP than the other cell type when 
compared to the negative controls.  
The growth of BHK cells in a solution of Fmoc-diphenylalanine showed levels of cell growth 
that were significantly lower than the negative control. Solutions of Fmoc-diphenylalanine 
were toxic to 3T3 cells but not as toxic to BHK cells. In addition to measurement of effects on 
cell proliferation and number the ATP assays may also provide information about sub-lethal 
cell damage. ATP is necessary for cell function and ATP production is depressed by many forms 
of cell stress (Cree and Andreotti, 1997). ATP can be used to test for first-order toxicity in cell 
lines and has been shown to have a high level of sensitivity to toxic agents, with the level of 
cellular ATP being reduced (Pasternak and Miller, 1995). This means that cells that are 
damaged in some way but not killed could show a significantly lower level of ATP compared to 
the negative control but a significantly higher level of ATP compared to the positive control. 
This suggested that Fmoc-diphenylalanine could have a cell dependent cytotoxic effect. This is 
supported in the literature where Fmoc-diphenylalanine has been observed to support the 
growth of chondrocytes but inhibit the growth of human dermal fibroblasts and 3T3 cells 
(Jayawarna et al., 2009).  
Cytotoxicity testing showed that the positive homo-polypeptides poly-l-lysine, poly-l-arginine 
and poly-l-ornithine were cytotoxic to both cell types. It has been previously demonstrated 
that poly-cations can bind to the surfaces of animal cells and produce toxic effects (Fischer et 
al., 2003). Using electrophoretic mobility testing this binding has been shown to be charge 
related, with the positive cations neutralising the natural negative anions on the surface of a 
cell and so changing cell mobility (Mayhew et al., 1973). It has been shown that poly-cations 
cause disruption to a cell membrane, at low concentrations and low molecular weights. This is 
a reversible process and has been investigated as a method of inserting genetic material into 
cells (Mayhew et al., 1973, Kabanov and Kabanov, 1995). A charge relationship has been 
observed related to cytotoxicity but a size relationship has also been observed that is likely 
linked to membrane disruption. High molecular weight poly-l-lysine has been shown to be 
cytotoxic whereas lower molecular weight poly-l-lysine has been shown to be less toxic 
(Mayhew et al., 1973, Fischer et al., 2003). This could explain why poly-l-lysine, poly-l-arginine 
and poly-l-ornithine were cytotoxic but the much smaller positively charged peptides in the P11 
series were not. 
 
181 
 
4.4.2 Effects of peptides on thrombus formation 
 
The thrombogenic potential of the peptides was assessed using the modified Chandler loop 
model. The majority of thrombi formed in the different peptide solutions showed no 
significant difference from the negative control without peptide indicating that the monomeric 
peptides had no effect upon thrombus formation.  
Peptides RAD16-1, poly-l-threonine, poly-l-tryptophan and complementary peptide hSAFAAA-W 
P1 & P2 showed a significant increase in the size of the thrombus formed compared to the 
negative control indicating that these peptides had an effect upon thrombus formation. The 
thrombi formed with the addition of poly-l-threonine, poly-l-tryptophan and complementary 
peptide hSAFAAA-W P1 & P2 showed no significant difference compared to the positive control 
of human -thrombin. The thrombi formed in the presence of RAD16-1 were significantly 
smaller than the positive control. This indicated that whilst RAD16-1 increased thrombus 
formation the effect was not as marked as the effect of -thrombin whereas peptides poly-l-
threonine, poly-l-tryptophan and complementary peptide hSAF AAA-W P1&2 resulted in 
thrombi that were indistinguishable from those formed by -thrombin. It is important to note 
that the blood coagulation pathway is complex with several activators, inhibitors, molecular 
and cellular pathways involved in thrombus formation and hence there are several possible 
explanations as to the cause of these effects.  
The peptides could have triggered part of the blood clotting cascade by directly activating 
blood clotting. This was unlikely as there are wide differences in the peptide structure and size 
of RAD16-1, poly-l-threonine, poly-l-tryptophan and complementary peptide hSAFAAA-W P1 & 
P2. There is also evidence in the literature that RAD16-1 has no effect upon levels of pro-
thrombin which would be expected if it directly triggered blood clotting (Song et al., 2009). 
However, based upon these results, direct triggering of blood clotting could be ruled out.  
The most likely explanation is that the peptides had an effect upon the blood clotting cascade 
that was reducing the time for clot formation. The added peptide could have increased the 
stability or activity of one of the functional components in the clotting cascade and so reduced 
clotting time. It is possible that the peptides could have inhibited one of the regulatory 
systems that maintain haemostasis, shortening the coagulation time as has been observed for 
antibodies that bind regulatory protein C (Hwang et al., 2003).  
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The peptides could have interacted with the formation of the clot.  The peptides could have 
increased the rate of fibrin formation, through protein induced enhancement in the enzymatic 
activity of clotting factors such as thrombin, co-assembly of added peptide with 
fibrin/fibrinogen or by non-specific steric volume exclusion increasing the fractional 
concentration of fibrin and other coagulation factors in solution. Thrombin is capable of a 
range of activities and is known to be able to cleave 12 substrates; thrombin recognition is 
largely controlled by cofactors that can have a pro-coagulation or anti-coagulation effect; 
glycoprotein Ib, fibrin and Na+ are known to be pro-coagulant cofactors (Adams and 
Huntington, 2006). It is possible that the peptides bound to one of the enzymes such as 
thrombin involved in the coagulation pathway and enhanced the activity of the enzyme, 
decreasing clotting time in a similar manner to the binding of other cofactors.  
Fibrin self-assembly has been shown to be influenced by temperature, pH and ionic 
concentration. Changes in the pH, ionic concentration and temperature change the energetics 
of the system and change the fibrin structures that are formed. pH and ionic concentration 
have been shown to influence fibrin assembly but temperature has been shown to influence 
the rate of fibrin monomer generation and assembly (Nair et al., 1986). The energetics of the 
system can also be altered by the introduction of a template or molecule that allows for co-
assembly. Proteins and peptides are known to preferentially self-assemble at the surface of a 
material or on a template as the energetics of the system are lower at surfaces. Thus self-
assembly will start at an interface with preference to in solution (Taylor and Osapay, 1990, 
Wattenbarger et al., 1990). In a similar manner if a peptide acted as a template or co-
assembled with fibrin in solution the peptide would lower the energetic barrier to fibrin 
assembly increasing the rate of thrombus formation. Neutral surfaces have been shown to 
facilitate higher rates of fibrin assembly compared to negatively and positively charged 
surfaces (Wang et al., 2007a). 
Steric exclusion occurs when interaction between non-reactive solutes results in an exclusion 
zone around the solute where other solute molecules are deficient compared to the 
concentration in bulk solution (Lee et al., 2012). This is influenced by the hydrodynamic radius 
of the excluding species and is related to the concentration and size of the solute added to the 
solution. As the other solutes are excluded from the area around the non-reactive solute the 
bulk solution has a higher concentration of solute; the discontinuity between the two zones 
leads to an increase in free energy that drives redistribution of the solutes within the system to 
a lower energy level (Lee et al., 2012). In this case the presence of the peptides could have 
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caused steric exclusion of the clotting factors, increasing the concentration of platelets and 
proteins such as fibrin in solution; the unfavourable increase in free energy could have driven 
the redistribution of fibrin and other clotting factors to a more favourable lower energy state 
where they formed a clot. Steric exclusion of fibrin and other clotting factors from volume 
following addition of neutral/inert polymer has been reported to have resulted in a decrease in 
fibrin clotting time (Minton, 1983, Wilf et al., 1985).  
It is possible to see a general relationship between RAD16-1, poly-l-threonine, poly-l-
tryptophan and complementary peptide hSAFAAA-W P1 & P2; with all the peptides having a 
neutral charge. Size also appears to be a factor in the propensity of a peptide to increase 
thrombus formation. Several of the P11 series of peptides have a net neutral charge but show 
no effect on thrombus formation; RAD16-1 larger than the P11 series of peptides showed a 
significant increase in thrombus formation compared to the negative control but was still 
significantly below the positive control. Peptides poly-l-threonine, poly-l-tryptophan and 
complementary peptide hSAFAAA-W P1 & P2 are all significantly larger than RAD16-1 and the P11 
series of peptides and showed no significant difference from the positive control. These results 
suggested that a neutral charge and increased size accelerated the rate of thrombus 
formation. This observed effect would suggest a direct effect of the peptides in increasing the 
stability or activity of one of the components in the clotting cascade was unlikely. Larger size 
should not increase the interaction of a peptide with clotting factors but would be expected to 
have the opposite effect as spatial orientation would become a major issue. However, there is 
not enough available information to rule this out.  
The size related effect would suggest that the peptide could have co-assembled with the fibrin 
or acted as a template as a larger size would allow for greater stability. The size relationship 
would also support the idea of steric exclusion as a larger peptide would take more space in 
solution and so increase the concentration of the platelets and proteins such as fibrin.  
However, the molar concentrations at which the effects were observed were very low and it is 
questionable whether volume exclusion events could have occurred. Given the limited data it 
is not possible to speculate what specifically accounted for the observed effect.  
Peptide blood mixtures of poly-l-lysine, poly-l-arginine and poly-l-ornithine all failed to form 
thrombi in the modified Chandler loop model. This result did not indicate anti-clotting activity 
related to these peptides but was the result of the peptides causing blood cell agglutination. 
Poly-l-lysine, poly-l-arginine and poly-l-ornithine are all large highly positively charged 
peptides. It has been demonstrated that positively charged poly-l-lysine can interact with the 
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naturally occurring negative charge on the surface of red blood cells causing agglutination 
(Karchalsky et al., 1959, Marikovsky and Danon, 1969). Rats injected with poly-l-lysine all died 
after injection due to the agglutination of their blood (de Vries et al., 1953). This appeared to 
be a size related effect as the smaller positively charges peptides in the P11 series had no 
significant effect upon the size of the thrombus formed. The size relationship of this effect is 
understandable as the smaller peptides may not be long enough to link adjacent cells and 
cause agglutination. 
 
4.4.3 Effects of peptides on haemolysis of ovine erythrocytes 
 
The interaction of peptides with cell surface membranes was assessed using a haemolysis 
assay. Erythrocytes act as a model standard cell membrane; with the advantage that 
haemoglobin can easily be detected in solution following release due to cell lysis. The majority 
of peptides showed no significant haemolytic activity over a 72 hour period indicating that the 
peptides were not haemolytic at the concentration tested. 
Peptides will cause haemolysis by some form of peptide membrane interaction. In nature 
there are a range of lytic peptides that form part of the normal defence and life cycle of a wide 
range of organisms. Most well known are the antibacterial peptides but there are examples of 
peptides against mammalian cells, for example hemolysin from Staphylococcus aureus, and 
some that do not distinguish between cell types (Shai, 1999). There are several proposed 
modes of peptide membrane interaction. Many involve the formation of -helix structures and 
so are not relevant to the majority of the peptides tested.  
The three proposed models of most interest are the “carpet” model, the -barrel-stave model 
and the toroidal model.  According to the “carpet” model the peptides initially bind onto the 
cell membrane by electrostatic interaction, hence the peptides are positively charged, the 
peptides preferentially bind to the phospholipid head groups and align along the surface of the 
membrane; the rotation of the peptide leads to reorientation of the hydrophobic residues 
towards the hydrophobic core of the membrane disrupting the bilayer curvature (Shai, 1999). 
The -barrel-stave model describes peptides that assemble on the cell membrane and insert 
into the phospholipid bilayer and form self-assembled pores similar to -sheet transmembrane 
proteins (Protopapa et al., 2009). The toroidal model describes how peptides assemble on the 
cell membrane and then insert into the phospholipid bilayer, unlike the -barrel-stave model 
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the peptide does not form a pore but causes the phospholipid bilayer to bend back on itself 
creating a phospholipid surrounded pore (Ludtke et al., 1996, Protopapa et al., 2009). The 
“carpet” model causes direct disruption of the cell membrane where the -barrel-stave and 
toroidal models create pores in the membrane that allow for the free passage of water and 
ions into the cell and cause cell rupture.  
After 6 and 12 hours P11-10, P11-18, poly-l-lysine, poly-l-threonine, poly-l-arginine and poly-l-
ornithine all showed haemolytic activity. After 24 hours P11-3 also showed haemolytic activity. 
Peptides P11-3, P11-10, P11-18, poly-l-lysine, poly-l-threonine, poly-l-arginine and poly-l-
ornithine all showed haemolytic activity at 24, 48 and 72 hour time points. At 72 hours Fmoc-
diphenylalanine also showed haemolytic activity. Poly-l-lysine and poly-l-arginine showed 
haemolytic activity which was not significantly different to the positive control. Poly-l-lysine, 
poly-l-arginine and poly-l-ornithine are all positively charged and it has been observed that 
poly-cationic materials cause membrane disruption in relation to the molecular weight of the 
poly-cationic material with higher molecular weight materials having a more pronounced 
effect (Mayhew et al., 1973). This size dependency was observed in this study, where the 
larger poly-l-lysine was indistinguishable from the positive control after 12 hours and the 
smaller poly-l-arginine was significantly lower than the positive control until 72 hours and poly-
l-ornithine remained significantly lower than the positive control at 72 hours. Whilst it is not 
possible to state which model is having an effect, it is likely that poly-l-lysine, poly-l-arginine 
and poly-l-ornithine all caused haemolysis by the “carpet” model. 
The haemolytic effect of poly-l-threonine was questionable as the peptide solution was 
naturally brown in colour and the blood solution was turned brown by the addition of poly-l-
threonine. The erythrocytes in poly-l-threonine did not remain red as in the other peptide 
solutions but became brown/gray in colour suggesting a more significant change was 
happening in the solution of poly-l-threonine.  
The method by which P11-3, P11-10 and P11-18 caused haemolysis is unknown; there is no 
charge, hydrophobicity or amino acid relationship between the peptides; P11-3 has a charge of 
+1 and is based on the amino acid glutamine, P11-18 has a charge of +2 and is based on the 
amino acid threonine and P11-10 has a neutral charge and is based on the amino acid 
asparagine. The structure of the P11 series of peptides is very similar for each peptide with 
several sharing a similar hydrophobic core structure and none of which show any significant 
levels of haemolysis. It was possible that these tests could have been infected with a 
microorganism that caused haemolysis; however, this was unlikely due to the limited 
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haemolysis observed. It was possible that peptides P11-3, P11-10 and P11-18 had a specific 
amino acid sequence that interfered with the cell membrane by one of the three models 
described above. For example, they could have formed a -barrel structure in the cell 
membrane resulting in the release of haemoglobin and that only the low peptide 
concentration prevented higher levels of haemolysis. The result observed for Fmoc-
diphenylalanine at 72 hours is likely the result of the natural lysis of the washed erythrocytes. 
 
4.4.4 Complement inhibition 
 
Complement inhibition was assessed using a modified CH50 assay. The results showed that 
peptides P11-4, P11-9, P11-12, P11-13, P11-29, P11-30 and complementary peptides P11-13 & 14 
and hSAFAAA-W P1 & P2 lowered the level of complement mediated lysis and so had an 
inhibitory effect upon the complement system.  
Peptides P11-4, P11-9, P11-13, P11-29, P11-30 and complementary peptide P11-13 & 14 all have 
similar design characteristics; the peptides all have a net negative charge equal to or greater 
than two. It has been shown that poly-anionic materials have several effects upon the 
complement system. Poly-anionic materials are known to inhibit complement C1; mainly by 
binding to complement C1q (Raepple et al., 1976). Poly-anionic materials have been shown to 
reversibly inhibit consumption of complements C2 and C4 by C1esterase in a concentration 
dependent manner; it is proposed that this is achieved by competitive binding of the poly-
anionic material at the enzyme binding site (Loos et al., 1976). Poly-anionic materials have also 
been shown to have an inhibitory effect upon complement C4 (Raepple et al., 1976). Several of 
the P11 series of peptides, P11-20, P11-24 P11-25 and P11-27, are poly-anionic but showed no 
inhibitory effect in the modified CH50 test. The main group of inhibitory peptides and the non-
inhibitory peptides share a poly-anionic charge, however, they have a distinct difference in 
their structure.  Peptides P11-4, P11-9, P11-13, P11-29, P11-30 and complementary peptide P11-13 
& 14 all have a hydrophobic core based around phenylalanine and tryptophan whereas 
peptides P11-20, P11-24 P11-25 and P11-27 do not. This result suggests that hydrophobicity plays 
a part in complement inhibition.  
It has been shown that hydrophobic residues in charged compounds enhance complement 
inhibition activity; it is believed that the hydrophobic units protect the charged groups from 
aqueous media and so enhance the electrostatic interaction between the compound and 
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target complement; it has been shown that hydrophobic residues are most effective in the 
middle of the inhibitory molecule (Bureeva et al., 2005). As the literature suggests that these 
materials have inhibitory effects upon complements C1, C2 and C4 the inhibitory effect could 
be limited to the classical complement pathway and would require testing to assess the effect 
upon the alternative pathway. The ability to inhibit the classical pathway could be an 
advantage as the classical complement pathway is the major cause of complement related 
tissue damage; the ability to target only the classical pathway would spare the alternative and 
lectin pathways that are involved in innate immunity against pathogens (Mollnes et al., 2002). 
The evidence that poly-anionic materials with a hydrophobic core inhibit the complement 
system did not explain the results observed for P11-12 and complementary peptide hSAFAAA-W 
P1 & P2. It is possible that the results observed for P11-12 and hSAFAAA-W P1 & P2 were due to 
the specific amino acid sequences of the two peptides being able to bind to some functional 
site on one of the complement proteins in the pathway. It is also possible that the peptides 
interfered with the normal mechanism of complement mediated cell lysis. The peptide could 
have prevented the binding of complement to the cell surface, it is also possible that the 
peptide could have interfered with antibody binding and so prevented activation of the 
complement system in the CH50 test. 
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4.4.5 Design characteristics 
 
 
Table 4-2; Collected results of biocompatibility and haemocompatibility testing 
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The majority of peptides investigated in this study were shown to be biocompatible and 
haemocompatible. Peptides RAD16-1, poly-l-threonine, poly-l-tryptophan and complementary 
peptide hSAFAAA-W P1 & P2 were shown to be biocompatible but had an effect upon thrombus 
formation. Several peptides, poly-l-lysine, poly-l-arginine and poly-l-ornithine were identified 
not to be biocompatible or haemocompatible. Several peptides, P11-3, P11-10 and P11-18 also 
gave rise to results that were equivocal. 
These results in Table 4-2 show some interesting possibilities for the use of peptides in 
biomedical applications. It was possible to identify several design characteristics for the further 
development of self-assembling peptides. Large positively charged peptides should be avoided 
as they were shown to be cytotoxic, haemolytic and cause the agglutination of whole blood; 
this makes them unsuitable for biomedical application. Large neutral charged peptides were 
shown to cause an increase in the formation of thrombus in a model system. This effect could 
be of advantage in haemostatic applications in which there is a desire to increase the rate of 
blood clotting. Even though the mechanism by which these peptides increased thrombus 
formation was unclear it would be unadvisable to use them in the body where they could 
come into contact with the blood as even if they do not trigger clotting they have the potential 
to disrupt the delicate balance between clotting and inhibitory factors. The effect of poly-
anionic peptides with hydrophobic cores could be of advantage or disadvantage in a 
biomedical application. Several disease states are associated with the complement system and 
a tissue engineering scaffold that could inhibit these effects could potentially be of great 
benefit. Conversely inhibition of the complement system could have a negative effect due to 
suppression of immunological reactions. 
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5 Effects of peptide coatings on decellularised arterial conduits 
 
5.1 Introduction 
 
It has been proposed that self-assembling peptides can be used to passivate the surface of a 
decellularised porcine internal carotid artery. In Chapter 3 it was shown that the peptide P11-4 
could self-assemble within the decellularised vessel, forming a coating over the ECM. The 
results from the screening of the biocompatibility and the haemocompatibility of peptides in 
Chapter 4 were used to identify model peptides for investigation. It has further been proposed 
that functional groups could be added to the self-assembled peptide to aid and enhance 
reendothelialisation. 
 
5.1.1 Anti-thrombogenic coatings 
 
Anti-thrombogenic coatings have been explored in detail in Section 1.6. Potential anti-
thrombogenic coatings can be non-fouling, anti-clotting or can work by passivating the surface. 
The use of non-fouling surfaces is not an ideal solution for preventing thrombus formation 
since the modification of the surfaces can lead to changes in chemical and mechanical 
properties (Morra and Cassineli, 1999). Degradation of the surface will naturally occur in long-
term use and the loss of the anti-fouling coating will allow for the formation of blood clots. The 
non-fouling surface often prevents the binding and growth of cells so may prevent the 
formation of a fully functional endothelial layer (Hoffman, 1999, Morra and Cassineli, 1999, 
Sarkar et al., 2007). The loss of control of protein binding and dissolution could also negatively 
impact on cellular interactions and negate one of the reasons for using naturally derived 
scaffolds as vascular grafts. 
Slow release anti-coagulants and anti-coagulant coatings can be effectively used to prevent 
clot formation and platelet activation, however, if the anti-coagulant is fully released or 
removed from the surface of a scaffold by degradation and a fully formed endothelial layer has 
not formed, platelets will become activated and thrombosis can occur; as has been observed 
with heparin coatings (Xue and Greisler, 2003, Sarkar et al., 2007, Venkatraman et al., 2008). 
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This means that anti-clotting behaviour may not be sufficient and that other factors are 
needed to allow for reendothelialisation. 
The use of a material to passivate the surface is based on the same principle as the non-fouling 
coating, in which a bio and haemo compatible non-thrombogenic material is used to prevent 
platelet activation and clot formation. The advantage of passivating the surface over non-
fouling surfaces is that a biocompatible surface should allow for normal cellular function whilst 
preventing clotting, unlike the non-fouling surface that prevents cell adhesion. Passivating the 
surface has advantages over anti-clotting coatings avoiding the risks associated with anti-
clotting treatments, present in even controlled delivery (Hoshi et al., 2012).  
 
5.1.2 Endothelial cells 
 
Endothelial cells produce and attach to a basal lamina that is supported on the internal elastic 
lamina of  blood vessels (Wagenseil and Mecham, 2009). It was originally believed that 
endothelial cells functioned as a mechanical barrier between blood and the underlying ECM; 
however, it has become evident that endothelial cells are critically involved in vascular 
function. Vascular endothelial cells have been explored in greater detail in Section 1.2.3. Site-
specific differences can be seen between endothelial cells from different locations in the 
vasculature, however, some fundamental features are maintained regardless of origin 
(Murphy et al., 1998, Sumpio et al., 2002). These basic characteristics of endothelial cells can 
be used to identify and characterise isolated cells from the vasculature.  
Endothelial cells that have been cultured to confluence form focal areas with a characteristic 
cobblestone structure of polygonal cells; the cobblestone morphology becomes more 
predominant with longer culture times (Jaffe et al., 1973, Schwartz, 1978, Schor et al., 1983). 
There have been reports that post-confluent cultures will start to form a secondary elongated 
morphology beneath the original monolayer (Schor et al., 1983). 
CD31 also known as PECAM1 is an integral membrane glycoprotein belonging to the 
immunoglobulin super-family of cell adhesion molecules (Dong et al., 1997). CD31 is expressed 
on the surface of endothelial cells and platelets; it has been designated as a platelet-
endothelial cell adhesion molecule (DeLisser et al., 1994). CD31 is expressed by all endothelial 
cells in the adult, it promotes cell-cell interactions in cultured endothelial cells and has been 
reported to be present in embryonic cardiovascular development (Baldwin et al., 1994, Sumpio 
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et al., 2002). CD31 is found in relatively small amounts on platelets but has been reported to 
be expressed in large amounts, up to 10 fold higher levels, on cultured endothelial cells and is 
expressed on the continuous endothelium of all blood vessels (DeLisser et al., 1994, Dong et 
al., 1997). 
The vWF is an adhesive glycoprotein involved in haemostasis; it is synthesised only by 
endothelial cells and megakaryocytes and is found in three pools in the body, plasma soluble 
vWF,  basement membrane vWF and cellular vWF found in granules of platelets and Weibel-
Palade bodies in endothelial cells (Wagner, 1990, Ruggeri, 1997). vWF is expressed by mature 
endothelial cells but to a varying extent by endothelial progenitor cells (Hristov et al., 2003). 
Weibel-Palade bodies vary in number in endothelial cells with the age of the culture having 
little effect upon the numbers present; it has been observed that although the Weibel-Palade 
bodies are present throughout the cytoplasm they are primarily located at the periphery of 
well-spread cells (Wagner et al., 1982). 
Endothelial cells have been isolated and characterised in a number of different ways from a 
number of different locations. Human micro-vascular endothelial cells have been isolated and 
identified by their characteristic cobblestone morphology and by immunofluorescence using 
antibodies against vWF (Ades et al., 1992). Endothelial cells have been isolated from murine 
lungs using anti-CD31 antibody labelled beads to isolate endothelial cells from suspension 
(Dong et al., 1997). Differentiation of embryonic stem cells into endothelial cells has been 
evaluated by immunochemical procedures using antibodies against vWF and CD31 (Levenberg 
et al., 2002). The results from several studies show that endothelial cells can be identified by 
the morphology of the cells and the presence of glycoproteins CD31 and vWF. 
 
5.1.3 Cell attachment motifs 
 
Cell attachment motifs have been explored in greater detail in Section 1.6.4.2. Natural cell 
attachment ligands such as RGD have been used to enhance cellular adhesion and retention in 
a wide range of applications. RGD is a naturally occurring attachment motif; it is often in the 
form of RGD, PRGDS or YRGDS and is known to enhance cell attachment to a surface (Drury 
and Mooney, 2003, Chen and Hunt, 2007, Wang et al., 2008). The inclusion of RGD variants on 
vascular grafts has been shown to enhance bovine aortic and human umbilical vein endothelial 
cell migration, attachment and retention (Patel et al., 2007, Wang et al., 2008). 
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5.1.4 Aims and objectives 
 
The aims of this chapter were to test the hypothesis that self-assembling peptides could be 
used to passivate the surface of the decellularised porcine arterial conduits and also to test the 
hypothesis that the attachment of ovine endothelial cells would be enhanced in the presence 
of cyclic RGD (cRGD) functionalised peptide. 
 Specific objectives; 
a) To determine the anti-thrombogenic properties of un-functionalised peptide 
coatings on the decellularised vessel 
b) To isolate and characterise ovine arterial endothelial cells 
c) To evaluate the attachment of ovine arterial endothelial cells to the 
decellularised porcine internal carotid artery and self-assembled peptide 
coated decellularised porcine internal carotid artery 
d) To evaluate the effect of adding cyclic RGD functionalised peptide to the self-
assembled peptide coating on the attachment of ovine arterial endothelial 
cells  
 
5.2 Methods 
5.2.1 Chandler loop thrombosis model 
 
Peptide coated decellularised porcine internal carotid artery was tested for thrombus 
formation in the Chandler loop model. Three peptides were chosen based on the results 
obtained in Chapter 4. Peptides P11-4, P11-8 and P11-12 were chosen as they were shown to be 
biocompatible and not have any effect upon thrombus formation. The amount of each peptide 
used was calculated to achieve a final concentration of 18.8 mol.m-3. This concentration of 
peptide was chosen as it has been shown to give a strong self-supporting gel and the tests of 
stability and self-assembly within the decellularised vessel (Chapter 3) were done using this 
peptide concentration. Peptide solutions, 1.8 ml, were made in sterile water. Lengths of 
decellularised vessel, 5 cm, were washed for 1 minute in 150 ml of sterile water to remove 
salts from storage in PBS. The decellularised vessel was added to the peptide solution and left 
overnight then 0.2 ml of 10X Ringer’s solution was added to trigger self-assembly.  
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All Chandler loop tests were set-up and run as described in the protocol in Section 2.2.15.2. Six 
replicates for each peptide and control were tested. Six samples were tested at a time with 
three loops to a spinner at 27°C. Citrated sheep blood was used to test for thrombus 
formation. Blood used was tested for normal clotting behaviour and a response to known 
triggers of blood clotting before use. 
 
5.2.2 Endothelial cell isolation and characterisation 
 
Endothelial cells were isolated from ovine superficial femoral arteries as per the protocol 
described in Section 2.2.18.1. Cells were initially grown in 5 ml of endothelial cell growth 
medium in 25 cm2 tissue culture flasks at 37°C in 5 % (v/v) CO2 in air. Spent medium was 
removed and the cells washed with 5 ml of sterile PBS, which was removed and replaced with 
5 ml of fresh endothelial cell growth medium. Images were then taken of the cell growth. Cells 
were subcultured and grown in 75 cm2 tissue culture flasks with 10 ml of endothelial cell 
growth medium at 37°C in 5 % (v/v) CO2 in air. After each passage cells were cryopreserved for 
long term storage. Cells were resurrected before use and grown to confluence and subcultured 
at least once before testing. Before antibody labelling as described in Section 2.2.18.4 cells 
were grown to confluence and imaged. Cell suspension, 20 µl, was added to each of the 8 
spots on an 8 spot slide (three slides for each antibody being used) and cultured for 4 hours at 
5 % (v/v) CO2 in air. Fresh endothelial cell culture medium was added to the cells and was 
incubated for 48 hours at 37°C in 5 % (v/v) CO2 in air. Following fixation in methanol and 
acetone (1:1) all slides were kept at 27°C until imaging. Cells were labelled with anti-CD31, 
anti-vWF to check for endothelial cell markers and with anti-smooth muscle cell actin and anti-
myosin heavy chain to check for the absence of smooth muscle cell markers; two 8 spot slides 
were labelled with antibody and one with the appropriate isotype control. All slides were kept 
in the dark and imaged immediately after mounting.  
 
5.2.3 Endothelial cell attachment and proliferation 
 
Following cell resurrection and characterisation as described in Section 2.2.18.2 the 
endothelial cells were used to determine their attachment and proliferation on the luminal 
surface of uncoated decellularised vessel and peptide coated vessel. Decellularised vessel was 
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cut into 1.5 cm lengths and cut longitudinally to open the vessel out. Decellularised vessel was 
coated in 30 mg.ml-1 (18.8 mol.m-3) of peptide P11-4 and 30 mg.ml
-1 (18.8 mol.m-3) of peptide 
P11-4 mixed 1:50 with P11-4-cRGD (synthesised by Dr Lik Ren Tai) as described in Section 2.2.19. 
Four replicates for each test condition were prepared. Four samples of P11-4 coated vessel and 
four samples of P11-4-cRGD for each time point, 4, 24 and 72 hours, were placed in one 12 well 
plate and four samples of uncoated vessel were placed in a second 12 well plate for each time 
point. Seeding rings with an internal diameter of 7.5 mm were placed on the vessel samples 
and 300 µl of endothelial cell growth medium without ECGF was added and incubated at 37°C 
in 5 % (v/v) CO2 in air for 24 hours. Medium was removed and 200 µl of cell suspension, 25,000 
endothelial cells per ml (5000 cells per sample), was added and incubated for 4 hours at 37°C 
in 5 % (v/v) CO2 in air. After 4 hours the medium and seeding rings were removed. Each sample 
was washed with 1 ml sterile PBS to remove unattached cells. Endothelial cell culture medium, 
1 ml, was added and the samples incubated at 37°C in 5 % (v/v) CO2 in air; changing the 
medium every 48 hours. Samples removed at each time point were washed with 1 ml of sterile 
PBS and 0.5 ml of live/dead stain (1 mol.m-3 calcein AM and 2 mol.m-3 ethidium homodimer-1 
in sterile PBS) was added and incubated in the dark for 40 minutes at 27°C. Staining solution 
was removed and the samples washed with 1 ml of sterile PBS. PBS was removed and the 
samples turned over and imaged using an inverted confocal fluorescent microscope. All 
manipulations were conducted in an aseptic environment. 
 
5.3 Results 
5.3.1 Thrombus formation in uncoated and peptide coated decellularised vessels 
 
Results were collected, graphed and analysed using one-way analysis of variance. For all 
results there was a significant difference between the positive, -thrombin in Chandler loop 
without decellularised vessel, and negative, blood run in Chandler loop without decellularised 
vessel, controls (Appendix Figure A.5). Results are presented in Figure 5.1 with the test 
peptides plus the relevant decellularised vessel control. 
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Figure 5.1; Weights of thrombus formed when peptide coated or uncoated (DPICA) decellularised 
vessel was evaluated in the Chandler loop model; Data is presented as the mean (n=6) ± 95 % 
confidence intervals. Data was analysed by one way analysis of variance followed by determination of 
the MSD (p < 0.05). Blue * = significant difference between coated and uncoated vessels, Red * = 
significant difference between peptide coated vessels. 
 
All the thrombi that were formed in this assay had a similar appearance with a single thrombus 
being formed with similar width to the PVC tubing and a visible white head at one end of the 
thrombus and a red tail, similar to arterial thrombi formed in vivo. 
The results in Figure 5.1 showed that the thrombi formed in decellularised vessels coated in 
peptides P11-4, P11-8 and P11-12 were all significantly smaller than the thrombi formed in 
uncoated decellularised vessel. The results also showed that the thrombi formed in P11-12 
coated vessels were significantly smaller than the thrombi formed in P11-4 and P11-8 coated 
vessels. 
 
5.3.2 Endothelial cell isolation and characterisation 
5.3.2.1 Observations from cell culture 
 
Images of the cells following isolation and at confluence after 6 passages are presented in 
Figure 5.2 showing different stages in cell culture.  
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Figure 5.2; Inverted microscope images of cultured ovine arterial cells following isolation. A & B; 
freshly isolated endothelial cells after 1 day of culture at 10 X magnification, C; confluent endothelial 
cells 4 X magnification, D; confluent endothelial cells 10 X magnification.  
 
Isolated cells that had attached to the tissue culture plastic and spread to form small 
epithelioid colonies after 1 day of culture are shown in Figure 5.2 images A & B. These colonies 
increased in size and gradually coalesced to form confluent monolayers of densely packed 
polygonal cells as shown in Figure 5.2 images C and D. Cells within these colonies and 
monolayers were predominantly uniform in appearance. The observed morphologies and 
behaviour observed could be attributed to endothelial cells. 
 
5.3.2.2 Phenotype of isolated ovine vascular cells 
 
Images of DAPI and fluorescently labelled antibody stained cells, cells after 5 passages, were 
taken from the same area and recorded. The images were combined using Corel PaintShop Pro 
X5. All assays were carried out with an isotype control. Images are presented in Figure 5.3 and 
Figure 5.4 as combined images showing antibody/isotype and DAPI staining with appropriate 
scale bars. 
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Figure 5.3; Confocal laser scanning microscope images of antibody labelling of isolated ovine 
endothelial cells, A; Anti-CD31 and DAPI staining, B; Anti-vWF and DAPI staining, C; Anti-CD31 isotype 
control and DAPI staining, D; Anti-vWF isotype control and DAPI staining. 10 X magnification. 
 
Figure 5.4; Confocal laser scanning microscope images of antibody labelling of isolated ovine 
endothelial cells, A; Anti-smooth muscle cell -actin and DAPI staining, B; Anti-Smooth muscle cell 
myosin heavy chain and DAPI staining, C; Anti-smooth muscle cell a-actin isotype control and DAPI 
staining, D; Anti-smooth muscle cell myosin heavy chain isotype control and DAPI staining. 10 X 
magnification. 
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The DAPI staining in all the images shown in Figure 5.3 and Figure 5.4 showed the presence of 
cell nuclei. One hundred percent of the cells were positive for CD31, an endothelial cell marker 
(Figure 5.3 image A). Approximately sixty percent of the cells were positive for vWF, a cell 
marker present on endothelial cells (Figure 5.3 image B). The staining of the cells (Figure 5.3 
images A & B) was distinctly different from the isotype controls (Figure 5.3 images C & D) and 
showed that the cells expressed both CD31 and vWF identifying them as endothelial cells. 
Minimal fluorescent staining was seen with antibodies specific to smooth muscle -actin and 
myosin heavy chain (Figure 5.4 images A & B). The staining of the cells showed no distinct 
visual difference from the isotype controls (Figure 5.4 images C & D). The presence of cells was 
confirmed by the DAPI staining of cell nuclei and showed that the cells were not expressing 
smooth muscle -actin or myosin heavy chain indicating that the cells were not smooth muscle 
cells. 
5.3.3 Effect of peptide and functionalised peptide on the attachment of ovine 
arterial endothelial cells 
 
Images of Live/Dead staining of endothelial cells on decellularised vessel (DPICA) and peptide 
P11-4 and P11-4-cRGD coated decellularised vessels were taken using confocal microscopy and 
recorded using Zen 2011. Endothelial cells were used after 6 passages and were identified as 
endothelial cells by morphology and by labelling with immunofluorescent antibodies at 
previous passage. The number of live stained cells and dead stained cells were recorded and 
analysed. Results are presented as representative images in Figure 5.5 with appropriate scale 
bars, in Figure 5.6 and Figure 5.7 as a series of graphs showing the number of cells counted per 
mm2 and the percentage of viable cells counted and a images showing cell alignment in Figure 
5.8. 
 
200 
 
 
Figure 5.5; Confocal laser scanning microscopy images of Live/Dead stain of ovine endothelial cells 
after 4, 24 and 72 hours attached to decellularised porcine internal carotid artery, decellularised 
porcine internal carotid artery with 30 mg.ml
-1
 (18.8 mol.m
-3
) P11-4 and decellularised porcine internal 
carotid artery with 30 mg.ml
-1
 (18.8 mol.m
-3
) P11-4-cRGD mixed with P11-4 at a ratio of 1:50. 10 X 
magnification. 
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Figure 5.6; Number of live cells per mm
2
 at 4, 24 and 72 hours. Data is presented as the mean (n=4) ± 
95 % confidence intervals. Data was analysed by two way analysis of variance followed by 
determination of the MSD (p < 0.05) for each time point and each test condition. Black * = significant 
increase in attached cells between test conditions at set time point, coloured * = significant increase 
in attached cells between time points for corresponding test condition, coloured ** = significant 
decrease in attached cells between time points for corresponding test condition. 
 
Figure 5.7; Percentage of cells counted that were viable over 4, 24 and 72 hours. Data is presented as 
the mean (n=4) ± 95 % confidence intervals. Data was analysed by two way analysis of variance 
followed by determination of the MSD (p < 0.05) for each time point and each test condition. Black * = 
significant increase in attached cell viability between test conditions at set time point, black ** = 
significant decrease in attached cell viability between test conditions at set time point, coloured * = 
significant increase in attached cell viability between time points for corresponding test condition, 
coloured * *= significant decrease in attached cell viability between time points for corresponding test 
condition. 
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Approximately 114 ovine arterial endothelial cells were seeded per mm2 on each vessel 
sample; the results (Figure 5.6) showed that over 60 % of the cells seeded on the decellularised 
vessels attached and approximately 100 % of the endothelial cells seeded on the P11-4 and P11-
4-cRGD coated decellularised vessels attached. 
The results observed in both the images shown in Figure 5.5 and the live cell count shown in 
Figure 5.6 showed that significantly more endothelial cells had attached to the P11-4 and P11-4-
cRGD coated decellularised vessels than on the uncoated vessels after 4 hours. There was no 
significant difference between the number of endothelial cells attaching to the P11-4 and P11-4-
cRGD coated decellularised vessels after 4 hours. The images (Figure 5.5) and the live cell 
count (Figure 5.6) showed that there was no significant difference between the number of 
cells attached to the coated and uncoated decellularised vessels after 24 hours of culture. The 
images (Figure 5.5) showed that there were no cells attached to the uncoated decellularised 
vessels and that few cells were attached to the P11-4 coated vessels after 72 hours of culture. 
Images of both the decellularised vessels and the P11-4 coated vessels showed what appeared 
to be cell remnants on the surface of the vessels. In contrast there were numerous endothelial 
cells attached to the P11-4-cRGD coated vessels. At 72 hours there were significantly lower 
numbers of live cells counted on the decellularised vessels and the P11-4 coated vessels 
compared to the P11-4-cRGD coated vessels. 
The images (Figure 5.5) and the live cell count (Figure 5.6) showed that there was a significant 
increase in the number of cells attached to the uncoated decellularised vessels at 24 hours 
compared to 4 hours and that there was a significant loss of cells after 72 hours. The results 
showed that there was no significant difference in the number of endothelial cells on the P11-4 
coated decellularised vessels after 24 hours compared to 4 hours and that there was a 
significant loss of cells after 72 hours (Figure 5.5 and Figure 5.6). The images (Figure 5.5) and 
live cell count (Figure 5.6) showed that there was no significant difference in the number of 
live endothelial cells on the P11-4-cRGD coated decellularised vessels after 24 hours compared 
to 4 hours. The results showed that there was a significant increase in the number of live cells 
on the P11-4-cRGD coated decellularised vessels after 72 hours compared to the number of live 
cells at 4 and 24 hours (Figure 5.6). 
There was no significant difference in the percentage of viable cells attached to the coated and 
uncoated decellularised vessels after 4 hours (Figure 5.7). After 24 hours there was no 
significant difference between the uncoated and P11-4 coated decellularised vessels. The 
results showed that there was a significant difference between the percentage of viable cells 
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attached to the P11-4 and P11-4-cRGD coated vessels after 24 hours. The count of live and dead 
cells after 72 hours showed that there was a significant reduction in the percentage of viable 
cells attached to the uncoated (no cells present) and P11-4 coated decellularised vessels (Figure 
5.7). There was a significant reduction in the percentage of viable cells present on the 
uncoated and P11-4 coated vessels after 72 hours compared to the percentage of viable cells at 
4 and 24 hours (Figure 5.7). The results also showed that there was a significant reduction in 
the percentage of viable cells present on the P11-4-cRGD coated vessels between 4 hours and 
24 hours. The count of live and dead cells also showed that there was a significant increase in 
the percentage of viable cells on the P11-4-cRGD coated decellularised vessels between 24 
hours and 72 hours but no difference between 4 hours and 72 hours. 
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Figure 5.8; Confocal laser scanning microscopy images of ovine endothelial cells after 24 hours showing alignment of cells with underlying extracellular matrix. A to C; 
Live cell stain, D to F; Dead cell stain and collagen auto-fluorescence, A and D; decellularised porcine internal carotid artery, B and E; decellularised porcine internal 
carotid artery with 30 mg.ml
-1
 (18.8 mol.m
-3
) P11-4, C and F; decellularised porcine internal carotid artery with 30 mg.ml
-1
 (18.8 mol.m
-3
) P11-4-cRGD. 10 X magnification.
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The results showed the endothelial cells had aligned along the ECM after 24 hours. The 
alignment of the ECM in the vessels was shown by collagen auto-fluorescence in Figure 5.8 
images D, E and F. The live staining of the endothelial cells demonstrated that the cells were 
aligning in the same direction as the vascular ECM (Figure 5.8 images A, B and C). 
 
5.4 Discussion 
5.4.1 Thrombus formation in uncoated and peptide coated decellularised vessels 
 
Peptides P11-4, P11-8 and P11-12 were shown to have pacified the surface of the decellularised 
vessel and lowered the level of thrombogenesis. The peptide coatings did not prevent 
thrombosis, this was because the peptide coated and uncoated decellularised vessels only 
formed part of the Chandler loop. As the PVC tubing and the exposure of blood to air in the 
Chandler loop are known to cause the formation of the thrombus it would be unlikely that 
replacing 5 cm of the 33 cm PVC loop with coated vessel would prevent thrombosis. The 
significantly lower level of thrombus formation observed for vessels coated in self-assembled 
P11-12 could have been due to an anti-clotting action of P11-12 which was not demonstrated at 
the significantly lower concentrations used in the tests conducted in Chapter 4. 
 
5.4.2 Endothelial cell isolation and characterisation  
 
From the images of the isolated ovine vascular cells morphology and the immuno-fluorescence 
staining it was possible to identify the isolated cells as primarily being ovine vascular 
endothelial cells. The morphology of the cells was characteristic of the early colonies and 
cobblestone morphology seen at confluence (Jaffe et al., 1973, Schor et al., 1983). The 100 % 
staining for CD31 and the over 60 % staining for vWF was characteristic of endothelial cells and 
corresponded to observations and techniques of identification used in the literature (Wagner 
et al., 1982, Dong et al., 1997, Levenberg et al., 2002). The lack of staining for smooth muscle 
-actin and myosin heavy chain showed that the isolated cells were not smooth muscle cells. 
The results showed that the method for isolating the endothelial cells from ovine arteries and 
the selective trypsin digestion when subculturing resulted in a high purity of isolated ovine 
vascular endothelial cells. 
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5.4.3 Endothelial cell attachment to peptide and functionalised peptide coated 
decellularised vessels 
 
Endothelial cells were shown to be alive by the Live/Dead stain. Ovine endothelial cells 
attached better to the P11-4 and P11-4-cRGD mixed 1:50 with P11-4 coated vessels compared to 
the uncoated vessels. After 24 hours the cells had multiplied on the decellularised vessel but 
not on the P11-4 and P11-4-cRGD coated vessels with a loss in the percentage of viable cells on 
the P11-4-cRGD coated vessels. Cells were not present on the uncoated decellularised vessel 
and few cells were present on the P11-4 coated vessel after 72 hours. The cells on the P11-4-
cRGD coated vessel had multiplied after 72 hours and had a higher percentage of viable cells. 
The increase in the number of endothelial cells on the decellularised vessel showed that the 
cells had attached and were proliferating. The lack of change in the endothelial cells on P11-4 
coated decellularised vessel indicated that the cells had attached but had not started to 
proliferate. The loss of all cells on the decellularised vessels and the majority of cells on the 
P11-4 coated vessels could have been caused by many different factors. It was possible that 
there was a cytotoxic effect of the vessel and that after 72 hours this cytotoxic effect could 
have been enough to kill the cells. This was unlikely as the same effect should have occurred to 
the P11-4-cRGD coated vessels.  
It has been reported that one major problem facing the recellularisation of decellularised 
vascular grafts in vitro is the detachment and delamination of cells and cell layers following cell 
culture (Ott and Ballermann, 1995, Conklin et al., 2004) It has been reported that endothelial 
cells statically seeded onto vascular grafts failed to form strong attachments and are easily 
removed under shear flow (Ott and Ballermann, 1995, Conklin et al., 2004). As the 
endothelium in vivo is normally exposed to shear stress the removal of the flow causes 
phenotypic changes in the cell. The changes cause the cells to form strong cell-cell interactions 
but weak attachments to the underlying ECM meaning the cells can more easily detach 
(García-Cardeña et al., 2001). It was possible that after 72 hours of static culture that the cells 
on the decellularised vessels and the P11-4 coated vessels had proliferated and detached or 
that the cells had been removed from the surface of the vessels by the washing steps and 
changing of media. This explanation would correspond to the observation of cell remnants left 
on the surface of the P11-4 coated decellularised vessels.  
The number of cells on the P11-4 and P11-4-cRGD mixed 1:50 with P11-4 coated vessels showed 
no increase at 24 hours whereas endothelial cells on the decellularised uncoated vessels did. 
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This could be explained by the growth cycle of cells following subculture. Cells enter a latent 
period or lag period as the cells recover from trypsinisation, reconstruct there cytoskeleton 
and secrete ECM to aid in attachment. This latent period can be between a few hours and 48 
hours but is dependent upon the surface the cells are attached to (Freshney et al., 2006). This 
could explain the difference in the growth of the endothelial cells observed between the 
decellularised vessels and the peptide coated vessels. 
The cells on the surface of the P11-4-cRGD mixed 1:50 with P11-4 coated vessels showed strong 
attachment and a high percentage of viability at 4 hours which significantly decreased after 24 
hours. The number of cells and the percentage of viability then increased as cells proliferated 
between 24 and 72 hours. This corresponded to the known cell growth and viability cycle 
observed when subculturing cells (Freshney et al., 2006). Not all the cells that attach onto a 
surface will survive to proliferate; some cells will have reached the end of their life cycle and 
some cells will have been less securely attached to the surface and will detach (Freshney et al., 
2006). This could have resulted in a dip in the number of viable endothelial cells on the P11-4-
cRGD mixed 1:50 with P11-4 coated vessels following attachment that then increased as the 
remaining viable cells proliferated.  
It is possible that the concentration of the RGD at P11-4-cRGD mixed 1:50 with P11-4 had an 
effect upon the cells. Studies using RGD motifs have highlighted the importance of distribution 
and density on cell function. Low concentrations of RGD result in poor cell migration, retention 
and function. High levels of RGD have been shown to significantly increase cell attachment but 
have been reported to have a detrimental effect upon cell migration and proliferation 
(Walluscheck et al., 1996, Chen and Hunt, 2007, Norman et al., 2008). 
Quantitative analysis of the cell adhesion could have been enhanced and confirmed with the 
use of cellular function assays such as the ATPLite-M® assay or the MTT assay which would 
have allowed for the assessment of the total number of cells attached to each sample and not 
just the number of cells imaged in each area.  
The results showed that the endothelial cells attached to the vessel and after 24 hours started 
to align with the underlying ECM. This effect has been observed where aligned materials have 
been used to align cells, even endothelial cells, grown on the surface (Dalby et al., 2002, 
Bischofs and Schwarz, 2003). Endothelial cells in a natural vessel are aligned longitudinally with 
the ECM in the direction of blood flow (Bou-Gharios et al., 2004, Zhang et al., 2007). The 
alignment of the endothelial cells on the peptide coated vessels showed the peptide coatings 
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were not affecting the natural topography of the decellularised vessel as far as endothelial cell 
attachment was concerned. 
The results showed that self-assembling peptides have the potential to be used to passivate 
the surface of a material against thrombogenesis. The results also showed that attachment 
ligands could be included in the peptide sequence to aid and enhance cell attachment and 
retention on the decellularised vessel.  
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6 Conclusions 
 
6.1 Summary 
 
The overall aim of this study was to determine whether self-assembling peptides could be used 
to enhance decellularised small diameter blood vessels for use as vascular grafts. The main 
issues facing the use of decellularised arterial grafts are thrombogenesis, due to the absence of 
an endothelium, and subsequently the need for reendothelialisation. This work had four main 
areas of focus.  
Firstly in Chapter 3 a model peptide was shown to self-assemble within a decellularised 
porcine internal carotid artery. It was shown that the peptide had to be added to the 
decellularised vessel as a monomer and self-assembly triggered. The peptide was shown to 
self-assemble and be in a self-assembled state within the decellularised artery. The peptide 
was shown to form a self-assembled gel coating around the ECM fibres of the decellularised 
vessel and to be present at visually observable levels in the acellular vessel after 7 days under 
model flow conditions.  
Secondly in Chapter 4 the peptides were tested for biocompatibility and the majority of the 
peptides were shown to be biocompatible. Peptides were also tested for haemocompatibility 
and the majority of peptides were shown to be haemocompatible. The results highlighted the 
potential of some peptides in alternative biomedical applications. The haemocompatibility and 
biocompatibility testing allowed the development of design characteristics for future 
development of self-assembling peptide for biological application. Large poly-cationic peptides 
were found to be non-bio or haemo compatible. Large neutral peptides were found to 
enhance the rate of thrombosis in the Chandler loop model; showing promise as potential 
haemostatic agents. Poly-anionic peptides with hydrophobic residues at the centre of the 
peptide sequence were found to inhibit complement activation; dependent upon the method 
of inhibition this could have advantages in a range of tissue engineering and restorative 
therapies.  
Thirdly in Chapter 5, three candidate peptides, identified from results presented in Chapter 4, 
were self-assembled within lengths of decellularised vessel and were shown to significantly 
reduce thrombus formation compared to uncoated decellularised vessel in the Chandler loop 
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model. This provided evidence that the peptide could be used to passivate the decellularised 
vessel and reduce or even prevent thrombogenesis.  
Finally, in Chapter 5 decellularised vessel coated in self-assembled peptide P11-4 and cyclic RGD 
functionalised peptide P11-4 (ratio 1:50) was shown to allow the attachment and growth of a 
higher number of ovine arterial endothelial cells compared to uncoated decellularised vessel. 
It was then shown that the addition of P11-4 functionalised with cyclic RGD to the self-
assembled peptide coating (ratio 1:50) enhanced the retention of endothelial cells on the 
peptide coated decellularised vessels compared to uncoated decellularised vessel. It was also 
shown in Chapter 5 that the isolated cells attached and aligned with the underlying ECM on 
both the self-assembled peptide coated and uncoated decellularised vessels. This provided 
evidence that the self-assembling peptide did not interfere with the attachment of the cells to 
the vessel as a non-fouling surface would have and that the peptide coating did not affect the 
natural alignment of the cells. These results also showed that the peptide could be used to add 
functionality to the decellularised vessel. 
 
6.2 Future work 
 
To continue the work in Chapter 3 a further study of the peptide stability under flow 
conditions could be performed. To act as a passivating material or to enhance 
reendothelialisation the peptide would have to remain present on the luminal surface of the 
decellularised vessel until a fully formed and functional endothelium was present. It would be 
worth testing a range of different peptides for possible application to assess which peptide had 
the highest stability under flow. Such a study would also be useful to develop design 
characteristics for the future development of self-assembling peptides for applications in 
which different stabilities and retention profiles might be needed. It would also be of interest 
to explore how the peptide is self-assembling around the fibres of the ECM, what structures 
are formed and if a smaller interpenetrating network is being formed that is too small to image 
by fluorescent microscopy. 
The work presented in Chapter 4 represented the first steps in the development and 
characterisation of self-assembling peptides for biomedical applications. Future work should 
focus on developing a better understanding of the cause of these effects. Research is needed 
to not only explore the cytotoxicity of the peptides but to assess the effects that the peptides 
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have on cell attachment, migration, growth and phenotype. It would also be useful to expand 
on the range of investigations to cover assessment of different cell types to assess for cell 
specific toxicity. A better understanding of the cause of increased thrombus formation needs 
to be established if peptides are to be used in haemostatic settings, whilst it may be 
unrealistic, to identify the precise mechanism of action of the peptide in thrombus formation it 
would be important to elucidate the general effect to better tailor and develop haemostatic 
agents for clinical translation. 
The haemolysis study demonstrated that the majority of peptides did not interact destructively 
with cell membranes; this did not, however, rule out non-destructive interactions. The effect 
of peptides on cell membranes is an area of potential interest that is very relevant to cell 
function and biocompatibility testing. The modified CH50 assay demonstrated that some of the 
peptides have the potential to inhibit the complement system, however, the exact nature of 
this inhibition needs exploring and whether this effect is limited to the classical pathway needs 
to be established.  
The work in Chapter 4 only covered complement inhibition. It would be useful to assess 
complement activation to obtain a fuller picture and further refine peptide design 
characteristics. The work presented here gives an overview of peptide biocompatibility and 
haemocompatibility, however, this information is limited to one low concentration of peptide. 
As well as expanding on the tests carried out in assessment of biocompatibility and 
haemocompatibility a range of different concentrations need to be explored to examine any 
possible concentration dependent effects and to assess if the results obtained at low peptide 
concentrations are applicable to higher concentrations of peptide. One area of research 
needed for further development is immunological testing to ascertain if there is any immune 
response generated by these peptides in vivo. 
To continue the work in Chapter 5 a larger more detailed study on the anti-thrombogenic 
nature of the peptide coating is needed. The results in Chapter 5 showed a reduction in the 
size of the thrombus formed when part of the Chandler loop was replaced with peptide coated 
vessel. Assessment of the anti-thrombogenic nature of the coatings in which blood is only 
coming into contact with the peptide coated decellularised vessel is needed to determine 
whether the anti-thrombogenic coating prevents thrombosis or just reduces the rate of 
thrombosis. This has huge implications regarding the effectiveness of the peptide coating to 
passivate the surface of a material.  
212 
 
212 
 
To continue the work of the overall project more work is needed on the addition of functional 
groups to the peptides to enhance reendothelialisation. Studies are needed to determine ideal 
ratios of functionalised peptide to un-functionalised peptide. There is also a need to analyse 
the thrombogenic potential of any functionalised peptide as some functional groups such as 
RGD have the potential to play a role in thrombus formation, by allowing the binding of cells 
involved in blood clotting. The possible use of cell adhesion molecules other than RGD also 
needs to be explored to optimise the attachment, retention, adhesion and spreading of 
endothelial cells.  
A longer term study is needed to further assess recellularisation and asses if endothelial cells 
are expressing the correct phenotype and cellular markers. Testing is also needed to assess if 
the endothelial cells are functional or not, simple tests for things such as nitric oxide can 
indicate if endothelial cells attached to the peptide coated decellularised vessel are in a anti-
coagulatory state or pro-coagulatory state. More complex gene sequencing techniques can be 
used to further assess the functionality of the endothelial cells. Work is needed on the 
recellularisation of the graft with vascular smooth muscle cells and with a combination of 
smooth muscle and endothelial cells to investigate the different rates of recellularisation and 
determine the potential for complications such as intimal hyperplasia. To further bring 
together the work in this study a model system is needed in which the recellularisation of the 
graft can be modelled in vitro or in vivo. This model system could allow for the assessment of 
the natural recellularisation of the vessel and further assess the effect of adding functional 
groups. 
 
6.3 Outlook 
 
The hopeful outcome of this line of work is the development of a vascular graft that can be 
used to replace small diameter blood vessels and produce a graft that has high patency rates 
and a long lifetime. It is hoped that over time such a graft would integrate and eventually 
become indistinguishable from the natural blood vessels of the patient. 
As decellularised materials are developed and taken into the clinic the understanding and 
potential application of these materials is growing. Whilst some decellularised products are 
being taken to the clinic there is still a large body of research to do. Work on the 
characterisation and enhancement of the antibacterial properties of the decellularised tissues 
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and on perfecting the decellularisation process for different tissues is being explored. Work on 
identifying the ideal sterilisation process and on the development of viable manufacturing 
processes is ongoing. There is a huge potential for decellularisation to provide not only graft 
materials but to provide the important first step in the production of artificial tissues and 
organs for transplant. 
Redesign and modification of the self-assembling peptides is a constant and evolving process. 
The use of co-assembling peptides, cross-linking agents and the incorporation of disulphide 
bridges into the peptide sequence are being explored in an attempt to make more resilient 
and stable self-assembled peptides. Provided that the assembly and disassembly of new 
peptides can be easily controlled, as with the current P11 series, there will be even more 
potential applications of these peptides. A common focus in biomaterials research is the 
attachment of functional groups in particular attachment ligands as explored in Section 
1.6.4.2. The RGD sequence is the most prevalent cell attachment sequence as it is the most 
commonly found in nature and interacts with most cell types, however, other adhesion 
sequences have been found to have cell specific effects. If a range of attachment ligands can 
be identified it may be possible to employ alternative functionalities to tailor a self-assembled 
peptide for a specific application. The functionalities that can be added to the peptide are not 
limited to attachment ligands; there are a range of biological and therapeutic molecules that 
could be attached to the peptides. Research into the development of tailored and 
functionalised peptides is ongoing. The range of properties possible from self-assembling 
peptides makes them ideal materials for a wide range of tissue engineering and regenerative 
applications. 
Despite research and development of self-assembling peptides and decellularisation 
techniques these new materials are still in the early stages of development, the work 
presented in this thesis aims to add to this base knowledge and hopes to illustrate the 
potential for the combination of new materials to better meet clinical needs.  
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A. Appendix 
A.1 Equipment 
 
Below is a list of all laboratory equipment used throughout the study unless otherwise stated. 
  
Equipment Model Supplier 
- 25 °C freezer Electrolux 3000 Jencons PLC 
- 80 °C freezer MDF-U53v SANYO Biomedical Europe BV 
Autoclave 5 L pressure cooker KUHN Rikon 
Automatic pipettes Gilson P2 – P500 Anachem UK 
Bench top centrifuge Harrier 15/80 SANYO Biomedical Europe BV 
Cell medium aspirator Vacusafe comfort Integra Biosciences (SLS) 
Class II safety cabinet  Heraeus H518 Kendro 
CO2 Incubator MCO-20AIC SANYO Biomedical Europe BV 
Confocal laser scanning 
microscope (CLSM) 
LSM510 META Carl Zeiss Ltd 
Cryostat CM1850 Lecia Microsystems 
Digital camera XC50 Olympus 
Dissection kit N/A Thackeray Instruments 
Field emission gun 
scanning electron 
microscope (FEGSEM) 
Gemini LEO 1530 Carl Zeiss Ltd 
Four figure balance AND GR-200 Jencons PLC 
Fourier transform infra-
red spectrometer 
Nicolet 6700 Thermo Electron Corporation 
Freeze dryer LL1500 Thermo Electron Corporation 
Fridge Lab cold 23 Jencons PLC 
Fume hood  Whiteley 
Histology water bath 3L histology Leica Microsystems 
Hot air oven SANYO OMT225 SANYO Biomedical Europe BV 
Hot plate E18.1 hotplate Raymond A Lamb 
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Hot wax dispenser E66 wax dispensor Raymond A Lamb 
Incubator Heraeus Jencons PLC 
Inverted microscope Olympus, IX71 
And 
CK40 
Microscopes, Medical Diagnostic Systems 
and Olympus Patient Systems Ltd 
(Olympus UK Ltd) 
Liquid nitrogen dewer BIO65 Jencons PLC 
Luminescence counter  Packard TopCount NX Perkin Elmer 
Magnetic Stirrer Stuart SB161 Scientific Laboratory Systems 
Micro centrifuge MSE Micro Centaur SANYO Biomedical Europe BV 
Microplate reader Multiskan Spectrum Thermo Electron Corporation 
Microtome RM212RTF Leica Microsystems 
Multi-photon laser 
scanning microscope 
(MPLSM) 
LSM 510 NLO Carl Zeiss Ltd 
pH Meter Jenway 3020 VWR International 
Pipette boy acu classic Scientific Laboratory Systems 
Peristaltic pump 323 S/D Watson Marlow Pumps 
Refrigerated centrifuge Harrier 18/80 SANYO Biomedical Europe BV 
Rotator Stuart SB2 Bibby Scientific Ltd 
Shaking table IKA KS 130 basic Jencons PLC 
Tissue processor Leica TP1020 Leica Microsystems 
Ultra high speed 
centrifuge 
Sorvall Discovery 100 
SE 
Thermo Electron Corporation 
Universal indicator paper MN/902.02 Camlab 
Upright microscope Olympus, BX51 Microscopes, Medical Diagnostic Systems 
and Olympus Patient Systems Ltd 
(Olympus UK Ltd) 
Vortexer Clifton CM-1 Scientific Laboratory Systems 
Water bath Grant Jencons PLC 
Wax oven GPwax/30/ss SLS 
Table A-1; List of laboratory equipment used throughout study with UK suppliers. 
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A.2 Chemicals 
 
Below is a list of all chemicals and reagents used in this study unless otherwise stated. 
 
Chemical/Reagent Supplier 
Acetone Fisher Scientific 
Aprotinin Mayfair house Leeds Teaching Hospital 
Pharmacy 
ATPLite-M® assay Sigma-Aldrich 
Avidin/biotin blocking kit Vector Laboratories 
Bovine serum albumin Sigma-Aldrich 
Calcium Chloride Cascade Biologics 
Cryoembed Bios Europe Ltd 
Dabco VWR International 
D20 Sigma-Aldrich 
DCL Sigma-Aldrich 
DMSO Sigma-Aldrich 
DNAase Sigma-Aldrich 
DPX mountant Bios Europe Ltd 
Dulbecco’s modified Eagle’s medium Invitrogen Ltd 
Eosin Bios Europe Ltd 
Ethanol VWR International 
Ethylene-diaminetetra-acetic acid (EDTA) VWR International 
Foetal calf serum Invitrogen Ltd 
Glycerol VWR International 
Hank’s balanced salt solution with calcium and 
magnesium 
Invitrogen Ltd 
Hydrogen peroxide Sigma-Aldrich 
Hydrophobic marker pen Vector Laboratories 
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Isopropanol VWR International 
L-glutamine Invitrogen Ltd 
Live/dead stain Invitrogen Ltd 
M199 Invitrogen Ltd 
Magnesium chloride VWR International 
Mayer’s haematoxylin Bios Europe Ltd 
Methanol VWR International 
Methylated spirits Bios Europe Ltd 
Neutracon® Scientific Laboratory Supplies Ltd 
Neutral Buffered formalin (NBF) Bios Europe Ltd 
Paraffin wax pellets Bios Europe Ltd 
PBSa Invitrogen Ltd 
PBS without calcium and magnesium Lonza Biopharmaceuticals 
PBSa tablets Oxoid 
Penicillin Invitrogen Ltd 
Peracetic acid Sigma-Aldrich 
RNAase Sigma-Aldrich 
Sodium Azide VWR International 
Sodium chloride VWR international 
Sodium dodecyl sulphate (SDS) Sigma-Aldrich 
Sodium hydroxide VWR International 
Streptavidin Vector Laboratories 
Streptomycin Invitrogen Ltd 
Tris base Sigma-Aldrich 
Trypsin/EDTA Invitrogen Ltd 
Tween 20 Sigma-Aldrich 
Xylene Bios Europe Ltd 
Virkon Scientific Laboratory Supplies Ltd 
Table A-2; List of chemicals and reagents with supplier. 
218 
 
218 
 
A.3 Images of peptide P11-4 self-assembly under different conditions 
 
Images summarised in Table 3-1 of the self assembled state of peptide P11-4 at pH 8, pH 7 and 
pH 5 with images of peptide self-assembled state of peptide P11-4 in PBS and Ringer’s solution. 
 
 
Figure A.1; Images of peptide P11-4 at concentrations of 30 mg.ml
-1
 (18.8 mol.m
-3
), 15 mg.ml
-1
 (9.4 
mol.m
-3
), 5 mg.ml
-1
 (3.13 mol.m
-3
) and 1 mg.ml
-1
 (0.63 mol.m
-3
) at pH 8, pH 7 and pH 5. 
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Figure A.2; Images of peptide P11-4 at concentrations of 30 mg.ml
-1
 (18.8 mol.m
-3
), 15 mg.ml
-1
 (9.4 
mol.m
-3
), 5 mg.ml
-1
 (3.13 mol.m
-3
) and 1 mg.ml
-1
 (0.63 mol.m
-3
) in solutions of PBS and Ringer’s 
solution. 
 
In Figure A.1 and Figure A.2 self-supporting peptide gels can be distinguished by inversion, 
non-stable gels and visible aggregates can be distinguished by cloudy solution at bottom of the 
inverted glass vial and peptide aggregates stuck to the side of the glass vial. Monomer or 
soluble aggregate can be observed by a clear fluid at the bottom of the inverted glass vial. 
  
A.4 Fluorescent image of fluorescein tagged P11-4 
 
Having been self-assembled, fluorescein tagged peptide P11-4 was embedded in cryostat 
embedding solution and sectioned as a control for the sectioning of the peptide coated vessel 
as described in Section 2.2.11  
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Figure A.3; Fluorescent cross section image of self-assembled peptide P11-4, 30 mg.ml
-1
 (18.8 mol.m
-3
) 
fluorescein tagged P11-4 mixed 1:50 with untagged P11-4. A; 10X magnification, B; 20X magnification. 
 
Fluorescent imaging showed that the sectioned peptide was visible using a fluorescein filter. 
 
A.5 CH50 assay 
 
To determine the dilution of serum to achieve 50 % lysis of the antibody sensitised 
erythrocytes in the complement inhibition test a CH50 assay was done. The CH50 assay was 
carried out as described in Section 2.2.17.1. 
 
 
Figure A.4; Results of CH50 assay showing percentage of erythrocytes lysed at different complement 
dilutions with a line highlighting the point of 50 % lysis. 
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The results of the CH50 assay (Figure A.4) showed that to achieve 50 % lysis the serum used for 
the complement inhibition testing has to be diluted 1:2 with Ringer’s solution. 
 
A.6 Test of normal clotting behaviour of sheep blood 
 
Sheep blood used in the Chandler loop thrombosis model (Section 2.2.15.2) was tested for 
normal clotting behaviour by the use of two controls. The positive control used 2 µl of -
thrombin to trigger thrombogenesis without decellularised vessel present. The negative 
control used sheep blood in the loop without decellularised vessel present as described in 
Section 2.2.15.2. 
 
 
Figure A.5; Positive and negative controls of Chandler loop thrombosis model, * = significant 
difference from the positive control. 
 
The results in Figure A.5 showed that the sheep blood used in the Chandler loop thrombosis 
model in Chapter 5 displayed normal behaviour to clotting factors. 
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A.7 Presentations and applications 
 
 R.S. Guilliatt, S-P. Wilshaw, E. Ingham, A. Aggeli. (2010) Self-assembly of peptide -
sheets within porous materials. European Materials Research Society (EMRS), 
Strasbourg, France (Poster presentation). 
 R.S. Guilliatt. (2010) Peptide -sheet self-assembly in decellularised tissue for 
applications in small diameter vascular grafts. Joint Doctoral Training Centre (DTC) 
conference, Loughbourgh, UK (Oral Presentation). 
 R.S. Guilliatt. (2011) Peptide -sheet self-assembly for the modification of acellular 
vascular grafts. Tissue and Cell Engineering Society (TCES) conference, Leeds, UK (Oral 
presentation). 
 R.S. Guilliatt, S-P. Wilshaw, E. Ingham, A. Aggeli. (2011) Functionalisation of acellular 
arterial conduits with self-assembled peptides. European Society for Biomaterials (ESB) 
conference, Dublin, Ireland (Poster presentation). 
 R.S. Guilliatt. (2011) Functionalisation of acellular arterial conduits with self-
assembled peptide. Biomaterials and Tissue Engineering Group (BiTEG) meeting, 
Sheffield, UK (Oral presentation). 
 R.S. Guilliatt, S-P. Wilshaw, E. Ingham, A. Aggeli. (2012) Biocompatibility and 
haemocompatibility of self-assembling peptides. Tissue Engineering and Regenerative 
Medicine Society (TERMIS) world conference, Vienna, Austria (Poster presentation). 
 
 R.S. Guilliatt, S. Homer-Vanniasinkam, E. Ingham, A. Aggeli. (2013) Application for 
funding to explore commercial potential of haemostatic peptides found within thesis. 
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